

14<sup>th</sup>

ANNUAL REPORT  
**2018-19**

**BETA DRUGS LIMITED**  
(CIN: L24230HP2005PLC028969)

Dedicated To Oncology....



**BETA DRUGS LIMITED**



## TABLE OF CONTENT

Company Information	1-2
Board Committees	3
Financial Highlights	4
Chairman Message	5
Notice to Shareholders	6-18
Directors Report	19-37
Secretarial Audit Report	38-41
Statement showing the name of the top ten employees in terms of remuneration	42
CSR Details	43-44
Annual Return	45-54
Management's Discussion and Analysis	55-57
Standalone Financial Statements of Beta Drugs Limited alongwith Auditors' Report	58-90
Consolidated Financial Statements alongwith Auditors' Report	91-125
Statement containing the salient feature of the financial statement of Subsidiary company in form AOC - 1	125
Standalone Financial Statements of Adley Formulations Private Limited (Wholly owned Subsidiary) alongwith Auditors' Report	126-154
Attendance Slip	155
Proxy Form	156-157
Ballot Form	158
AGM Venue Map	159



---

**14<sup>TH</sup> ANNUAL REPORT 2018-19**  
**COMPANY INFORMATION**  
**CIN NO. L24230HP2005PLC028969**

**Board of Directors**

Chairperson & Managing Director	: Mr. Vijay Kumar Batra (DIN: 01083215)
Whole Time Director	: Mr. Rahul Batra (DIN: 02229234)
Whole Time Director	: Mr. Varun Batra (DIN: 02148383)
Whole Time Director	: Mr Balwant Singh (DIN: 01089968)
Whole-time Director	: Mrs. Seema Chopra (DIN: 08510586)
Independent Director	: Mr Rohit Parti (DIN: 07889944)
Independent Director	: Mr Manmohan Khanna(DIN:07888319)

**Chief Financial Officer**

: Mr Jayant Kumar  
Email:info@betadrugslimited.com

**Company Secretary & Compliance Officer**

: Mrs Rajni Brar  
Email:cs@betadrugslimited.com  
Mb 7889257964

**Registered Office**

:Village Nandpur, Lodhimajra Road  
Baddi, Distt Solan, Himachal Pradesh-174101  
Website: www.betadrugslimited.com  
Email: info@betadrugslimited.com

**Corporate Office**

:SCO-184, Sector-5, Panchkula-134114  
Ph no. 0172-2585481

**Export & Mktd Office**

:1101, 11<sup>th</sup> Floor, Peninsula Park, Andheri West,  
Mumbai-400053

**Statutory Auditors**

:M/s Kalra Rai & Associates, Chartered Accountants  
Chandigarh

**Secretarial Auditors**

:Dinesh Bhandari, Practising Company Secretary  
Chandigarh

**Internal Auditor**

: M/s Srivastva V.K. & Associates, Chartered Accountants  
Chandigarh

**Cost Auditor**

: M/s Charu Jindal & Company, Cost Accountants  
Dehradun

**Shares Listed w.e.f..12.10.2017**

: National Stock Exchange of India Limited (SME)  
Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla  
Complex, Bandra (E), Mumbai-400051, Maharashtra, India



## 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

---

<b>Registrar &amp; Transfer Agent</b>	: Link Intime India Pvt Ltd. C-101, 247 Park, L.B.S. Marg, Vikhroli(W), Mumbai-400083
<b>ISIN No.</b>	: INE351Y01019
<b>Bankers</b>	: Vijaya Bank, Panchkula AXIS Bank, Chandigarh
<b>AGM Date</b>	: 30.09.2019
<b>Venue</b>	: Village Nandpur, Lodhimajra Road Baddi, Distt Solan, Himachal Pradesh-174101
<b>Book Closure Date</b>	: From 23.09.2019 to 30.09.2019



---

**BOARD COMMITTEES****AUDIT COMMITTEE**

Mr Rohit Parti	: Chairman
Mr Vijay Kumar Batra	: Member
Mr Manmohan Khanna	: Member

**NOMINATION & REMUNERATION COMMITTEE**

Mr Rohit Parti	: Chairman
Mr Vijay Kumar Batra	: Member
Mr Manmohan Khanna	: Member

**STAKEHOLDER RELATIONSHIP COMMITTEE**

Mr Rohit Parti	: Chairman
Mr Vijay Kumar Batra	: Member
Mr Manmohan Khanna	: Member


**CORPORATE SOCIAL RESPONSIBILITY COMMITTEE**

Mr Vijay Kumar Batra	: Chairman
Mr Rohit Parti	: Member
Mr Rahul Batra	: Member


## FINANCIAL HIGHLIGHTS

(STANDALONE)


### Net Sales (In Lacs)




### EBITDA (In Lacs)



### Net Profit (In Lacs)



### Net Profit Margin



## CHAIRMAN MESSAGE



Dear Friends,

It is my privilege to interact with you and present annual report with financial statements of your Company for the FY 2018-19.

Indian economy slowed down, albeit slightly in the FY 2018-19 primarily due to declining growth of private consumption, tepid growth in fixed investment, and muted exports. The government however, is cautiously optimistic for FY 19-20.

However, India's domestic pharmaceutical market grew by 9.4% to reach Rs 129,015 crore (US\$ 18.12 billion) in 2018 from Rs 116,389 crore (US\$ 17.87 billion) in 2017. While on the export front Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the USFDA. The country accounts for around 30% (by volume) and about 10% (value) in the US\$ 70-80 billion US generics market.

Beta Drugs Ltd posted strong results for FY 18-19. Its standalone sales grew by 15% to Rs 58.05 crores compared with the same period a year ago while consolidated sales stood at Rs 66 crore. Beta's standalone net profit increased by 14% to Rs7.7 crores.

During the year under review Beta Drugs Ltd has incorporated a wholly owned subsidiary named M/s Adley Formulations Pvt Ltd who has acquired the entire business of Adley Formulations. Adley Formulations was a proprietorship firm specializing in manufacturing of Oncology medicines both in form of tablets & injectable since 2008. This acquisition is helping the company cement its position as India's leading manufacturer of Oncology drugs.

The company recently allotted 6.45 lakhs shares @Rs 91 each to Suryavanshi Commotrade India Pvt Ltd. to fund the acquisition of Adley Lab Limited, a promoter company specialized in Oncology API manufacturing and supplying the same to Beta Drugs Ltd. This backward integration will help improve Beta's profitability across the board.

**Future Growth Plans**

**To increase market share of own branded drugs:** Beta is continuing to strengthen and expand its branded sales team and is planning to launch many new innovative molecules this fiscal. The company is also expanding its domestic partnerships/tie-ups with corporate hospitals. Recently the company for the first time has entered into an agreement to supply its drugs to Tata Memorial Hospital.

**Increase export sales:** By 2019-20 company targets to open at least 10 countries from (Non & Semi regulated & Regulated markets). In September, 2018 the company entered into a 60-40% joint venture with SILUJIN Private Co. Ltd, to manufacture Oncology drugs in Uzbekistan. Beta becomes the first Indian company to manufacture Oncology drugs in the whole of Uzbekistan. As Uzbekistan has a free trade agreement with many CIS countries, Beta intends to export Oncology drugs to these countries from Uzbekistan.

On behalf of the Board and management, I would like to thank our shareholders, customers, distributors and other stakeholders for their continued support and trust. And a special thanks to all our employees for their sheer hardwork and commitment, which has helped the company to deliver strong performance.

It is an honor to serve you all.

**With Warm Regards**

Sd/-

**Vijay Kumar Batra**

**Chairman cum Managing Director**



## **NOTICE TO SHAREHOLDERS**

Notice is hereby given that the 14<sup>th</sup> Annual General Meeting of the Company will be held on **Monday, the 30<sup>th</sup> day of September, 2019 at 12.30 p.m.** at Registered Office of the company situated at Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, Himachal Pradesh-174101 to transact the following business:

### **ORDINARY BUSINESS:**

#### **1. Adoption of Financial Statements**

- (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2019 and the Reports of the Board of Directors and Auditors thereon;  
and
- (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2019, together with the Report of the Auditors thereon

- 2. To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re appointment.**
- 3. To appoint a Director in place of Mr Balwant Singh (DIN: 01089968), who retires by rotation and being eligible, offers himself for re appointment.**
- 4. To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Nineteenth Annual General Meeting and to fix their remuneration:**

To consider and if thought fit to pass with or without modification the following resolution as **Ordinary Resolution:**

**"RESOLVED THAT** pursuant to Sections 139, 142 of the Companies Act, 2013 ("Act") and other applicable provisions, if any, of the said Act and Companies (Audit and Auditors) Rules, 2014 made thereunder and other applicable rules, if any, under the said Act (including any statutory modification(s) or re-enactment thereof for the time being in force) **M/s Kalra Rai & Associates, (FRN- 008859N)**, be and is hereby appointed as the Statutory Auditors of the Company commencing from the conclusion of this Annual General Meeting till the conclusion of Nineteenth Annual General Meeting at a remuneration to be fixed by the Audit Committee and/or Board of Directors of the Company, in addition to the re-imbursement of applicable taxes and actual out of pocket and travelling expenses incurred in connection with the audit and billed progressively."

**"RESOLVED FURTHER THAT Mr Vijay Kumar Batra, (DIN:01083215)** Chairman cum Managing Director of the Company be and is hereby authorized to file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard."

### **SPECIAL BUSINESS:**

#### **5. To regularize Mrs Seema Chopra (DIN:08510586) as a Director of the company**

To consider and if thought fit to pass with or without modification the following resolution as **Ordinary Resolution:**

**"RESOLVED THAT** Mrs. Seema Chopra (DIN:08510586) who was appointed as an Additional Director on 1<sup>st</sup> August, 2019 pursuant to the provisions of section 161 of the Companies Act, 2013, and who holds office upto the date of the ensuing General Meeting, be and is hereby appointed as Director of the Company."





## 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

**“RESOLVED FURTHER THAT** pursuant to section 160 of the Companies Act, 2013 requirements of deposit of amount shall not apply in case of appointment of a director is recommended by the Nomination & Remuneration Committee of the Company.”

- 6. To appoint Mrs Seema Chopra (DIN:08510586) as Whole-time director of the Company & approve the remuneration.**

To consider and if thought fit to pass with or without modification the following resolution as **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to the provisions of sections 196 and 197 read with the schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force), **Mrs Seema Chopra (DIN: 08510586)** be and is hereby appointed as a Whole-time Director of the Company w.e.f. 1<sup>st</sup> August, 2019 to hold office for a period of 5 years on the terms and condition as mentioned below :-

a) Remuneration: **Rs 45,269/-** per month w.e.f. **01.08.2019**

b) Perquisites:

The Following perquisite shall not be included in the computation of the ceiling on remuneration :

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961
- ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service.
- iii) Encashment of leave at the end of tenure.

**“RESOLVED FURTHER THAT Mrs. Seema Chopra (DIN: 08510586)** will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by her in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

**“RESOLVED FURTHER THAT** Board of the Directors are authorized to revised the remuneration from time to time by giving suitable increment / decrement after review of her performance each year, subject to the condition that total remuneration not to exceed **Rs. 5,00,000 p.m.** in any case.”

**“RESOLVED FURTHER THAT** In case of absence or inadequacy of profits in any financial year, remuneration payable to **Mrs. Seema Chopra (DIN 08510586)** shall not exceed the minimum limits prescribed under Schedule V of Companies Act, 2013.”

**“RESOLVED FURTHER THAT Mr. Vijay Kumar Batra (DIN: 01083215),**Managing Director and/or **Mr Rahul Batra, (DIN: 02229234)** Director of the Company be and are hereby authorized severally to sign & issue letter of appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard.”

**“RESOLVED FURTHER THAT** the Board of Directors of the company be and is hereby authorized to do all such acts deeds matters and things as in its absolute discretion, it may consider necessary expedient or desirable and to settle any question or doubt that may arise in relation to modifications in the terms and conditions as may approved by the agreeable acceptable to **Mrs. Seema Chopra, (DIN: 08510586)** whole-time director and to modify the same as may be otherwise considered by it to be in the best interest of the company.”



**7. Remuneration to Cost Auditor for the Financial Year ended 31<sup>st</sup> March, 2020.**

*To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:*

**“RESOLVED THAT** pursuant to provisions of Section 148 and all other applicable provisions of the Companies Act 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any modifications or re-enactment thereof for the time being in force), the company hereby approved the remuneration of **Rs.1,00,000/- (Rupees One Lac Only)** with reimbursement of conveyance expenses at actual and GST as applicable, as approved by the Board of Directors, payable to **M/s Charu Jindal & Co, Cost Accountants**, bearing Firm Registration Number **103508**, appointed by Board of Directors to carry out audit of Company’s cost records for year ending **31<sup>st</sup> March 2020**”.

**“RESOLVED FURTHER THAT Mr Vijay Kumar Batra, (DIN:01083215)** Chairman cum Managing Director of the Company be and is hereby authorized to do all such acts, deeds, matters and things as it may in its absolute discretion consider necessary, proper or desirable for the purpose of giving effect to this resolution.”

**8. Re-appointment of Shri Vijay Kumar Batra (DIN:01083215) as Chairman Cum Managing Director of the company w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025.**

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Ordinary Resolutions**:

**“RESOLVED THAT** pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 (‘Act’) and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Shri Vijay Kumar Batra (DIN 01083215)**, as Chairman & Managing Director of the Company for a period of 5 (five) years with effect from **2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025** on the following terms and conditions :

- 1) Remuneration : Rs. NIL per month
- 2) Nature of Duties and Powers

**Shri. Vijay Kumar Batra (DIN-01083215)**, Managing Director, shall be entrusted with the special and substantial powers of the Management which he shall exercise all such powers as may be assigned, granted and entrusted to him by the Board of Directors of the Company from time to time for the proper performance, discharge and execution of his duties and responsibilities.

**“RESOLVED FURTHER THAT Mr. Vijay Kumar Batra (DIN 01083215)** will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by him in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

**“RESOLVED FURTHER THAT Mr. Rahul Batra (DIN : 02229234)**, Director of the Company be and is hereby authorized to issue letter of re-appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard.”



**9. Re-appointment of Mr Rahul Batra (DIN: 02229234) as Whole-time Director of the Company w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025.**

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Ordinary Resolutions**:

**“RESOLVED THAT** pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 ('Act') and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mr Rahul Batra (DIN 02229234)**, as Whole-time Director of the Company for a period of 5 (five) years with effect from **2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025** on the terms and conditions including remuneration as mentioned below:-

**a) Remuneration : Rs 3 lakhs per month**

**b) Perquisites :**

The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961.
- ii) gratuity payable at the rate not exceeding half a month's salary for each completed year of service.
- iii) encashment of leave at the end of tenure.

**“RESOLVED FURTHER THAT Mr. Rahul Batra (DIN 02229234)** will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by him in connection with the company's business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

**“RESOLVD FURTHER THAT** Board of the Directors are authorized to revised the remuneration from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total remuneration not to exceed **Rs. 6,00,000 p.m.** in any case.”

**“RESOLVED FURTHER THAT** In case of absence or inadequacy of profits in any financial year, remuneration payable to **Mr. Rahul Batra (DIN 02229234)** shall not exceed the minimum limits prescribed under Schedule V of Companies Act, 2013.”

**“RESOLVED FURTHER THAT Mr. Vijay Kumar Batra (DIN:01083215),** Chairman cum Managing Director of the Company be and is hereby authorized to issue letter of re-appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard.”

**10. Re-appointment of Mr Varun Batra (DiN:02148383) as Whole-time Director of the Company w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025**

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Ordinary Resolutions**:

**“RESOLVED THAT** pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 ('Act') and pursuant to the Companies (Appointment and



Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mr Varun Batra (DIN 02148383)**, as Whole-time Director of the Company for a period of 5 (five) years with effect from **2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025** on the terms and conditions including remuneration as mentioned below:-

**a) Remuneration: Rs 3 lakhs per month**

**b) Perquisites:** The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961
- ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service.
- iii) Encashment of leave at the end of tenure.

**“RESOLVED FURTHER THAT Mr. Varun Batra (DIN 02148383)**, will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by him in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

**“RESOLVD FURTHER THAT** subject to approval of shareholders, Board of the Directors are authorized to revised the remuneration from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total remuneration not to exceed **Rs. 10,00,000 p.m.** in any case.”

**“RESOLVED FURTHER THAT** In case of absence or inadequacy of profits in any financial year, remuneration payable to **Mr. Varun Batra (DIN 02148383)**, shall not exceed the minimum limits prescribed under Schedule V of Companies Act, 2013.”

**“RESOLVED FURTHER THAT Mr. Vijay Kumar Batra (DIN:01083215)**, Chairman cum Managing Director of the Company be and is hereby authorized to issue letter of re-appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard.”

**11. Re-appointment of Mr Balwant Singh (DIN:01089968) as Whole-time Director of the Company w.e.f. 5<sup>th</sup> August, 2019 till 4<sup>th</sup> August, 2024.**

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Ordinary Resolutions:**

**“RESOLVED THAT** pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 (‘Act’) and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mr Balwant Singh (DIN 01089968)**, as Whole-time Director of the Company for a period of 5 (five) years with effect from **5<sup>th</sup> August, 2019 upto period ended 4<sup>th</sup> August, 2024** on the terms and conditions including remuneration as mentioned below:-

- 1) **REMUNERATION :** Rs 1,36,000/- p.m.



---

However Board of the Directors are authorized to revised the same from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total remuneration not to exceed **Rs. 4,00,000 p.m.** in any case.

**2) NATURE OF DUTTES & POWERS:**

**Mr. Balwant Singh (DIN- 01089968)**, Executive Director, shall look after the entire day to day operations of the Company including as occupier of the factory premises of the Company at Baddi, subject to superintendence, control and Directors of the Board of Directors and he shall exercise all such powers as may be assigned, granted and entrusted to him by the Board of Directors of the Company from time to time for the proper performance, discharge and execution of his duties and responsibilities under various applicable laws / Acts to Company.

**“RESOLVED FURTHER THAT** In case of absence or inadequacy of profits in any financial year, remuneration payable to **Mr. Balwant Singh (DIN 01089968)** shall not exceed the minimum limits prescribed under Schedule V of Companies Act, 2013.”

**“RESOLVED FURTHER THAT Mr. Vijay Kumar Batra (DIN:01083215)**, Chairman cum Managing Director of the Company be and is hereby authorized to issue letter of re-appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard.”

**Dated: 31.08.2019**  
**Place: Panchkula**

**By Order of the Board of Directors**

**sd/-**  
**Vijay Kumar Batra**  
**Chairman & Managing Director**  
**(DIN: 01083215)**



## 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

### NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL INSTEAD OF HIMSELF AND PROXY NEED NOT BE A MEMBER. PROXIES, IN ORDER TO BE EFFECTIVE, MUST BE RECEIVED BY THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE TIME OF MEETING.
2. A PERSON CAN ACT AS PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS PROXY FOR ANY OTHER PERSON OR SHAREHOLDER.
3. Pursuant to the provisions of SEBI (LODR) Regulations, 2015 and section 91 of the Companies Act, 2013, Register of Members and Shares Transfer Books of the Company will remain closed from **Monday, 23<sup>rd</sup> September, 2019 to Monday, 30<sup>th</sup> September, 2019. (both days inclusive).**
4. Members intending to require information about accounts at the meeting are requested to write to the Company at least 10 days in advance of the Annual General Meeting.
5. Shareholders holding shares in dematerialized form should communicate the change of address, if any, to their Depository Participant and other who hold shares in physical form should communicate the change of address, to the Registrar and Share Transfer Agent of the Company at the following address:  
  
**Link Intime India Pvt Limited.**  
  
**C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai-400083.**
6. Members/Proxies should bring their attendance slip duly filed in for attending the meeting.
7. The Notice of the **14<sup>th</sup> AGM** along with the attendance slip and proxy form are being sent by electronic mode to all the members whose email addresses are registered with Company/ Depository Participant(s) unless a member has requested for a hard copy of the same. For members who have not registered their email addresses, physical copies of the aforesaid documents are being sent by the permitted mode.
8. The Company, being listed on SME Exchange and in view of provisions of Rule 20 of the Companies (Management and Administration) Rules, 2014 is not required to provide remote e-voting facility to its members.
9. Members may also note that the notice of the Annual General Meeting and the Annual Report will also be available on the Company's website for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office at Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101, for inspection during normal business hours on working days. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same by post free of cost.
10. An Explanatory Statement pursuant to Section 102 of the Act in respect of **Item nos. 4 to 11** of the Notice set out above, is annexed hereto.



---

**EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 IN RESPECT OF SPECIAL BUSINESSES MENTIONED IN THE NOTICE OF 14TH ANNUAL GENERAL MEETING TO BE HELD ON 30.09.2019.**

---

**ITEM NO. 4:**

In terms of Section 139 of the Companies Act, 2013 ("the Act"), and the Companies (Audit and Auditors) Rules, 2014, made thereunder, the present Statutory Auditors of the Company **M/s Kalra Rai & Associates, Chartered Accountants (FRN- 008859N)**, will hold office until the conclusion of the ensuing Annual General Meeting and will seek re-appointment for one more term. Therefore the Company has decided to re-appoint **M/s Kalra Rai & Associates, Chartered Accountants** for a period of **five years** to hold office from the conclusion of this Annual General Meeting till the conclusion of the **Nineteenth Annual General Meeting**. The Board of Directors at its meeting held on **31<sup>st</sup> August, 2019**, after considering the recommendations of the Audit Committee, had recommended the re-appointment of **M/s. Kalra Rai & Associates, Chartered Accountants, (FRN- 008859N)**, as the Statutory Auditors of the Company for approval of the members. The proposed Auditors shall hold office from the conclusion of this Annual General Meeting till the conclusion of **Nineteenth Annual General Meeting** of the Company. **M/s. Kalra Rai & Associates, Chartered Accountants**, have consented to the aforesaid appointment and confirmed that their appointment, if made, will be within the limits specified under Section 141(3)(g) of the Companies Act, 2013. They have further confirmed that they are not disqualified to be appointed as the Statutory Auditors in terms of the Companies Act, 2013 and the rules made thereunder. Pursuant to Section 139 of the Companies Act, 2013, approval of the members is required for re-appointment of the Statutory Auditors and fixing their remuneration by means of an **ordinary resolution**. Accordingly, approval of the members is sought for re-appointment of **M/s. Kalra Rai & Associates, Chartered Accountants** as the Statutory Auditors of the Company and to fix their remuneration.

**ITEM NO.5 & 6**

The Board of directors of the Company in their meeting held on **1<sup>st</sup> August, 2019** and Nomination & Remuneration Committee in their meeting held on **1<sup>st</sup> August, 2019** has recommended and appointed **Mrs Seema Chopra (DIN:08510586)** as Additional as well as Whole-time Director of the Company and Mrs. Seema Chopra holds office of the Director till the conclusion of next Annual General Meeting. Accordingly, in terms of the requirements of the provisions of Companies Act, 2013 approval of the members of the Company is required for regularization of **Mrs Seema Chopra (DIN:08510586)** as Director of the Company. Further pursuant to section 160 of the Companies Act, 2013 requirements of deposit of amount shall not apply in case of appointment of a director is recommended by the Nomination & Remuneration committee of the Company."

**Mrs Seema Chopra** is a post graduate and working with the adley group from last 20 years as marketing executive.

Further Board of Directors has decided to promote and appoint her as Whole-time Director of the company for a period of 5 years w.e.f. **1<sup>st</sup> August, 2019** at Remuneration of **Rs 45, 269/- p.m. w.e.f. 1<sup>st</sup> August, 2019**.

She is presently director in NIL companies & holding Nil Equity Shares constituting in the Company.

None of the Directors and Key Managerial Personnel of the Company and their relatives except **Mrs. Seema Chopra** is concerned or interested, financial or otherwise, in the resolution. The Board recommends the resolution set forth in **Item no.5 & 6** for the approval of the members as **ordinary resolution**.

**ITEM NO. 7**

The Board of Directors in its meeting held on **1<sup>st</sup> May, 2019** had approved the appointment of **M/s Charu Jindal & Co, Cost Accountants** bearing Firm Registration Number **103508**, as Cost Auditors of the Company to conduct audit of cost records for the year ending **31<sup>st</sup> March, 2020** at a remuneration of **Rs.1,00,000/- (Rupees One Lac only)** with reimbursement of conveyance expenses at actual and GST as applicable.

In accordance with provisions of Section 148 of the Companies Act 2013 and Companies (Audit and Auditors) Rules, 2014, remuneration payable to cost auditors has to be approved by the shareholders of the company.

Accordingly consent of the members is sought for passing an **ordinary resolution** as set out at **item No.7** of the notice for approval of remuneration payable to Cost Auditors for the financial year ending **31<sup>st</sup> March, 2020**.



None of the Directors/ Key Managerial Personnel of the company/ their relatives are in, anyway concerned or interested, financially or otherwise, in the resolution set out at **item No.7** of the notice.

The Directors recommend the resolution for approval of the members as **ordinary resolution**.

#### **ITEM NO. 8**

**Shri Vijay Kumar Batra (DIN: 01083215)**, aged 65 years, is promoters and main contributor to the growth and development of “**Beta Drugs Limited**” (“the Company”), having net worth of **Rs 40.59 crores** with a turnover of **Rs 58.05 crores** (financial year **2018-19**). Over a decade’s performance, the Company continues to be the most profitable Company in the pharmaceutical industry, with a net profit of **Rs 7.71 crores**. He is a perfect executionist of the mission and vision of the Company. **Shri Vijay Kumar Batra**, who is well versed in understanding Pharmaceutical markets, is equally excellent in ensuring growth by improving productivity, cost control, large size operations & consistently improving quality. There has been considerable synergy in his leading in segments of business and his effective contribution has fostered the growth of the Company’s business. **Shri Vijay Kumar Batra** is overseeing the day-to-day functioning of the Company at all levels.

He is presently director in following companies :

1. Adley Lab Limited
2. Adley Formulations Pvt Limited

He is presently holding **61,83,628** Equity Shares constituting **64.32 %** in the Company.

Presently he is member of Audit Committee, Nomination & Remuneration Committee, Stakeholder Relationship Committee and Corporate Social Responsibility Committee of the company. He is neither Chairman nor member of committee in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on **1<sup>st</sup> August, 2019**, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of **Shri Vijay Kumar Batra** in development and growth of the Company, consent of the Members was sought for the re-appointment of **Shri Vijay Kumar Batra** as a **Chairman cum Managing Director** of the Company for further period of 5 years w.e.f. **2<sup>nd</sup> February, 2020 to 1<sup>st</sup> February, 2025**, on the terms and conditions as set out in this item of the Notice. Shri Vijay Kumar Batra satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Ordinary Resolution** as set out in this item of the Notice for re-appointment of Shri Vijay Kumar Batra as Chairman & Managing Director of the Company **w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025**.

Shri Vijay Kumar Batra, Chairman & Managing Director of the Company may be considered to be concerned or interested in the said resolution it relates to his own re-appointment. Mr Rahul Batra, Whole-time Director and Mr. Varun Batra, Whole-time Director of the company may also be considered as concerned or interested in the same, being relative of Shri Vijay Kumar Batra. None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution. The Board recommends the resolution set forth in **Item no.8** for the approval of the members as **ordinary resolution**.



**ITEM NO. 9**

**Mr Rahul Batra (DIN: 02229234)**, aged 35 years, is Whole-time Director of the company. He holds Master of Science degree in Business and Management from University Strathclyde Scotland. His Scope of work includes Marketing and Sales segment of the Company.

He is presently director in following companies :

1. Kedge Pharmacia Pvt Ltd
2. Adley Formulations Pvt Ltd
3. Adley Lab Limited
4. B.T. Associates Pvt td

He is presently holding **34,450** Equity Shares constituting **0.16 %** in the Company.

Presently he is member of Corporate Social Responsibility Committee of the company. He is neither Chairman nor member of committee in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on **1<sup>st</sup> August, 2019**, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of Mr Rahul Batra in development and growth of the Company, consent of the Members was sought for the re-appointment of Mr Rahul Batra as a Whole-time Director of the Company for further period of 5 years w.e.f. 2<sup>nd</sup> February, 2020 to 1<sup>st</sup> February, 2025, on the terms and conditions as set out in this item of the Notice. Mr Rahul Batra satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Ordinary Resolution** as set out in this item of the Notice for re-appointment of Mr Rahul Batra as Whole-time Director of the Company w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025. Mr Rahul Batra, Whole-time Director of the Company may be considered to be concerned or interested in the said resolution it relates to his own re-appointment. Sh.Vijay Kumar Batra, Chairman cum Managing Director and Mr Varun Batra, Whole-time Director of the company may also be considered as concerned or interested in the same, being relative of Mr. Rahul Batra. None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution. The Board recommends the resolution set forth in **Item no.9** for the approval of the members as **ordinary resolution**.

**ITEM NO. 10**

**Mr Varun Batra (DIN: 02148383)**, aged 34 years, is Whole-time Director of the company. He holds Degree in Business Management from Toronto Canada .His Scope of work includes monitoring Production Department and Export sales of the Company.

He is presently director in following companies :

1. B.T. Associates Pvt td
2. Adley Formulations Pvt Ltd
3. Adley Lab Limited

He is presently holding **33,230** Equity Shares constituting **0.16 %** in the Company.

He is neither Chairman nor member of committee in the company and in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on **1<sup>st</sup> August, 2019**, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of Mr Varun Batra in development and growth of the Company, consent of the Members was sought for the re-appointment of **Mr Varun Batra** as a **Whole-time Director**



of the Company for further period of 5 years w.e.f. **2<sup>nd</sup> February, 2020 to 1<sup>st</sup> February, 2025**, on the terms and conditions as set out in this item of the Notice. Mr Varun Batra satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Ordinary Resolution** as set out in this item of the Notice for re-appointment of Mr Varun Batra as Whole-time Director of the Company w.e.f. 2<sup>nd</sup> February, 2020 till 1<sup>st</sup> February, 2025. Mr Varun Batra, Whole-time Director of the Company may be considered to be concerned or interested in the said resolution it relates to his own re-appointment. Sh. Vijay Kumar Batra, Chairman cum Managing Director and Mr. Rahul Batra, Whole-time Director of the company may also be considered as concerned or interested in the same, being relative of Mr. Varun Batra. None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution. The Board recommends the resolution set forth in **Item no.10** for the approval of the members as **ordinary resolution**.

#### **ITEM NO. 11**

Mr Balwant Singh (DIN: 01089968), aged 49 years, is Whole-time Director of the company. He holds a degree in PGDPM-HR IR from DAV College of Management, Chandigarh. He holds 15 years of experience in the field of pharmaceuticals and his scope of work includes managing over all affairs of the Company.

He is presently director in NIL companies

He is presently holding **590** Equity Shares constituting **0.01 %** in the Company.

He is neither Chairman nor member of committee in the company and in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on **1<sup>st</sup> August, 2019**, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of Mr Balwant Singh in development and growth of the Company, consent of the Members was sought for the re-appointment of **Mr Balwant Singh** as a Whole-time Director of the Company for further period of 5 years w.e.f. **5<sup>th</sup> August, 2019 to 4<sup>th</sup> August, 2024**, on the terms and conditions as set out in this item of the Notice. Mr Balwant Singh satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Ordinary Resolution** as set out in this item of the Notice for re-appointment of Mr Balwant Singh as Whole-time Director of the Company w.e.f. **5<sup>th</sup> August, 2019 to 4<sup>th</sup> August, 2024**. Mr Balwant Singh, Whole-time Director of the Company may be considered to be concerned or interested in the said resolution it relates to his own re-appointment. None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution. The Board recommends the resolution set forth in **Item no.11** for the approval of the members as **Ordinary resolution**.

**Dated: 31.08.2019**

**Place: Panchkula**

**By Order of the Board of Directors**

sd/-

**Vijay Kumar Batra**  
Chairman & Managing Director  
(DIN: 01083215)

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

## DETAILS OF DIRECTORS SEEKING APPOINTMENT/ RE-APPOINTMENT AT THE ENSUING ANNUAL GENERAL MEETING UNDER REGULATION 36 OF SEBI(LODR) REGULATIONS

Name of Director	Mr. Vijay Kumar Batra	Mr Rahul Batra	Mr.Varun Batra	Mr Balwant Singh	Mrs. Seema Chopra
Director Identification Number	01083215	02229234	02148383	01089968	08510586
Date of Birth	07/07/1954	08/10/1983	15/06/1985	04/04/1970	03/07/1975
Educational Qualification	Graduation	Master of Science degree in Business and Management from University Strathclyde Scotland	Degree in Business Management from Toronto Canada	PGDPM-HR IR	Post Graduation
Experience	30 Years	14 Years	14 years	20 Years	20 years
Details of remuneration to be paid, if any	NIL	Rs 3,00,000 p.m.	Rs 3,00,000 p.m.	Rs 1,36,000 p.m.	Rs 45269/- p.m.
Date of first appointment to the Board	11/07/2014	01/08/2014	01/08/2014	01/08/2014	01.08.2019
No. of Share held by Directors in the Company	61,83,628	34,450	33,230	590	Nil
Relationship with other Directors / KMPs	Father of Mr Rahul Batra & Mr Varun Batra	Son of Mr Vijay Kumar Batra & Brother of Mr Varun Batra	Son of Mr Vijay Kumar Batra & Brother of Mr Rahul Batra	N.A.	N.A.
No. of meetings attended during the year	10	10	10	11	0
Profile	Vijay Kumar Batra, (DIN: 01083215) aged 65 years, is the Managing Director of our Company. He has 30 years of experience in Pharmaceutical Industry. He is the guiding force behind all the corporate decisions and is responsible for the entire business operation of the	Rahul Batra, (DIN: 02229234) aged 35 years is the Whole time Director of our Company. He holds Master of Science degree in Business and Management from University Strathclyde Scotland. His Scope of work includes Marketing and	Varun Batra, (DIN: 02148383) aged 34 years, is the Whole time Director of our Company. He holds Degree in Business Management from Toronto Canada .His Scope of work includes monitoring Production Department and Export sales of the Company.	Balwant Singh,(DIN: 01089968) aged 49 years is the Whole time Director of our Company. He holds a degree in PGDPM-HR IR from DAV College of Management, Chandigarh. He holds 15 years of	Mrs. Seema Chopra (DIN: 0008510586) is a Post Graduate and working with Adley Group from last 23years. She has having an experience in the field of Marketing & Purchase.

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

	Company.	Sales segment of the Company.		experience in the field of pharmaceuticals and his scope of work includes managing over all affairs of the Company.	
Expertise in specific Functional areas	Entire business operation of the Company.	Marketing and Sales segment	Production Department and Export sales	Managing over all affairs of the Company.	Marketing & Purchase.
Directorship in other Companies	<ul style="list-style-type: none"> <li>Adley Formulations Pvt Ltd</li> <li>Adley Lab Limited</li> </ul>	<ul style="list-style-type: none"> <li>Kedge Pharmacia Pvt Ltd</li> <li>Adley Formulations Pvt Ltd</li> <li>Adley Lab Limited</li> <li>B.T. Associates Pvt td</li> </ul>	<ul style="list-style-type: none"> <li>B.T. Associates Pvt td</li> <li>Adley Formulations Pvt Ltd</li> <li>Adley Lab Limited</li> </ul>	NIL	NIL
Chairman/ Member of Committees of the Board of other Companies in which he is a Director	NIL	NIL	NIL	NIL	NIL
Relationship, if any, with the other members of the Board	Father of Mr Rahul Batra & Mr Varun Batra	Son of Mr Vijay Kumar Batra & Brother of Mr Varun Batra	Son of Mr Vijay Kumar Batra & Brother of Mr Rahul Batra	N.A.	N.A.
Terms and Conditions of appointment and remuneration sought and remuneration last and justification	<p>Re-appointment for 5 years w.e.f. 2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025 @ remuneration of NIL</p> <p>Last remuneration Rs NIL</p>	<p>Re-appointment for 5 years w.e.f. 2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025 @ remuneration of Rs 3.00 lacs p.m.</p> <p>Last remuneration Rs 3.00 lacs p.m.</p>	<p>Re-appointment for 5 years w.e.f. 2<sup>nd</sup> February, 2020 upto period ended 1<sup>st</sup> February, 2025 @ remuneration of Rs 3.00 lacs p.m.</p> <p>Last remuneration Rs 3.00 lacs p.m.</p>	<p>Re-appointment for 5 years w.e.f. 25<sup>th</sup> August, 2019 upto period ended 24<sup>th</sup> August, 2024 @ remuneration of Rs 1,36,000 p.m.</p> <p>Last remuneration Rs 1,36,000 p.m.</p>	<p>Appointment for period of 5 years w.e.f. 1<sup>st</sup> August, 2019 upto period ended 31<sup>st</sup> July 2024 @remuneration of Rs 45,269/- p.m.</p>



## DIRECTORS' REPORT

To

**The Members of  
BETA DRUGS LIMITED**

Your Directors take pleasure in presenting the 14<sup>th</sup> Annual Report of the Company together with the Audited Accounts for the financial year ended on 31<sup>st</sup> March, 2019. The Management Discussion and Analysis has also been incorporated in this report.

### ❖ FINANCIAL SUMMARY/HIGHLIGHTS:

The brief financial results are as under:

PARTICULARS	STANDALONE		CONSOLIDATED	
	YEAR ENDED 31.03.2019	YEAR ENDED 31.03.2018	YEAR ENDED 31.03.2019	YEAR ENDED 31.03.2018
Revenue from Operations	58,04,86,838.99	50,56,67,871.26	65,92,90,672.52	50,56,67,871.26
Other Income	31,57,848.77	24,43,898.26	37,42,886.77	24,43,898.26
Total Revenue	58,36,44,687.76	50,81,11,769.52	66,30,33,559.29	50,81,11,769.52
Less: Other expenses excluding depreciation	48,47,51,050.43	42,12,48,142.91	55,55,53,833.97	42,12,48,142.91
Less: Depreciation & Preliminary expenses written off	2,42,32,093.54	1,85,06,706.56	2,84,15,646.53	1,85,06,706.56
Profit / (loss) before Taxation	7,46,61,543.79	6,83,56,920.05	7,90,64,078.79	6,83,56,920.05
Less : Provision for Taxation				
Current Tax	0	0	15,34,047.90	0
Deferred Tax	-24,79,381.06	7,20,255.20	-28,68,769.87	7,20,255.20
Profit/ (loss) after Taxation	7,71,40,924.85	6,76,36,664.85	8,03,98,800.75	6,76,36,664.85

### ❖ DIVIDEND:

In order to conserve the financial resources for the future requirement of the company, the Board of Directors has not recommended any dividend for the year.

### ❖ TRANSFER TO RESERVE:

Profit of Rs. 7,71,40,924.85 was transferred to surplus a/c.

### ❖ REVIEW OF FINANCIAL PERFORMANCE AND STATE OF COMPANY'S AFFAIRS

During the year, your Company has emerged as one of the fastest growing company in the Oncology product segment which have contributed to significant increase in the profitability of the company.




---

- **STANDALONE**

During the year, Revenue of the Company increased by 14.86% i.e. from Rs. 5081.11 lakhs to Rs.5836.44 lakhs. Profit before tax increase by 9.22% i.e. from Rs. 683.56 lakhs to Rs.746.61 lakhs. Profit after tax increase by 14.05% to Rs. 771.40 lakhs from Rs. 676.36 lakhs.

- **CONSOLIDATED**

The Consolidated Financial Statements of the Company have been prepared as per Accounting Standard 21 of the Institute of Chartered Accountants of India. The Company's consolidated revenue from operations in the year under review aggregated Rs 6630.33 lakhs on which it made net profit of Rs 803.98 lakhs.

- ❖ **CHANGE IN THE NATURE OF BUSINESS:**

During the year the Company has not changed its business.

- ❖ **MATERIAL CHANGES:**

There are no Material change occurred between the end of the financial year of the company to which the financial statements related and the date of the report, which is affecting the financial position of the company.

- ❖ **LISTING:**

The Equity Shares of the Company are listed on SME Platform of National Stock Exchange of India Limited (NSE Emerge). The Company is regular in payment of Annual Listing Fees. The Company has paid Listing fees up to the year 2019-20.

- ❖ **SUBSIDIARY COMPANIES/JOINT VENTURE COMPANY/ASSOCIATE COMPANY:**

During the year under review Company had incorporate following Subsidiary Companies:-

- ***Beta Ubk International Private Limited***, a newly incorporated subsidiary in Uzbekistan having works & registered office at: 27, Alimkent Street, Yashnobod District, Tashkent City, Uzbekistan **with 60% Shareholding**.  
**Business:** Manufacturing of Oncology Products.
- ***Adley Formulations Private Limited***, a wholly owned subsidiary of Beta Drugs Limited having Registered office at SCO-184, Sector-5, Panchkula-134114 & Works at Kotla, Barotiwala, Distt Soan, Himachal Pradesh **with 100% Shareholding**  
**Business:** Manufacturing & Trading of Oncology Products

A statement containing the salient feature of the financial statement of Subsidiary company under the first proviso to sub-section (3) of section 129 in form AOC - 1 is appended as **Annexure – 6**

The Company is not having any other Joint Venture or Associate Company.



#### ❖ PERFORMANCE OF SUBSIDIARY COMPANIES

- **Beta Ubk International Private Limited** is engaged primarily in **manufacturing of Oncology Products**. Since medicines are under registration yet and the company has no commercial activity till March, 2019 therefore no sales happened so far during the period, April 1, 2018 to March 31, 2019.
- **Adley Formulations Private Limited** is engaged primarily in **Manufacturing & Trading of Oncology Products**. During the period under review, **Adley Formulations Private Limited** achieved a turnover of **Rs 788.03 lakhs** with a profitability of **Rs 32.57 lakhs**.

#### ❖ REASONS FOR REVISION OF FINANCIAL STATEMENT OR REPORT:

During the year, the financial statement or report was not revised. Hence further details are not applicable.

#### ❖ INCREASE IN AUTHORISED SHARE CAPITAL:

During the year under review there is no change in the authorized Share capital of the company.

#### ❖ ALLOTMENT OF SHARES:

During the financial year 2018-19 the Company has not allotted any shares. On **1<sup>st</sup> May, 2019** company has allotted **6,45,244** Equity Shares of **Rs 10/-** each at a price of **Rs 91/-** each (including **Rs 81/-** as premium) under preferential issue & on **1<sup>st</sup> July, 2019** company has allotted **3,19,046** Equity Shares of **Rs 10/-** each at a price of **Rs 90/-** each (including **Rs 80/-** as premium) under preferential issue.

#### ❖ DEPOSITORY SYSTEM

As the Members are aware, your Company's shares are trade-able compulsorily in electronic form and your Company has established connectivity with both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). In view of the numerous advantages offered by the depository system, the members are requested to avail the facility of dematerialization of the Company's shares on NSDL & CDSL. The ISIN allotted to the Company's Equity shares is INE351Y01019.

#### ❖ UTILISATION OF IPO PROCEED:

Utilization of proceed by the Company till March, 2019 raised from IPO is detailed below (Figures in lacs)

PARTICULAR	HEAD	AMOUNT
AMOUNT RECEIVED - SHARE CAPITAL AND PREMIUM		1951.60
<b>EXPENSES</b>		
IPO EXPENSES	ISSUE EXPENSES	369.44
TRFD. TO VIJAYA C/C ( FOR WORKING CAPITAL)	WORKING CAPITAL	129.20
BALANCE WITH AXIS BANK	UNUTILISED	1.72
BALANCE RBL BANK	-	0.00
BALANCE WITH ICICI BANK	UNUTILISED	73.45
FDR WITH AXIS	-	0.00
FDR WITH SIDBI	CORPORATE EXPENSE	34.00
FDR WITH VIJAYA	-	0.00

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

BUILDING	CIVIL CONSTRUCTION	157.80
CORPORATE	CORPORATE EXPENES	90.95
MACHINERY PAYMENT INCLUDING ADVANCE	PURCHASE OF MACHINERY	1067.54
LAND	CIVIL CONSTRUCTION	27.49
<b>TOTAL</b>		<b>1951.60</b>

There was no deviation/variation in the utilization of the proceeds of the public issue from the objects stated in the prospectus of the issue. The company has utilized the above-mentioned unutilized amount of IPO by 30<sup>th</sup> June, 2019.

### ❖ **DIRECTORS & KEY MANAGERIAL PERSONNEL:**

Pursuant to the provisions of Section 152 of the Companies Act, 2013 Mr. Varun Batra (DIN: 02148383) and Mr. Balwant Singh (DIN: 01089968), Directors of the Company retires by rotation at the ensuing Annual General Meeting and being eligible, has offered himself to be re-appointed as Directors of the Company.

The Board recommends the re-appointment of Mr. Varun Batra (DIN: 02148383) and Mr. Balwant Singh (DIN: 01089968), as Directors of the Company liable to retire by rotation.

During the year under review, Mr. Nipun Arora (DIN: 05333399) Independent Director of the Company has resigned from the post of Independent Director on 22<sup>nd</sup> February, 2019. On 1<sup>st</sup> August, 2019 Mrs Seema Chopra (DIN: 08510586) was appointed as Additional as well as Whole-time Director of the company subject to the approval of shareholders in the ensuing Annual General Meeting whereas Mrs Neeraj Batra (DIN: 02229217) has resigned from the directorship of the company w.e.f. 1<sup>st</sup> August, 2019.

### ❖ **DIRECTORS' RESPONSIBILITY STATEMENT:**

Pursuant to the requirement of section 134(5) of the Companies Act, 2013, with respect to Directors' Responsibility Statement, it is hereby confirmed:

1. that in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
2. that the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
3. that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. that the Directors had prepared the annual accounts on a going concern basis; and
5. that the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
6. that the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.





❖ **FORMAL EVALUATION BY BOARD OF ITS OWN PERFORMANCE:**

The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc. The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.

The Board and the Nomination and Remuneration Committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the chairman was also evaluated on the key aspects of his role.

In a separate meeting of independent directors, performance of non-independent directors, performance of the board as a whole and performance of the chairman was evaluated, taking into account the views of executive directors and non-executive directors. Performance evaluation of independent directors was done by the entire board, excluding the independent director being evaluated.

❖ **NUMBER OF MEETINGS OF BOARD:**

During the FY 2018-19, the Board of Directors met eleven times viz. 20<sup>th</sup> April, 2018, 8<sup>th</sup> May, 2018, 17<sup>th</sup> August, 2018, 6<sup>th</sup> September, 2018, 26<sup>th</sup> September, 2018, 26<sup>th</sup> October, 2018, 12<sup>th</sup> December, 2018, 4<sup>th</sup> February, 2019, 1<sup>st</sup> March, 2019, 23<sup>rd</sup> March, 2019 & 28<sup>th</sup> March, 2019.

Name of the Director	Number of Board Meetings Attended
Vijay Kumar Batra	10
Rahul Batra	10
Varun Batra	10
Balwant Singh	11
Neeraj Batra	11
Rohit Parti	11
Nipun Arora	8
Manmohan Khanna	11

Last Annual General Meeting of the company was held on 28<sup>th</sup> September, 2018.

No Extraordinary General Meeting was held during the FY 2018-19.

❖ **DECLARATION BY INDEPENDENT DIRECTORS:**

The Company has received necessary Declaration from each Independent Director/s under section 149(7) of the Companies Act, 2013 that they meets the criteria of Independence laid down in section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

❖ **ISSUE OF EQUITY SHARES WITH DIFFERENTIAL VOTING RIGHTS / SWEAT EQUITY SHARES / EMPLOYEE STOCK OPTION SCHEME:**

During the year, the Company has not issued any equity shares with differential voting rights or sweat equity shares or shares under employee stock option scheme. Hence disclosure regarding the same is not given.



---

#### ❖ STATUTORY AUDITORS

The term of Company's Statutory Auditor **M/s.Kalra Rai & Associates, Chartered Accountants, Chandigarh** having firm registration no.**008859N**, is expiring on conclusion of this 14th Annual General Meeting, Accordingly on the recommendation of the Audit Committee, the Board has proposed the re-appointment of **M/s.Kalra Rai & Associates, Chartered Accountants, Chandigarh (FRN- 008859N)**, for a term of 5 years, i.e. from the conclusion of the 14th Annual General Meeting until the conclusion of the 19th Annual General Meeting subject to approval of members in an ensuing Annual General Meeting.

The Company has also received a confirmation from **M/s.Kalra Rai & Associates, Chartered Accountants, Chandigarh**, to the effect that they are eligible and not disqualified under Section 141 of the Companies Act, 2013 and the Rules framed thereunder, for being appointed as Auditors of the Company. As required under Regulation 33(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Auditors have also confirmed that they hold a valid certificate issued by the Peer Review Board of the Institute of Chartered Accountants of India.

#### ❖ AUDITORS' REPORT:

M/s Kalra Rai & Associates, Chartered Accountants, Chandigarh, Firm Registration Number **008859N** have issued their Report (Standalone & Consolidated) for the financial year ended on March 31, 2019 forms part of this Annual Report and the same does not contain any qualification, reservation or adverse remark hence no explanation or comments of the Board is required in this matter. .

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Companies Act, 2013.

#### ❖ COMMENTS ON AUDITOR'S REPORT

The notes referred to in the Auditor Report are self-explanatory and they do not call for any further explanation as required under section 134 of the Companies Act, 2013.

#### ❖ COST AUDITOR

The Board of Directors of your Company has appointed M/s Charu Jindal & Company, Cost Accountants, Dehradun as Cost Auditors to conduct audit of the Cost Records for Financial Year to be ended on March 31, 2020.

#### ❖ COST RECORDS

The Central Government has prescribed the maintenance of cost records under section 148(1) of the act, for the goods supplied by the Company. The Company had maintained proper cost records.

#### ❖ INTERNAL AUDITOR

The Board of Directors of your Company has appointed M/s Srivastva V.K. & Associates, Chartered Accountants, Chandigarh as Internal Auditors to conduct Internal audit for Financial Year to be ended on March 31, 2020.

#### ❖ SECRETARIAL AUDIT:

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Mr. Dinesh Bhandari, Company

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as “Annexure-1”.

### ❖ COMPANY REPLY TO THE SECRETARIAL AUDITOR QUALIFICATION

Sr No.	Qualification	Company Reply
<u>1.</u>	Clause 33(3)(d) of LODR- submission of non consolidated annual audited financial results as at 31.3.2019 to Stock Exchange with respect to one non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd., Consolidation of Annual Audited Financial Statements as at 31.3.2019 not done in respect of non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd. u/s 129,136 and other relevant provisions of Companies Act, 2013, Company has not made compliance of provisions of Section 96(2) with respect to Annual General Meeting held.	Beta Drugs Limited has incorporated subsidiary company named Beta Ubk International Pvt Ltd. in Uzbekistan, Russia in the month of September, 2018. No commercial activity has taken place till March, 2019 which will have financial impact on the consolidated results of Beta Drugs Limited, therefore the company has not consolidated the Financial Statement of that subsidiary company. The results depict the true and correct picture of the consolidated financial results of the company. The company has done the duly compliance of Section 129,136 and other relevant provisions of Companies Act, 2013; the AGM was duly held as per section 96(2) and attended by the shareholder with requisite quorum required under the Companies Act 2013.
<u>2.</u>	It is further drawn to your attention that on account of vacancy caused by resignation of one independent director w.e.f. 22.02.2019 there is shortfall of one independent Director as on 31.3.2019 required u/s 149 of the Companies Act, 2013, but resultant vacancy of independent Director was to be filled either in the immediate next board meeting held by the Company or within period of 3 months from the date of vacancy i.e. upto 31.5.2019, whichever is later. But no such vacancy of independent Director was filled by the Board within above mentioned time covered under FY 2019-20.	Till date company has not found any suitable & competent candidate who act as guide to the company. The company is in process of finding suitable candidate and fill the vacancy at the earliest possible.

### ❖ INTERNAL AUDIT CONTROLS AND THEIR ADEQUACY

The Company has a proper and adequate system of internal controls, commensurate with the size scale and complexity of its operations. This ensures that all transactions are authorized, recorded and reported correctly, and assets are safeguarded and protected against loss from unauthorized use or disposition. In addition, there are operational controls and fraud risk controls, covering the entire spectrum of internal financial controls.

To maintain its objectivity and independence, the Internal Audit function reports to the Chairman of the audit committee of the Board and to the Chairman and Managing Director. The Internal Audit department monitors and evaluate the efficiency and adequacy of the internal control system in the Company, its compliance with operating systems, accounting procedures and policies at all locations of the Company. Based on the report of internal audit



functions, process owner undertake corrective actions in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

#### ❖ **ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS**

The Company has internal Auditors and the Audit Committee constituted are in place to take care of the same. During the year, the Company continued to implement their suggestions and recommendations to improve the control environment. Their scope of work includes review of processes for safeguarding the assets of the Company, review of operational efficiency, effectiveness of systems and processes, and assessing the internal control strengths in all areas. Internal Auditors findings are discussed with the process owners and suitable corrective actions taken as per the directions of Audit Committee on an ongoing basis to improve efficiency in operations.

#### ❖ **AUDIT COMMITTEE:**

As required under the provisions of section 177 of the Companies Act, 2013 and Rules made there under the Board of Director at its meeting held on 26<sup>th</sup> July, 2017 constituted the Audit Committee. The Audit Committee comprises of the following members:

1.	Mr. Rohit Parti	Chairperson
2.	Mr. Vijay Kumar Batra	Member
3.	Mr. Manmohan Khanna	Member
4.	Mr Nipun Arora	Member

On 22<sup>nd</sup> February, 2019, Mr Nipun Arora (DIN: 05333399) Independent Director of the Company & member of the committee has resigned from the post of Independent Director.

During the year, Audit Committee has met Six times details of the same are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	20 <sup>th</sup> April, 2018	4	4
2.	8 <sup>th</sup> May, 2018	4	4
3.	17 <sup>th</sup> August, 2018	4	4
4.	26 <sup>th</sup> October, 2018	4	4
5.	4 <sup>th</sup> February, 2019	4	4
6.	1 <sup>st</sup> March, 2019	3	3

The term of references of audit committee are to recommend for appointment of statutory auditor, approve related party transactions, examination of financial statements and auditor's report, scrutinize inter corporate loans and investments, evaluation of internal financial control and risk management, review and monitor auditors independence and performance and effectiveness of audit process.

#### **Term of Reference of the Committee**

1. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible.
2. Recommending to the Board, the appointment, re-appointment and, if required, the replacement or removal of the statutory auditor and the fixation of audit fees.
3. Approval of payment to statutory auditors for any other services rendered by the statutory auditors



- 
4. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to:
    - i. Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of section 134 of the Companies Act, 2013;
    - ii. Changes, if any, in accounting policies and practices and reasons for the same;
    - iii. Major accounting entries involving estimates based on the exercise of judgment by management;
    - iv. Significant adjustments made in the financial statements arising out of audit findings;
    - v. Compliance with listing and other legal requirements relating to financial statements;
    - vi. Disclosure of any related party transactions;
    - vii. Qualifications in the draft audit report.
  5. Reviewing, with the management, the half yearly financial statements before submission to the board for approval.
  6. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, right issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/Draft Prospectus/ Prospectus /notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter.
  7. Review and monitor the auditor's independence, performance and effectiveness of audit process.
  8. Approval or any subsequent modification of transactions of the company with related parties;
  9. Scrutiny of inter-corporate loans and investments;
  10. Valuation of undertakings or assets of the company, wherever it is necessary;
  11. Evaluation of internal financial controls and risk management systems;
  12. Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems
  13. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
  14. Discussion with internal auditors any significant findings and follow up there on.
  15. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.
  16. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
  17. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
  18. To oversee and review the functioning of the vigil mechanism which shall provide for adequate safeguards against victimization of employees and directors who avail of the vigil mechanism and also provide for direct access to the Chairperson of the Audit Committee in appropriate and exceptional cases.



19. Call for comments of the auditors about internal control systems, scope of audit including the observations of the auditor and review of the financial statements before submission to the Board;
20. Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience & background, etc. of the candidate.
21. To investigate any other matters referred to by the Board of Directors;
22. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee.

The Audit Committee shall mandatorily review the following information:

- a. Management discussion and analysis of financial information and results of operations;
- b. Statement of significant related party transactions (as defined by the Audit Committee), submitted by the management;
- c. Management letters / letters of internal control weaknesses issued by the statutory auditors;
- d. Internal audit reports relating to internal control weaknesses; and
- e. The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the Audit Committee.

#### ❖ **NOMINATION & REMUNERATION COMMITTEE:**

As required under the provisions of section 178 of the Companies Act, 2013 and Rules made there under the Board of Director at its meeting held on 26<sup>th</sup> July, 2017 constituted the Nomination and Remuneration Committee. The Nomination and Remuneration Committee consists of the following members:

1.	Mr. Rohit Parti	Chairperson
2.	Mr. Vijay Kumar Batra	Member
3.	Mr. Manmohan Khanna	Member
4.	Mr Nipun Arora	Member

On 22<sup>nd</sup> February, 2019, Mr Nipun Arora (DIN: 05333399) Independent Director of the Company & member of the committee has resigned from the post of Independent Director.

During the year, two meeting of the nomination and remuneration committee was held. Details of the Meeting are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	20 <sup>th</sup> April, 2018	4	4
2.	17 <sup>th</sup> August, 2018	4	4

#### (i) **Term of Reference of the Committee**

- To identify persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal and shall carry out evaluation of every Director's performance.
- To formulate the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy, relating to the remuneration for the Directors, Key Managerial Personnel and other employees.
- The Nomination and Remuneration Committee shall, while formulating the policy ensure that:



- (i) the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully;
- (ii) relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
- (iii) remuneration to Directors, Key Managerial Personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals:
- Regularly review the Human Resource function of the Company.
  - Discharge such other function(s) or exercise such power(s) as may be delegated to the Committee by the Board from time to time.
  - Make reports to the Board as appropriate.
  - Review and reassess the adequacy of this charter periodically and recommend any proposed changes to the Board for approval from time to time.
  - Any other work and policy, related and incidental to the objectives of the committee as per provisions of the Act and rules made there under.

(ii) **Remuneration Policy:**

**Website link:-**

**<http://www.betadrugslimited.com/pdfs/betapolicies/PolicyonRemunerationNominationandBoarDiversity.PDF>**

**(a) Remuneration to Executive Directors:**

The remuneration paid to executive directors of the Company is recommended by the Nomination and Remuneration Committee of the Company and then Board of the Company approve in their duly held meeting. The remuneration of executive directors are decided by considering various criteria like qualification, experience, responsibilities, value addition to the Company and financial position of the Company. Board is taking permission of the members if required at any time for paying remuneration to executive directors.

**(b) Remuneration to Non-Executive Directors:**

Company is not paying any remuneration to non-executive and independent directors of the Company except sitting fees of Rs 5000/- per meeting.

❖ **STAKEHOLDERS RELATIONSHIP COMMITTEE:**

As required under the provisions of section 178 of the Companies Act, 2013 and Rules made there under the Board of Director at its meeting held on 26<sup>th</sup> July, 2017 constituted the Stakeholders Relationship Committee. The Stakeholders Relationship Committee consists of the following members:

1.	Mr. Rohit Parti	Chairperson
2.	Mr. Vijay Kumar Batra	Member
3.	Mr. Manmohan Khanna	Member
4.	Mr Nipun Arora	Member

The Company has not received any complaints during the year. There was no valid request for transfer of shares pending as on 31st March, 2019. Mrs. Rajni Brar, Company Secretary is the Compliance Officer for the above purpose. On 22<sup>nd</sup> February, 2019, Mr Nipun Arora (DIN: 05333399) Independent Director of the Company & member of the committee has resigned from the post of Independent Director.



## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

During the year, three meeting of the Stakeholders Relationship Committee was held. Details of the Meeting are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	20 <sup>th</sup> April, 2018	4	4
2.	17 <sup>th</sup> August, 2018	4	4
3.	4 <sup>th</sup> February, 2019	4	4

### **Term of Reference of the Committee**

- i. Efficient transfer of shares; including review of cases for refusal of transfer / transmission of shares and debentures;
- ii. Redressal of security holder's/investor's complaints Efficient transfer of shares; including review of cases for refusal of transfer / transmission of shares and debentures;
- iii. Reviewing on a periodic basis the approval/refusal of transfer or transmission of shares, debentures or any other securities;
- iv. Issue of duplicate certificates and new certificates on split/consolidation/renewal;
- v. Reference to statutory and regulatory authorities regarding investor grievances; and
- vi. To otherwise ensure proper and timely attendance and redressal of investor queries and grievances;
- vii. To take note of Dematerialisation and Rematerialisation requests received from the shareholders of the company.
- viii. Any other power specifically assigned by the Board of Directors of the Company

### **❖ POLICY ON PRESERVATION OF THE DOCUMENTS**

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents to ensure safe keeping of the records and safeguard the Documents from getting manhandled, while at the same time avoiding superfluous inventory of Documents.

### **❖ POLICY ON CRITERIA FOR DETERMINING MATERIALITY OF EVENTS**

The Policy is framed in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The objective of the Policy is to determine materiality of events or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall governance framework for such determination of materiality.

### **❖ RISK MANAGEMENT POLICY/PLAN:**

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Hence, the company has not developed and implemented any risk management policy/plan but the Company has adequate internal control systems and procedures to combat the risk.

### **❖ VIGIL MECHANISM:**

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.





---

Hence, there is no vigil mechanism in the company.

❖ **CODE OF BUSINESS CONDUCT AND ETHICS:**

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of Internal Procedures and code for prevention of insider trading ("Code of Conduct"), as approved by the Board from time to time, are in force by the Company. The objective of this Code of Conduct is to protect the interest of shareholders at large, to prevent misuse of any price sensitive information and to prevent any insider trading activity by dealing in shares of the Company by its Directors, designated employees and other employees.

The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, designated employees and other employees from trading in the securities of Beta Drugs Limited at the time when there is unpublished price sensitive information. The COC is available on the website of the Company [www.betadrugslimited.com](http://www.betadrugslimited.com).

❖ **DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:**

The company has a policy and it provides for protection against sexual harassment of woman at work place and for prevention and redressal of such complaints. The Company has zero tolerance on Sexual Harassment at workplace. During the year under review, no complaints were received against the sexual harassment at workplace.

❖ **REMUNERATION POLICY:**

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration.

The Company's shareholders may refer the Company's website for the detailed Nomination & Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under sub-section (3) of section 178.

The Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically.

The remuneration policy is in consonance with the existing industry practice.

❖ **ANALYSIS OF REMUNERATION:**

The details of remuneration paid to Directors and Key Managerial Personnel is given in extract of Annual Return attached with this report.

Disclosure/details pursuant to provisions of Section 197(12) of the Companies Act 2013 read with Companies (appointment and Remuneration of managerial personnel) Rules, 2014 are given as follows:

1) The percentage increase in Remuneration of each Director, Chief Financial Officer and Company Secretary in the financial year 2018-19 and ratio of remuneration of each key managerial personnel (KMP) against the performance are as under:-



Sr No.	Name of Director/KMP and Designation	Remuneration of Director/KMP for the Financial Year 2018-19 (In Rs.)	% age Increase in Remuneration for the Financial Year 2018-19	Ratio of Remuneration of each director to the Median Remuneration of Employees
1.	Mr. Vijay Kumar Batra, Chairman cum Managing Director	NIL	NIL	NIL
2.	Mrs. Neeraj Batra, Whole Time Director	32,00,000	33.33%	26.27
3.	Mr. Varun Batra, Whole Time Director	36,00,000	50%	29.55
4.	Mr Balwant Singh, Whole Time Director	16,32,000	12.40%	13.40
5.	Mr. Rahul Batra, Whole Time Director	12,00,000	NIL	9.85
6.	Mr Manmohan Khanna, Independent Director	Only sitting fee of Rs20,000/-	NIL	NIL
7.	Mr. Rohit Parti, Independent Director	Only sitting fee of Rs20,000/-	NIL	NIL
8.	Mr. Nipun Arora, Independent Director (resigned w.e.f. 22 <sup>nd</sup> Feb, 2019)	Only sitting fee of Rs20,000/-	NIL	NIL
9.	Mrs Rajni Brar, Company Secretary	5,28,000	38.36%	4.33
10.	Mr Jayant Kumar, CFO	11,04,000	25.11%	9.06

2) The Median Remuneration of Employees of the Company during the financial year 2018-19 was Rs.1,21,816/-

3) There was a decrease of 31.70% in median remuneration of employees during the financial year.

4) The number of permanent employees on the rolls of the Company is 181 for the year ended March 31, 2019.

5) There was an increase of 12.60% in salaries of employees other than the managerial personnel during the financial year 2018-19 .

6) It is affirmed that remuneration paid during the year ended March 31st, 2019 is as per the Remuneration Policy of the Company.

#### ❖ **PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:**

There was no employee drawing remuneration in excess of limits prescribed under section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The Disclosure pertaining to remuneration as required under section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016 are as per **Annexure - 2**.

#### ❖ **REGULATORY ORDERS:**

During the year, there were no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

❖ **CSR COMMITTEE:**

During the year under company has constitute a CSR Committee comprising following members:

1.	Mr Vijay Kumar Batra	Chairman
2.	Mr Rahul Batra	Member
3.	Mr Rohit Parti	Member

During the year, three meeting of the Corporate Social Responsibility Committee was held. Details of the Meeting are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	4 <sup>th</sup> May, 2018	3	3
2.	26 <sup>th</sup> September, 2018	3	3
3.	18 <sup>th</sup> March, 2019	3	3

The Committee has been entrusted with the responsibility of formulating and recommending to the Board, a Corporate Social Responsibility Policy (CSR Policy), indicating the activities to be undertaken by the Company, recommending the amount to be spent on CSR activities and monitoring the implementation of the framework of the CSR Policy.

During the year 2018-19, the Company was required to incur CSR expenditure of **Rs 9,64,392** being 2% of the average net profits for the immediately preceding three Financial Years. In compliance with this requirement, the Company has spent **Rs 4,59,668** on eligible projects approved by the Board on the recommendation of the CSR Committee and amount of **Rs 5,04,724** remain unspent for the year under review. Brief particulars of the CSR projects undertaken are given in **Annexure 3**, forming part of the Board's Report.

❖ **DETAILS ON CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:**

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3) (m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014.

**(A) CONSERVATION OF ENERGY**

(i)	the steps taken or impact on conservation of energy	The Company accords high priority to conservation of energy. However, there are no specific steps taken in this regard.
(ii)	the steps taken by the company for utilizing alternate sources of energy	The Company is not utilizing alternate sources of energy.
(iii)	the capital investment on energy conservation equipments	NIL

**(B) TECHNOLOGY ABSORPTION**

(i)	the efforts made towards technology absorption	NIL
(ii)	the benefits derived like product improvement, cost reduction, product development or import substitution	NIL
(iii)	in case of imported technology (imported during the last three years reckoned from the beginning	The Company has not imported any technology during the year. Hence, there are no details to be



	of the financial year) (a) the details of technology imported;  (b) the year of import;  (c) whether the technology been fully absorbed;  (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	furnished under this clause.
(iv)	the expenditure incurred on Research and Development	There are no expenditure incurred on Research and Development by the Company.

**(C) Foreign exchange earnings and Outgo:**

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows are given below :

Particulars	Amt. as on 31.3.2019	Amt. as on 31.3.2018
Earnings in Foreign Exchange	4,85,00,674	1,44,15,249.91
Foreign Exchange Outgo	46,31,700	1,08,46,771

❖ **INTERNAL FINANCIAL CONTROL:**

The Company has a well placed, proper and adequate internal financial control system which ensures that all the assets are safeguarded and protected and that the transactions are authorized recorded and reported correctly.

The internal audit covers a wide variety of operational matters and ensures compliance with specific standard with regards to availability and suitability of policies and procedures. During the year no reportable material weakness in the design or operation were observed.

The Directors has laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and have been operating effectively.

❖ **COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND ANNUAL GENERAL MEETINGS**

The Company has complied with Secretarial Standards issued by the Institute of Company Secretaries of India on Board meetings and Annual General Meetings.

❖ **DEPOSITS:**

The Company has not invited/ accepted any deposits from the public during the year ended March 31, 2019. There were no unclaimed or unpaid deposits as on **March 31, 2019**. No unsecured loan has been received from the Directors of the company.



### ❖ CORPORATE GOVERNANCE:

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Hence, the Report on Corporate Governance is not forming part of the Directors' Report.

### ❖ TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND

Your Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

### ❖ EXTRACT OF ANNUAL RETURN:

Extract of Annual Return in Form No. MGT-9 as per Section 134 (3) (a) of the Companies Act, 2013 read with Rule 8 of Companies (Accounts) Rules, 2014 and Rule 12 of Companies (Management & Administration) Rules, 2014 is attached as **Annexure-4**, forming part of the Board's Report. The same is also available on the Company's website at [www.betadrugslimited.com](http://www.betadrugslimited.com).

### ❖ PARTICULARS OF LOANS, INVESTMENTS OR GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The company has not provided any guarantee or provided any security to any person for the loans availed by others. The details regarding the loan and advances, investment if any are provided in the Balance Sheet.

### ❖ RELATED PARTY TRANSACTIONS:

The particulars of every contract or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso Form No. AOC -2, given below:

#### Related Party Transactions:

#### **Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the form AOC-2:**

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business.

Information Pursuant to *clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014:*

#### 1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NIL
b)	Nature of contracts/arrangements/transaction	-



c)	Duration of the contracts / arrangements /transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	-
e)	Justification for entering into such contracts or arrangements or transactions'	-
f)	Date of approval by the Board	-
g)	Amount paid as advances, if any	-
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	-

## 2. Details of material contracts or arrangements or transactions at Arm's length basis.

SL. No.1	Particulars	Details
a)	Name (s) of the related party & nature of relationship	<b>Adley Lab Limited</b>
b)	Nature of contracts/Arrangements /transaction	Purchase of Goods
c)	Duration of the contracts/Arrangements /transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Total amount involved during the year is Rs 7,18,82,648.20/-
e)	Date of approval by the Board	14 <sup>th</sup> March, 2018
f)	Amount paid as advances, if any	-
SL. No.2	Particulars	Details
a)	Name (s) of the related party & nature of relationship	<b>Adley Formulations</b>
b)	Nature of contracts/ arrangements /transaction	i) Sale of Goods-Rs 20,72,137.47 ii) Purchase of Goods-Rs 5,29,257
c)	Duration of the contracts/Arrangements /transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Total amount involved during the year is Rs 26,01,394.47/-
e)	Date of approval by the Board	14 <sup>th</sup> March, 2018
f)	Amount paid as advances, if any	-
SL.No.3	Particulars	Details
a)	Name (s) of the related party & nature of relationship	<b>BT Associates Pvt Ltd.</b>



b)	Nature of contracts /arrangements /transaction	Payment of Building Rent
c)	Duration of the contracts /arrangements /transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Total amount involved during the year is Rs 34,08,595/-
e)	Date of approval by the Board	14 <sup>th</sup> March, 2018
f)	Amount paid as advances, if any	-
<b>SL.No.4</b>	<b>Particulars</b>	<b>Details</b>
g)	Name (s) of the related party & nature of relationship	<b>Adley Formulations Pvt Ltd</b>
h)	Nature of contracts /arrangements /transaction	Sale of Goods
i)	Duration of the contracts /arrangements /transaction	-
j)	Salient terms of the contracts or arrangements or transaction including the value, if any	Total amount involved during the year is Rs 10,64,392/-
k)	Date of approval by the Board	31 <sup>st</sup> August, 2019
l)	Amount paid as advances, if any	-

❖ **MANAGEMENT DISCUSSION AND ANALYSIS:**

As per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, the Management Discussion and Analysis Report is given in **Annexure - 5**.

❖ **APPRECIATION:**

Your Directors wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Your Directors also take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, Practicing Company Secretary, Auditors, Supplier, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

**Dated: 31.08.2019**

**Place: Panchkula**

**By Order of the Board of Directors**

**sd/-**

**Vijay Kumar Batra**

**Chairman & Managing Director  
(DIN: 01083215)**



**Secretarial Audit Report for the Financial Year Ended March 31, 2019**

To

The Members of

**BETA DRUGS LIMITED (CIN : L24230HP2005PLC028969)**

Regd. Office :Village Nandpur, Baddi, Himachal Pradesh-174101.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **BETA DRUGS LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2019 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2019 according to the provisions of :

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder to the extent of Regulation 55A;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
  - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013 ;
  - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ;
  - c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and amended thereon.;
  - d) The Securities and Exchange Board of India (Share Based employee Benefits) Regulations, 2014;





e) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client to the extent of securities issued;

f) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendment thereon;

g) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.

(vi) The other laws, as informed and certified by the management of the Company which are specifically applicable to the Company based on their sectors/ industry are :

- (a) Drugs & Cosmetics Act, 1940
- (b) Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954
- (c) Narcotic Drugs and Psychotropic Substances Act, 1985
- (d) Conservations of Foreign Exchange And Prevention of Smuggling Activities Act, 1974
- (e) The Medicinal & toilet Preparations Substances (Excise Duties) Act, 1955
- (f) The Environment (Protection) Act, 1986
- (g) Hazardous Waste Management Rules, 2016
- (h) The Indian Copyright Act, 1957
- (i) The Patents Act, 1970
- (j) The Trade Marks Act, 1999

We have also examined compliance with the applicable clauses of the following :

(i) Secretarial Standards issued by The Institute of Company Secretaries of India.

(ii) The Listing Agreements entered into by the Company with NSE Limited (SME segment) and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations mentioned above in this report **except the following :**

*Clause 33(3)(d) of LODR- submission of non consolidated annual audited financial results as at 31.3.2019 to Stock Exchange with respect to one non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd.; Consolidation of Annual Audited Financial Statements as at 31.3.2019 not done in respect of non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd. u/s 129,136 and other relevant provisions of Companies Act, 2013; Company has not made compliance of provisions of Section 96(2) with respect to Annual General Meeting held.*

We further report that compliance by the Company of applicable financial laws like direct and indirect tax laws and maintenance of financial record and books of accounts has not been reviewed in this Audit, since the same has been subject to review by statutory financial audit and other designated professionals.

We further report that :

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act. ***It is further drawn to your attention that on account of vacancy caused by resignation of one independent director w.e.f. 22.2.2019 there is***

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

*shortfall of one independent Director as on 31.3.2019 required u/s 149 of the Companies Act, 2013, but resultant vacancy of independent Director was to be filled either in the immediate next board meeting held by the Company or within period of 3 months from the date of vacancy i.e. upto 31.5.2019, whichever is later. But no such vacancy of independent Director was filled by the Board within above mentioned time covered under FY 2019-20.*

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period no specific events / actions took place that having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards.

Sd/-

**CS. Dinesh Bhandari / Proprietor**

Practising Company Secretary

Membership No. FCS No.: 5887

Certificate of Practice No.: 10300

**Place : Chandigarh**

**Date : 31.08.2019**

**Note : This report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.**



Annexure -A

The Members

**BETA DRUGS LIMITED (CIN : L24230HP2005PLC028969)**

Regd. Office : Village Nandpur, Baddi, Himachal Pradesh-174101.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the random test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and major events during the audit period.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on the random test basis for the purpose of the Secretarial Audit Report.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Sd/-

**CS. Dinesh Bhandari**

Practising Company Secretary

Membership No. FCS No.: 5887

Certificate of Practice No.: 10300

**Place : Chandigarh**

**Date : 31.08.2019**

**Annexure:2**

Statement showing the name of the top ten employees in terms of remuneration drawn:

Name	Designation/Nature of Duties	Nature of employment whether contractual or otherwise	Relation with Director or Manager of Company	Remuneration in Rs per month	Qualification	Experience	Date of Joining	Age (years) / DOB	Last Employment before	% Equity Shares held
Varun Batra	Whole Time Director	otherwise	Son of Mr Vijay Kumar Batra & Mrs Neeraj Batra and Brother of Mr Rahul Batra	3,00,000	Degree in Business Management from Toronto Canada	14	01/08 /2014	15/06 /1985	NA	0.35 %
Rahul Batra	Whole Time Director	otherwise	Son of Mr Vijay Kumar Batra & Mrs Neeraj Batra and Brother of Mr Varun Batra	3,00,000	Master of Science degree in Business and Management from University Strathclyde Scotland	14	01/08 /2014	08.10.1983	NA	0.36 %
Ashutosh Shukla	VP Sales & Marketing	otherwise	Nil	2,33,333	MBA	18	27/03 /2019	07.09.1977	Torrent Pharmaceuticals Limited	Nil
Sudhir Rajput	Sales Head	otherwise	Nil	1,64,000	Post Graduation	21	01/07 /2017	08.12.1975	Ferring International MNC	Nil
Balwant Singh	Whole Time Director	otherwise	Nil	1,36,000	MA, PGDPM/HR/IR	20	01/04 /2015	04.04.1970	Adley Formulations	0.01 %
Siddhartha Kundu	Marketing Head	otherwise	Nil	1,16,533	Post Graduation	30	01/07 /2017	23.06.1967	Alchem	Nil
Jayant Kumar	C.F.O	otherwise	Nil	99,964	B.Com	23	17/07 /2017	28.04.1974	Adley Formulations	Nil
Rohit Modi	Production Head	otherwise	Nil	99,542	B.Pharma + MBA in Prod. Mng.	13	13/02 /2016	07.11.1981	Nector Life Science Baddi	Nil
Rajesh Kumar Mishra	Production Head (OSD)	otherwise	Nil	95000	B.Pharma	10	01/11 /2014	07.05.1983	Adley Formulations	Nil
Raval Nitin Kumar	Zonal Business Manager	otherwise	Nil	95700	B.Sc.	16	01/07 /2017	13.06.1973	United Biotech Pvt Ltd.	Nil

**ANNEXURE TO BOARD'S REPORT**

**A brief outline of the Company's CSR Policy, including overview of projects or programmes proposed to be undertaken and a reference to the web-link to the CSR Policy and projects or programmes:**

The Company's CSR Policy is in adherence to the updated Section 135 of the Companies Act, 2013 read with rules framed thereunder and provides for carrying out CSR activities and Initiate projects that benefit communities, encourage an increased commitment from employees towards CSR activities and volunteering and contribution towards some specific project being undertaken by any of the organisations or directly by the Company.

The web-link for the CSR Policy of the Company is as under:

**<http://www.betadrugslimited.com/pdfs/betapolicies/CSRPOLICY.pdf>**

**Composition of CSR Committee:** Our CSR Committee consists of Mr. Vijay Kumar Batra, Chairman, Mr. Rahul Batra & Mr Rohit Parti, Members.

**Average Net Profits of the Company for the last three Financial Years for FY 2017-18: Rs 2,29,83,404.75**

**Average Net Profits of the Company for the last three Financial Years for FY 2018-19: Rs 4,82,19,593.77**

**Prescribed CSR Expenditure (2% of the above amount) FY 2017-18: Rs 4,59,668**

**Prescribed CSR Expenditure (2% of the above amount) FY 2018-19: Rs 9,64,392**

**Details of CSR spend during the Financial Year**

**Figures in Rs**

Sr No.	Particulars	Financial Year 2017-18	Financial Year 2018-19
a)	Total amount to be spent for the Financial Year	4,59,668	9,64,392
b)	Amount Spent	NIL	4,59,668
c)	Amount unspent, if any	4,59,668	5,04,724
d)	Reason for unspent	The reason for under spending is that Company is yet to identify social works/project as per schedule VII of the Companies Act 2013 and the Company proposed to spend the amount on CSR preferably near to the units of the Company and has already devised a CSR Policy and is in process of contributing towards social development in its nearby areas.	



The manner in which the amount was spent during the Financial Year 2018-19 is detailed below:

CSR Project/ activity/ beneficiary	Sector	Location of the project / program	Amount outlay (Budget)	Amount spent on the projects or programs	Cumulative expenditure up to the reporting period	Amount spent directly / implementing agency
Chief Minister Distress Relief Fund (Flood in Kerala)	Department of Health & Family Welfare	Kerala	200000	200000	200000	Implementing Agency
Blood Donation Camp	Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh	Saketri, Panchkula	151891	151891	151891	Implementing Agency
Vishwa Prakash Mission	Education	Faridabad, Haryana	107777	107777	107777	Implementing Agency

**Responsibility Statement:**

The responsibility statement of CSR Committee of the Board of Directors of the Company is reproduced below:

“The implementation and monitoring of Corporate Social Responsibility (CSR) Policy is in compliance with the CSR Objectives and Policy of the Company.”

Place: Panchkula

Date: 31<sup>st</sup> August, 2019

sd/-

**Vijay Kumar Batra**  
Chairman of CSR Committee  
(DIN: 01083215)

sd/-

**Rahul Batra**  
Whole-time Director  
(DIN: 02229234)



## ANNEXURE-4

## EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31.3.2019

*[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]*

**I. REGISTRATION AND OTHER DETAILS:**

i.	<b>CIN</b>	L24230HP2005PLC028969
ii.	<b>Registration Date</b>	21/09/2005
iii.	<b>Name of the Company</b>	<b>BETA DRUGS LIMITED</b>
iv.	<b>Category/Sub-Category of the Company</b>	LIMITED COMPANY/ LISTED WITH NATIONAL STOCK EXCHANGE OF INDIA LIMITED
v.	<b>Address of the Registered office and contact details</b>	Village Nandpur, Baddi Himachal Pradesh-174101 INDIA
vi.	<b>Whether listed company</b>	YES
vii.	<b>Name, Address and Contact details of Registrar and Transfer Agent, if any</b>	Link Intime India Pvt Ltd. C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai-400083.

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10% or more of the total turnover of the company shall be stated : -

Sr. No.	Name and Description of main products/ services	NIC Code of the Product/ service	% to total turnover of the company
1	Manufacture of Pharmaceuticals	2100	100

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES**

Sr. No.	Name And Address Of The Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable Section
1.	Beta Ubk International Private Limited, having works & registered office at: 27, blind alley of Alimkent, Yashnabad District, Tashkent City, Uzbekistan	Registered in Unified State Register of business entities under record No. 633854 on 07.09.2018	Subsidiary	60%	2(87)

# 14<sup>TH</sup> ANNUAL REPORT



BETA DRUGS LIMITED

2.	Adley Formulations Private Limited, having Registered office at SCO-184, Sector-5, Panchkula-134114 & Works at Kotla, Barotiwala, Distt Solan, Himachal Pradesh	U24303HR2018PTC076347	Subsidiary	100%	2(87)
----	-----------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------	------------	------	-------

## IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

### i. Category-wise Shareholding

Category of Shareholders	No. of Shares held at the beginning of the year 1 <sup>st</sup> April, 2018				No. of Shares held at the end of the year 31 <sup>st</sup> March, 2019				% Change during The year
	Demat	Physical	Total	% of Total Shares	Dem at	Physical	Total	% of Total Shares	
<b>A. Promoter</b>									
1) Indian									
a) Individual/ HUF	5958410	-	5958410	68.89	6007210	-	6007210	69.45	+0.56
b) Central Govt	-	-	-	-	-	-	-	-	-
c) State Govt(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp	-	-	-	-	-	-	-	-	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any Other (firm)	-	-	-	-	-	-	-	-	-
Sub-total(A)(1):-	5958410	-	5958410	68.89	6007210	-	6007210	69.45	+0.56
2) Foreign									
g) NRIs-Individuals	-	-	-	-	-	-	-	-	-
h) Other-Individuals	-	-	-	-	-	-	-	-	-
i) Bodies Corp.	-	-	-	-	-	-	-	-	-
j) Banks / FI	-	-	-	-	-	-	-	-	-
k) Any Other....	-	-	-	-	-	-	-	-	-



# 14<sup>TH</sup> ANNUAL REPORT



BETA DRUGS LIMITED

Sub-total(A)(2):-	-	-	-	-	-	-	-	-	-
Total shareholding of promoters	5958410	0	5958410	68.89	6007210	-	6007210	69.45	+0.56
<b>B. Public Shareholding</b>									
1. Institutions	-	-	-	-	-	-	-	-	-
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total(B)(1)	-	-	-	-	-	-	-	-	-
2. Non Institutions									
a) Bodies Corp.									
(i) Indian	866800	-	866800	10.02	647019	-	647019	7.48	-2.54
(ii) Overseas									
b) Individuals									
(i) Individual shareholders holding nominal share capital upto Rs. 2 lakh	967425	22000	989425	11.43	1220371	-	1220371	14.11	+2.68
(ii) Individual shareholders holding nominal						-			

# 14<sup>TH</sup> ANNUAL REPORT



BETA DRUGS LIMITED

share capital in excess of Rs 2 lakh	513800	-	513800	5.94	501800		501800	5.80	-0.14
<b>c) Others(Specify)</b>									
Trust	32000	-	32000	0.37	64800	-	64800	0.75	+0.38
Hindu Undivided Family	95200	-	95200	1.1	95400	-	95400	1.10	-
Non Resident Indians (Non Repat)	4000	-	4000	0.04	10400	-	10400	0.12	+0.08
Non Resident Indians (Repat)	11200	-	11200	0.12	22400	-	22400	0.26	+0.14
Clearing Member	178665-	-	178665	2.01	72100	-	72100	0.83	-1.18
NBFCs registered with RBI	-	-	-	-	8000	-	8000	0.09	+0.09
Sub-total(B)(2)	2669090	22000	2691090	31.11	2642290	-	2642290	30.55	-0.56
Total Public Shareholding (B)=(B)(1)+ (B)(2)	2669090	22000	2691090	31.11	2642290	-	2642290	30.55	-0.56
C.Shares held by Custodian for GDRs&ADRs	-	-	-	-					
Grand Total (A+B+C)	8627500	22000	8649500	100	8649500	-	8649500	100	-

## ii. Shareholding of Promoters

Sr. No	Shareholder's Name	Shareholding at the beginning of the year 1 <sup>st</sup> April, 2018			Shareholding at the end of the year 31 <sup>st</sup> March, 2019			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Vijay Kumar Batra	5924780	68.50%	-	5973580	69.06%	-	+0.56%
2.	Varun Batra	14750	0.17%	-	14750	0.17%	-	-
3.	Rahul Batra	14750	0.17%	-	14750	0.17%	-	-
4.	Neeraj Batra	2950	0.03%	-	2950	0.03%	-	-
5.	Aditi Batra	590	0.01%	-	590	0.01%	-	-
6.	Heena Batra	590	0.01%	-	590	0.01%	-	-

# 14<sup>TH</sup> ANNUAL REPORT



BETA DRUGS LIMITED

	TOTAL	5958410	68.89%	-	6007210	69.45	-	+0.56%
--	-------	---------	--------	---	---------	-------	---	--------

## iii. Change in Promoters' Shareholding : YES

Sr. no		Shareholding at the beginning of the year 1 <sup>st</sup> April, 2018		Cumulative Shareholding during the year i.e. 31 <sup>st</sup> March, 2019	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Vijay Kumar Batra	5924780	68.50%	5973580	69.06%
2.	Varun Batra	14750	0.17%	14750	0.17%
3.	Rahul Batra	14750	0.17%	14750	0.17%
4.	Neeraj Batra	2950	0.03%	2950	0.03%
5.	Aditi Batra	590	0.01%	590	0.01%
6.	Heena Batra	590	0.01%	590	0.01%

## (iii) Shareholding Pattern of top ten Shareholders:

(Other than Directors, Promoters and Holders of GDRs and ADRs):

Sr No	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year 1 <sup>st</sup> April, 2018		Cumulative Shareholding during the Year i.e. 31 <sup>st</sup> March, 2019	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Pantomath Stock Brokers Private Limited	134,400	1.5538	1,20,800	1.3966
2.	Jmp Securities Pvt. Ltd.	112,000	1.2949	48,00	0.0555
3.	Adesh Ventures Llp	105,600	1.2209	1,60,000	1.8498
4.	Valuworth Capital Management Pvt Ltd	104,000	1.2024	0	0
5.	Edelweiss Broking Ltd	75,200	0.8694	21,600	0.2497
6.	Sandla Bhandari	75,000	0.8671	600	0.0069
7.	Ecap Equities Limited	70,400	0.8139	0	0
8.	Globe Capital Market Ltd	70,000	0.8093	1600	0.0184
9.	Chetan M. Kothari Priti Chetan Kothari	60,800	0.7029	51,200	0.5919
10.	Sudhir Kumar	57,600	0.6659	50,400	0.5827



## (iv) Shareholding of Directors and Key Managerial Personnel:

Sr. No.	Shareholding of Directors and Key Managerial Personnel	Shareholding at the beginning of the year 1 <sup>st</sup> April, 2018		Cumulative Shareholding during the Year i.e. 31 <sup>st</sup> March, 2019	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Mr. Vijay Kumar Batra, Chairman cum Managing Director	5924780	68.50%	5973580	69.06%
2	Mr. Varun Batra, Whole Time Director	14750	0.17%	14750	0.17%
3	Mr. Rahul Batra, Whole Time Director	14750	0.17%	14750	0.17%
4	Mr. Balwant Singh, Whole Time Director	590	0.01%	590	0.01%
5	Mr. Neeraj Batra, Whole Time Director	2950	0.03%	2950	0.03%
6	Mr. Manmohan Khanna, Independent Director	-	-	-	-
7	Mr. Rohit Parti, Independent Director	-	-	-	-
8	Mrs. Rajni Brar, Company Secretary	-	-	-	-
9	Mr. Jayant Kumar, Chief Financial Officer	-	-	-	-

**V. INDEBTEDNESS**

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	6,99,89,997.35	67,29,255	-	7,67,19,252.35
i) Principal Amount				
ii) Interest due but not paid				
iii) Interest accrued but not				
Total(i+ii+iii)	6,99,89,997.35	67,29,255	-	7,67,19,252.35
Change in Indebtedness during the financial year				
- Addition				
- Reduction	65,97,547.53	-		65,97,547.53
	-	(11,54,074)		(11,54,074)
Net Change	65,97,547.53	(11,54,074)	-	54,43,473.53
Indebtedness at the end of the financial year				
i) Principal Amount				
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	7,65,87,544.88	55,75,181.00	-	8,21,62,725.88

**VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL****A. Remuneration to Managing Director, Whole-time Directors and /or Manager**

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount
1.	(i) Gross salary	Mr. Vijay Batra, Chairman cum Managing Director	-
	(a) Salary as per provisions contained in section 17(1) of the Income- tax Act, 1961		
	(b) Value of perquisites u/s 17(2) Income- tax Act, 1961		
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961		
	(ii) Gross salary	Varun Batra, whole time director	36 lacs
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961		
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961		
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961		
	(iii) Gross salary	Rahul Batra, whole time Director from 01.12.2018 to 31.03.2019	12 lac
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961		
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961		
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961		
	(iv) Gross salary	Neeraj Batra, whole Time Director (paid till 30 <sup>th</sup> Nov, 2018) from 5 <sup>th</sup> December, 2018 Mrs Neeraj Batra step down from the post of Whole- time director to Non-Executive Director	32 lacs
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961		
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961		

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

	(c)Profits in lieu of salary under section17(3)Income- taxAct,1961  (v) Gross salary (a)Salary as per provisions contained insection17(1) of the Income-tax Act, 1961  (b)Value of perquisites u/s 17(2) Income-tax Act,1961  (c)Profits in lieu of salary under section17(3)Income- taxAct,1961	Balwant Singh, Whole Time Director				16.32 lacs
2.	Stock Option					NIL
3.	Sweat Equity					NIL
4.	Commission - as % of profit - others, specify					NIL
5.	Others, please specify					NIL
6.	Total(A)					96.32 lacs
	Ceiling as per the Act	Within prescribed limit of Schedule V of the Companies Act, 2013.				

## **B. Remuneration to other directors:**

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount
	<u>Independent Directors</u>	Manmohan Khanna	Rohit Parti	Nipun Arora		
	·Fee for attending board committee meetings ·Commission ·Others,please specify	20,000	20,000	20,000		60,000
	Total(1)	20,000	20,000	20,000		60,000
	<u>Other Non-Executive Directors</u>					
	·Fee for attending board committee meetings					NIL

# 14<sup>TH</sup> ANNUAL REPORT



BETA DRUGS LIMITED

	·Commission ·Others, please specify					
	Total(2)					NIL
	Total(B)=(1+2)					NIL
	Total Managerial Remuneration					60,000
	Overall Ceiling as per the Act					-

## C. Remuneration to Key Managerial Personnel Other Than MD/Manager/WTG :

Sr. no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a)Salary as per provisions contained in section17(1)of the Income-tax Act,1961  (b)Value of perquisites u/s 17(2)Income-tax Act,1961  (c)Profits in lieu of salary under section 17(3)Income-tax Act,1961	-	528000	11,04,000	16,32,000
2.	Stock Option				NIL
3.	Sweat Equity				NIL
4.	Commission - as %of profit -others, specify...				NIL
5.	Others ,please specify				NIL
6.	Total		528000	11,04,000	16,32,000

## VII. PENALTIES/ PUNISHMENT/ COMPOUNDING OF OFFENCES: YES

Type	Section of the companies Act	Brief description	Details of Penalty/ Punishment/Compounding fees imposed	Authority[RD /NCLT/Court]	Appeal made. If any(give details)
A. Company					
Penalty	NIL				
Punishment	NIL				
Compounding	87	Compounding of	Rs 4000/-	RD	-

**14<sup>TH</sup> ANNUAL REPORT****BETA DRUGS LIMITED**

		charge amounting Rs 43 lac			
B. Directors					
Penalty	NIL				
Punishment	NIL				
Compounding	NIL				
C. Other Officers In Default					
Penalty	NIL				
Punishment	NIL				
Compounding	NIL				

**For BETA DRUGS LIMITED**

**Place: Panchkula**  
**Date: 31.08.2019**

**Sd/-**  
**Vijay Kumar Batra**  
**DIN: 01083215**  
**Managing Director**

**Sd/-**  
**Rajni Brar**  
**ACS-24684**  
**Company Secretary**



**MANAGEMENT DISCUSSION AND ANALYSIS**

In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:

- Industry structure and developments
- Opportunities & Threats
- Segment-wise or product-wise performance
- Outlook
- Risk and Concerns
- Internal Control System
- Financial and operational performance
- Material Development in Human Resources

Some Statements in this discussion may be forward looking. Future performance may however differ from those stated in the management discussion and analysis on account of various factors such as changes in Government regulations, tax regimes, impact of competition, etc.

**❖ INDUSTRY STRUCTURE AND DEVELOPMENTS**

After a strong growth in 2017 and early 2018, the global economic growth weakened in the second half of 2018 and growth is estimated to be 3.6% in 2018 down from 3.8% in 2017. Growth in advanced economies decreased from 2.4% in 2017 to 2.2% in 2018 and emerging economies decreased from 4.8% in 2017 to 4.5% in 2018. Global economic activity in 2018 softened amidst an increase in trade tensions and tariff hikes between US and China, weak intra trade in euro area countries (Germany, France, Italy and Spain), tightening of financial conditions and higher uncertainty of fiscal policy in the wake of policy actions across all economies. Global economic growth is projected to decline further to 3.3% in 2019. However, the growth in 2020 is forecasted to rebound at 3.6% with expectations of trade agreement between US and China, shift towards more accommodative monetary policies, improvement in global financial market sentiments and gradual stabilization of conditions in stressed emerging market economies.

**❖ OPPORTUNITIES & THREATS**

While the domestic and International economic conditions continue to remain challenging and are expected to remain for some more time, we expect that with wide range of products, quality standards and team efforts, your Company will be in a position to weather this situation. Your Company has continued to be the preferred supplier of many leading companies and has been successful in expanding its approval base, adding leading players from the industry. Therefore, we expect that your Company will continue to be in a position to gradually expand its market reach and improve its market share. The Company regularly insures all its assets to enable itself in case of any mis-happening. The Company has formed a risk management team which constantly monitors the Indian and international markets and guides the management of any sort of prevailing risk to the company. The commodities prices being internationally traded are affected by the global market demand and supply forces and the dollar rate. The risk management team plays a major role here. Moreover, the industry is labour oriented and business operations of the Company may be materially affected by strikes, lock outs or work stoppage.



---

❖ **SEGMENT WISE OR PRODUCT WISE PERFORMANCE**

Your company has only one segment that is trading and manufacturing of pharmaceutical products.

❖ **OVERVIEW & OUTLOOK**

Indian pharmaceuticals industry is well respected worldwide and is one of the most successful industries in India contributing greatly to country's healthcare outcomes and GDP. Top notch capabilities and advantageous market conditions over the last many years have ensured that India continues to be one of the most profitable pharma markets across the world. It remains an attractive destination for generic R&D and manufacturing of pharmaceuticals owing to its strong capabilities across the value chain.

Oncology drugs market is expected to grow at a fast clip across the world primarily driven by an ageing population and lifestyle changes making population susceptible to cancer. In India the Oncology drugs market is expected market to grow in double digits for the next many years to come. Therefore, Beta Drugs being a leader in the oncology segment has long runaway ahead both in terms of opportunities and growth.

❖ **RISK AND CONCERNS**

Pharmaceutical industry is most regulated industry in whole word. Being pharmaceutical company we have to follow various government regulations. Change in regulatory norms in India or else where in exporting countries shall effect the operation of Company.

❖ **INTERNAL CONTROL SYSTEM**

The Company has in place an adequate system of internal control commensurate with its size and nature of its business. These have been designed to provide reasonable assurance that all assets are safeguarded and protected against loss from unauthorized use or disposition and that all transactions are authorized, recorded and reported correctly and the business operations are conducted as per the prescribed policies and procedures of the Company. The Audit committee and the management have reviewed the adequacy of the internal control systems and suitable steps are taken to improve the same.

❖ **FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE**

Beta's net sales grew by 14.79% to Rs 58.04 crores compared with the same period a year ago. This was primarily driven by company increasing its market share in the domestic oncology segment. Beta added some marquee names to its clients list and expanded its presence across corporate hospitals in India.

Net profit too surged by 14.05% to Rs 7.71 crores. This increase in net profits was due to the fact that the company was able to reduce its operating expenses. This also reflected in margins expanding across the board.

❖ **HUMAN RESOURCES DEVELOPMENT AND INDUSTRIAL RELATIONS**

Your Company firmly believes that its human resources are the key enablers for the growth of the Company and important asset. Hence, the success of the Company is closely aligned to the goals of the human resources of the Company. Taking into this account, your Company continued to Invest in developing its human capital and establishing its brand on the market to attract and retain the best talent. Employee relations during the period under review



---

continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees.

❖ **CAUTIONARY STATEMENT**

Statement in this Management Discussion and Analysis Report, describing the Company's objectives, estimates and expectations may constitute 'Forward Looking Statements' within the meaning of applicable laws or regulations. Actual results might differ materially from those either expressed or implied.

**Dated: 31.08.2019**  
**Place: Panchkula**

**By Order of the Board of Directors**

**sd/-**  
**Vijay Kumar Batra**  
**Chairman & Managing Director**  
**(DIN: 01083215)**



---

# STANDALONE FINANCIAL

## STATEMENTS

### OF

### “BETA DRUGS LIMITED”

### FOR THE FINANCIAL YEAR

**2018-19**



---

**KALRA RAI & ASSOCIATES  
CHARTERED ACCOUNTANTS****Head Office: Kothi No. 667, 1<sup>st</sup> floor, Sector-43-A  
Chandigarh-160022**

---

**Independent Auditors' Report**  
Members of Beta Drugs Limited**Report on the Standalone Financial Statements**

We have audited the accompanying standalone Ind-AS financial statements of Beta Drugs Limited ('the Company'), which comprise the Balance Sheet as at March 31, 2019, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these standalone Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the stand alone Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.



### Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection(11) of Section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143 (3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid stand alone Ind-AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
- e. On the basis of written representations received from the directors as on March 31, 2019, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2019, from being appointed as a director in terms of Section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure B" ;
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. Since the company has gone public for the financial year 2017-18, there has been no amounts available which is required to be transferred, to the Investor Education and Protection Fund by the Company;

Place:- Chandigarh

Date: 13/05/2019

For KALRA RAI & ASSOCIATES

Sd/-

Chartered Accountants

(Lajpat Rai Kalra)

Partner

M. No- 087438

FRN: 008859N

**CARO****Annexure 1 referred to in paragraph 1 of our report of even date****Re: Beta Drugs Limited ('the Company')**

i. a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

b. All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

c. According to information and explanations given by the management, the title deeds of immovable properties, included in property, plant and equipment except for the following, are held in the name of the Company. As explained to us, registration of title deeds is in progress in respect of immovable properties.

Category	Address	Freehold/ Leasehold	Cost of Land
Land	Kharsa No. 370 / 00-02, 371 / 01-06, 01 Bigha, 17 Biswa, Nandpur, Dharampur, Tehsil Baddi, Zila Solan, Himachal Pradesh	Freehold	2500000

ii. The management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies were noticed on such physical verification.

iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii)(a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.

iv. In our opinion and according to the information and explanations given to us, the Company has not advanced loans to directors/to a Company in which the director is interested to which, the provisions of Section 185 of the Companies Act, 2013 apply and hence not commented upon. In our opinion and according to the information and explanations given to us, the Company has made investments and given guarantees/provided security which is in compliance with the provisions of Section 186 of the Companies Act, 2013.

v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.

vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under Section 148(1) of the Companies Act, 2013, related to the manufacture of Active Pharmaceutical Ingredients and Formulations and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the Cost Audit Report.

vii. a. The Company is regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, service tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues applicable to it.



b. According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income tax, service tax, sales tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.

viii. In our opinion and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans or borrowings to a bank or government. There are no dues which are payable to financial institutions or debenture holders.

ix. In our opinion and according to the information and explanations given by the management, the Company has utilized the monies raised by way of term loans for the purposes for which they were raised..

x. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.

xi. According to the information and explanations given by the management, the managerial remuneration has been paid/ provided in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Companies Act, 2013.

xii. In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.

xiii. According to the information and explanations given by the management, transactions with the related parties are in compliance with Sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.

xiv. According to the information and explanations given to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.

xv. According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in Section 192 of Companies Act, 2013.

xvi. According to the information and explanations given to us, the provisions of Section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

**Place:- Chandigarh**

**Date: 13/05/2019**

**For KALRA RAI & ASSOCIATES**

**sd/-**

**Chartered Accountants**

**(Lajpat Rai Kalra)**

**Partner**

**M. No- 087438**

**FRN: 008859N**





---

**"ANNEXURE-B" TO THE AUDITORS' REPORT**

*Referred to in Paragraph 7 of Our Report of Even Date*

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Beta Drugs Limited** ("the Company") as of 31 March 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

***Management's Responsibility for Internal Financial Controls***

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 ("the Act").

***Auditors' Responsibility***

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ("the Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



---

***Meaning of Internal Financial Controls over Financial Reporting***

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

***Inherent Limitations of Internal Financial Controls Over Financial Reporting***

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Opinion***

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**Place:- Chandigarh****Date: 13/05/2019****For KALRA RAI & ASSOCIATES****sd/-****Chartered Accountants****(Lajpat Rai Kalra)****Partner****M. No- 087438****FRN: 008859N**

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

BETA DRUGS LIMITED VILLAGE NANDPUR, BADDI, SOLAN 174101 CIN: L24230HP2005PLC028969 BALANCE SHEET AS AT 31 MARCH ' 2019				
Particulars		Note No.	As at 31 March' 2019	As at 31 March' 2018
			Amount in Rs.	Amount in Rs.
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1	<b>Shareholders' funds</b>			
	(a) Share capital	1	86,495,000.00	86,495,000.00
	(b) Reserves and surplus	2	319,465,064.64	242,324,139.79
	(c) Money received against share warrants		-	-
			<b>405,960,064.64</b>	<b>328,819,139.79</b>
2	<b>Share application money pending allotment</b>		-	-
3	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	3	52,713,933.16	27,515,726.91
	(b) Deferred tax liabilities (net)	4	-	1,499,675.95
	(c) Other long-term liabilities	5	2,500,000.00	2,500,000.00
	(d) Long-term provisions		-	-
			<b>55,213,933.16</b>	<b>31,515,402.86</b>
4	<b>Current liabilities</b>			
	(a) Short-term borrowings	6	11,566,270.95	35,865,012.02
	(b) Trade payables	7	101,616,650.51	61,058,593.71
	(c) Other current liabilities	8	66,349,604.44	35,289,931.92
	(d) Short-term provisions		5,833,606.00	3,254,956.00
			<b>185,366,131.90</b>	<b>135,468,493.65</b>
	<b>TOTAL</b>		<b>646,540,129.70</b>	<b>495,803,036.30</b>
<b>B</b>	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Fixed assets			
	(i) Tangible assets	9	117,688,316.93	131,870,936.38
	(ii) Intangible assets		-	-
	(iii) Capital work-in-progress		150,415,738.88	13,474,652.00
	(iv) Intangible assets under development		-	-
	(v) Fixed assets held for sale		-	-
			<b>268,104,055.81</b>	<b>145,345,588.38</b>
	(b) Non-current investments	10	16,120,592.62	-
	(c) Deferred tax assets (net)	4	979,705.11	-
	(d) Long-term loans and advances	11	42,587,046.70	27,216,624.00
	(e) Other non-current assets		-	-
			<b>59,687,344.43</b>	<b>27,216,624.00</b>
2	<b>Current assets</b>			
	(a) Current investments		-	-
	(b) Inventories	12	64,097,049.94	28,034,802.00
	(c) Trade receivables	13	173,294,672.62	144,422,475.31
	(d) Cash and cash equivalents	14	29,180,194.79	119,066,796.46
	(e) Short-term loans and advances	15	13,606,337.48	14,129,962.48
	(f) Other current assets	16	38,570,474.63	17,586,787.67
			<b>318,748,729.46</b>	<b>323,240,823.92</b>
	<b>TOTAL</b>		<b>646,540,129.70</b>	<b>495,803,036.30</b>
See accompanying notes forming part of the financial statements				
In terms of our report attached. For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N) sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 Place : Chandigarh Date : 13.05.2019				
For and on the behalf of the Board of Directors sd/- JAYANT KUMAR C.F.O. sd/- RAJNI BRAR Company Secretary. sd/- BALWANT SINGH Whole-time Director DIN: 1089968 sd/- VIJAY KUMAR BATRA MANAGING DIRECTOR DIN: 01083215				

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

BETA DRUGS LIMITED				
VILLAGE NANDPUR, BADDI, SOLAN 174101				
CIN: L24230HP2005PLC028969				
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH' 2019				
Particulars		Note No.	As at 31 March' 2019	As at 31 March' 2018
			Amount in Rs.	Amount in Rs.
A	CONTINUING OPERATIONS			
1	Revenue from operations (gross)	17	580,486,838.99	505,667,871.26
	Less: Excise duty		-	-
	Revenue from operations (net)		580,486,838.99	505,667,871.26
2	Other income	18	3,157,848.77	2,443,898.26
3	Total revenue (1+2)		583,644,687.76	508,111,769.52
4	Expenses			
	(a) Cost of materials consumed	19	331,192,739.65	278,622,734.42
	(b) Purchases of stock-in-trade		-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20	-26,731,181.11	-6,776,658.00
	(d) Other manufacturing expenses	21	73,695,199.13	63,810,807.26
	(d) Employee benefits expense	22	34,173,569.73	18,827,475.77
	(e) Finance costs	23	7,336,363.47	10,142,990.07
	(f) Depreciation and amortisation expense	9	24,232,093.54	18,506,706.56
	(g) Other expenses	24	65,084,359.56	56,620,793.39
	Total expenses		508,983,143.97	439,754,849.47
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		74,661,543.79	68,356,920.05
6	Exceptional items		-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)		74,661,543.79	68,356,920.05
8	Extraordinary items/Prior period items		-	-
9	Profit / (Loss) before tax (7 ± 8)		74,661,543.79	68,356,920.05
10	Tax expense:			
	(a) Current tax expense for current year		15,370,422.70	13,937,189.89
	(b) (Less): MAT credit (where applicable)		-15,370,422.70	-13,937,189.89
	(c) Current tax expense relating to prior years		-	-
	(d) Net current tax expense		-	-
	(e) Deferred tax		-2,479,381.06	720,255.20
			-2,479,381.06	720,255.20
11	Profit / (Loss) from continuing operations (9 ± 10)		77,140,924.85	67,636,664.85
B	DISCONTINUING OPERATIONS			
12	Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C	TOTAL OPERATIONS		77,140,924.85	67,636,664.85
13	Profit / (Loss) for the year (11 ± 12)		77,140,924.85	67,636,664.85
14	Earnings per share (of ` Rs 10/- each):			
	(a) Basic			
	(i) Continuing operations		8.92	7.82
	(ii) Total operations		8.92	7.82
	(b) Diluted			
	(i) Continuing operations		8.92	7.82
	(ii) Total operations		8.92	7.82
	See accompanying notes forming part of the financial statements			

In terms of our report attached.

**For KALRA RAI AND ASSOCIATES**

Chartered Accountants

(FRN: 008859N)

sd/-

**LAJPAT RAI KALRA**

Partner

MEMBERSHIP NO. 087438

Place : Chandigarh

Date : 13.05.2019

**For and on the behalf of the Board of Directors**

sd/-

**JAYANT KUMAR**

C.F.O

sd/-

**RAJNI BRAR**

Company Secretary.

sd/-

**BALWANT SINGH**

Whole-time Director

DIN: 1089968

sd/-

**VIJAY KUMAR BATRA**

MANAGING DIRECTOR

DIN: 01083215

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

BETA DRUGS LIMITED VILLAGE NANDPUR, BADDI, SOLAN 174101 CIN: L24230HP2005PLC028969 CASHFLOW STATEMENT FOR THE YEAR ENDED 31 MARCH' 2019			
Particulars		As at 31 March' 2019	As at 31 March' 2018
		Amount in Rs.	Amount in Rs.
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit before tax and extraordinary items(as per Statement of Profit & Loss)	74,661,543.79	68,356,920.05
	Adjustments for non Cash/Non trade items:		
	Depreciation & Amortization Expenses	24,232,093.54	18,506,706.56
	Finance Cost	7,336,363.47	10,142,990.07
	Interest received	(2,351,892.00)	(2,110,151.00)
	Other inflows/ (outflows) of cash	(12,791,772.70)	124,078,206.98
	<b>Operating profits before Working Capital Changes</b>	<b>91,086,336.10</b>	<b>218,974,672.66</b>
	<b>Adjusted For:</b>		
	(Increase)/Decrease in trade receivables	(28,872,197.31)	(39,280,470.19)
	Increase/ (Decrease) in trade payables	40,558,056.80	(9,505,336.60)
	(Increase)/Decrease in inventories	(36,062,247.94)	(4,067,195.00)
	Increase/ (Decrease) in other current liabilities	31,059,672.52	16,142,321.92
	(Increase)/Decrease in short term loans and advances	523,625.00	3,935,052.37
	(Increase)/Decrease in other current assets	(20,983,686.96)	(15,153,737.67)
	<b>Cash generated from Operations</b>	<b>77,309,558.21</b>	<b>171,045,307.49</b>
	<b>Net cashflow from Operating Activities (A)</b>	<b>77,309,558.21</b>	<b>171,045,307.49</b>
<b>B</b>	<b>CASHFLOW FROM INVESTING ACTIVITIES</b>		
	Purchase of tangible assets	(146,990,560.97)	(82,783,181.06)
	Interest received	2,351,892.00	2,110,151.00
	Cash advances and loans made to other parties	(16,120,592.62)	(27,216,624.00)
	<b>Net cash used in Investing Activities (B)</b>	<b>(160,759,261.59)</b>	<b>(107,889,654.06)</b>
<b>C</b>	<b>CASHFLOW FROM FINANCING ACTIVITIES</b>		
	Finance Cost	(7,336,363.47)	(10,142,990.07)
	Increase in/ (Repayment) of Short term Borrowings	(24,298,741.07)	(1,650,116.05)
	Increase in/ (Repayment) of Long term Borrowings	25,198,206.25	(10,133,224.07)
	Increase/ (Decrease) in share capital	-	76,395,000.00
	Other Inflows/ (Outflows) of cash	-	-
	<b>Net cash used in Financing Activities (C)</b>	<b>(6,436,898.29)</b>	<b>54,468,669.81</b>
<b>D</b>	<b>Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>(89,886,601.67)</b>	<b>117,624,323.24</b>
<b>E</b>	Cash & Cash equivalents at beginning of period	119,066,796.46	1,442,473.22
<b>F</b>	Cash & Cash equivalents at end of period	29,180,194.79	119,066,796.46
<b>G</b>	<b>Net Increase/(Decrease) in cash &amp; cash equivalents (F-E)</b>	<b>(89,886,601.67)</b>	<b>117,624,323.24</b>

In terms of our report attached.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN: 008859N)

sd/-

LAJPAT RAI KALRA

Partner

MEMBERSHIP NO. 087438

Place : Chandigarh

Date : 13.05.2019

sd/-

JAYANT KUMAR

C.F.O

sd/-

RAJNI BRAR

C.S.

sd/-

BALWANT SINGH

DIRECTOR

DIN: 1089968

sd/-

VIJAY KUMAR BATRA

MANAGING DIRECTOR

DIN: 01083215



<b>BETA DRUGS LIMITED</b>				
<b>Notes forming part of the financial statements</b>				
<b>Note 1 Share capital</b>				
Particulars	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares	Amount in Rs.	Number of shares	Amount in Rs.
(a) Authorised - Equity shares of Rs. 10 each	10,000,000.00	100,000,000.00	10,000,000.00	100,000,000.00
	-	-	-	-
(b) Issued - Equity shares of Rs. 10 each	8,649,500.00	86,495,000.00	8,649,500.00	86,495,000.00
	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	8,649,500.00	86,495,000.00	8,649,500.00	86,495,000.00
	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
<b>Total</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
Details of shares held by each shareholder holding more than 5% shares:				
Class of shares / Name of shareholder	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mr. Vijay Kumar Batra	5,973,580	69.06%	5,924,780	68.50%
<b>Note 2 Reserves and surplus</b>				
Particulars	As at 31 March' 2019		As at 31 March, 2018	
	Amount in Rs.		Amount in Rs.	
(a) Capital reserve				
Opening balance	-	-	-	-
Closing balance	-	-	-	-
(b) Securities premium account				
Opening balance	-	-	-	-
Closing balance	161,612,604.98	161,612,604.98	161,612,604.98	161,612,604.98
(c) Surplus / (Deficit) in Statement of Profit and Loss				
Opening balance	80,711,534.81	50,609,267.96	50,609,267.96	50,609,267.96
Add :- Opening Provision For Mat	-	13,279,434.00	13,279,434.00	13,279,434.00
Less :- Provision for Gratuity	-	1,323,832.00	1,323,832.00	1,323,832.00
Less :- Used In Issue Of Share Capital ( Right Issue)	-	49,490,000.00	49,490,000.00	49,490,000.00
	80,711,534.81	13,074,869.96	13,074,869.96	13,074,869.96
Add: Profit / (Loss) for the year	77,140,924.85	67,636,664.85	67,636,664.85	67,636,664.85
Closing balance	<b>157,852,459.66</b>	<b>80,711,534.81</b>	<b>80,711,534.81</b>	<b>80,711,534.81</b>
<b>Total</b>	<b>319,465,064.64</b>	<b>242,324,139.79</b>	<b>242,324,139.79</b>	<b>242,324,139.79</b>



<b>Note 3 Long-term borrowings</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Term loans</b>		
<b>From banks</b>		
<b>Secured</b>		
Vijaya Bank ( Building)	-	1,216,714.88
Vijaya Bank ( Machinery New)	1,696,562.00	3,031,371.00
Vijaya Bank ( Machinery Old)	-	3,614,131.00
SIDBI ( Machinery New canada)	7,036,000.00	8,512,000.00
SIDBI ( Term Loan new)	35,560,000.00	-
HDFC Bank Car Loan	916,629.16	1,929,307.03
Vijaya Bank ( Car Loan)	1,523,555.00	1,063,037.00
Axis Bank (Car Loan)	2,211,328.00	4,051,270.00
	<b>48,944,074.16</b>	<b>23,417,830.91</b>
<b>From other parties</b>		
Unsecured ( From Related Parties)	-	-
Secured	-	-
Edelweiss Limited	423,726.00	1,936,836.00
ICICI Bank	-	392,715.00
<b>Total - A</b>	<b>423,726.00</b>	<b>2,329,551.00</b>
Unsecured ( From Unrelated Parties)		
Provision For Gratuity	3,346,133.00	1,768,345.00
<b>Total - B</b>	<b>3,346,133.00</b>	<b>1,768,345.00</b>
	3,769,859.00	4,097,896.00
<b>The Above Amount Includes</b>		
Secured Borrowings	<b>48,944,074.16</b>	<b>23,417,830.91</b>
Unsecured Borrowings	<b>3,769,859.00</b>	<b>4,097,896.00</b>
<b>Total</b>	<b>52,713,933.16</b>	<b>27,515,726.91</b>

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

<b>BETA DRUGS LIMITED</b>						
<b>Notes forming part of the financial statements</b>						
<b>Notes: 3 Long-term borrowings</b>						
<b>Particulars</b>	<b>As at 31 March' 2019</b>			<b>As at 31 March, 2018</b>		
	<b>Amount in Rs.</b>			<b>Amount in Rs.</b>		
	<b>Non- Current</b>	<b>Current Maturities</b>	<b>Total</b>	<b>Non- Current</b>	<b>Current Maturities</b>	<b>Total</b>
<b>Term loans</b>						
<b>From banks</b>						
<b>Secured</b>						
Vijaya Bank ( Building)*	-	1,162,845.88	1,162,845.88	1,216,714.88	1,044,269.00	2,260,983.88
Vijaya Bank ( Machinery New)**	1,696,562.00	1,162,785.00	2,859,347.00	3,031,371.00	865,645.00	3,897,016.00
Vijaya Bank ( Machinery Old)***	-	3,258,698.00	3,258,698.00	3,614,131.00	3,132,788.00	6,746,919.00
SIDBI ( Machinery New Canada)	7,036,000.00	1,476,000.00	8,512,000.00	8,512,000.00	1,353,000.00	9,865,000.00
SIDBI ( Term Loan new)	35,560,000.00	4,440,000.00	40,000,000.00	-	-	-
HDFC Bank (Car Loan)	916,629.16	1,660,172.89	2,576,802.05	1,929,307.03	1,398,841.32	3,328,148.35
ICICI Bank (Car Loan)	-	-	-	-	341,413.10	341,413.10
Vijaya Bank ( Force Traveller Loan)	-	-	-	-	209,961.00	209,961.00
Vijaya Bank ( Car Loan)	1,523,555.00	402,521.00	1,926,076.00	1,063,037.00	182,234.00	1,245,271.00
Axis Bank ( Car Loan)	2,211,328.00	2,514,177.00	4,725,505.00	4,051,270.00	2,179,003.00	6,230,273.00
	<b>48,944,074.16</b>	<b>16,077,199.77</b>	<b>65,021,273.93</b>	<b>23,417,830.91</b>	<b>10,707,154.42</b>	<b>34,124,985.33</b>
<b>From other parties</b>						
Unsecured ( From Related Parties)	-	-	-	-	-	-
Secured	-	-	-	-	-	-
Edelweiss Limited****	423,726.00	1,412,607.00	1,836,333.00	1,936,836.00	1,207,628.00	3,144,464.00
ICICI Bank	-	392,715.00	392,715.00	392,715.00	1,423,731.00	1,816,446.00
<b>Total - A</b>	<b>423,726.00</b>	<b>1,805,322.00</b>	<b>2,229,048.00</b>	<b>2,329,551.00</b>	<b>2,631,359.00</b>	<b>4,960,910.00</b>
Unsecured ( From Unrelated Parties)	-	-	-	-	-	-
Provision For Gratuity	3,346,133.00	-	3,346,133.00	1,768,345.00	-	1,768,345.00
<b>Total - B</b>	<b>3,346,133.00</b>	<b>-</b>	<b>3,346,133.00</b>	<b>1,768,345.00</b>	<b>-</b>	<b>1,768,345.00</b>
	3,769,859.00	1,805,322.00	5,575,181.00	4,097,896.00	2,631,359.00	6,729,255.00
<b>The Above Amount Includes</b>						
Secured Borrowings	48,944,074.16	16,077,199.77	65,021,273.93	23,417,830.91	10,707,154.42	34,124,985.33
Unsecured Borrowings	3,769,859.00	1,805,322.00	5,575,181.00	4,097,896.00	2,631,359.00	6,729,255.00
Amount disclosed under "Other Current		-17,882,521.77	-17,882,521.77		-13,338,513.42	-13,338,513.42
<b>Total</b>	<b>52,713,933.16</b>	<b>-</b>	<b>52,713,933.16</b>	<b>27,515,726.91</b>	<b>-</b>	<b>27,515,726.91</b>

\* The rate of interest changed from 13.25% to 9.55% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\* The rate of interest changed from 13% to 9.45% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\*\* The rate of interest changed from 14.05% to 9.55% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\*\*\* TDS on interest paid - Rs. 1,00,503 is recoverable from Edelweiss.





<b>BETA DRUGS LIMITED</b>		
<b>Note 4 Deferred Tax</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Deferred tax liabilities</b>		
Deferred tax on depreciation	-	1,499,675.95
<b>Deferred tax assets</b>		
Deferred tax on depreciation	1,423,908.01	-
Deferred tax on unabsorbed depreciation	-	-
Deferred tax on provision of gratuity	324,866.55	-
Deferred tax on provision of bonus	532,038.19	-
Deferred tax on provision of CSR	198,568.31	-
Less: Deferred tax liability as at 31.03.2018	-1,499,675.95	
<b>Net Deferred tax liabilities/assets</b>	<b>979,705.11</b>	<b>1,499,675.95</b>

<b>Continue Note 4 Current tax Provision</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Current Year Tax	15,370,422.70	3,254,956.00
Less :- Advance Tax Including TDS	-9,536,816.70	
<b>Short term Provision</b>	<b>5,833,606.00</b>	<b>3,254,956.00</b>
<b>Net Current Tax provision</b>	<b>5,833,606.00</b>	<b>3,254,956.00</b>

<b>Note 5 Other long-term liabilities</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
(a) Trade Payables: *	-	-
(i) Acceptances	-	-
(ii) Other than Acceptances	-	-
(b) Others:		
(i) Payables on purchase of fixed assets	-	-
(ii) Contractually reimbursable expenses	-	-
(iii) Interest accrued but not due on borrowings	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(vii) Advances from customers	-	-
(viii) Income received in advance (Unearned revenue)	-	-
(ix) Security received from customers	2,500,000.00	2,500,000.00
<b>Total</b>	<b>2,500,000.00</b>	<b>2,500,000.00</b>



# 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

<b>BETA DRUGS LIMITED</b>		
<b>Note 6 Short-term borrowings</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Other loans and advances		
Secured		
- From Vijaya Bank CC Limit Secured	11,566,270.95	35,865,012.02
<b>Total</b>	<b>11,566,270.95</b>	<b>35,865,012.02</b>
<b>Note 7 Trade payables</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Trade payables:		
Micro Enterprises And Small Enterprises	58,421,720.40	20,428,610.00
Others	43,194,930.11	40,629,983.71
<b>Total</b>	<b>101,616,650.51</b>	<b>61,058,593.71</b>
<b>Note 8 Other current liabilities</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Other payables	9,285,106.00	7,003,026.50
(i) Current Maturities of Long Term Debt ( Note No. 3)	17,882,521.77	13,338,513.42
(ii) Payables on purchase of fixed assets	24,092,372.34	-
(iii) Contractually reimbursable expenses	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(ii) Advances from customers	-	-
(viii) Others (specify nature)	-	-
(b) Cheque issued yet not presented for Payment	9,407,385.00	10,210,666.00
Advances From Customers	5,682,219.33	4,737,726.00
<b>Total</b>	<b>66,349,604.44</b>	<b>35,289,931.92</b>
<b>Note 8 (a) Other current liabilities</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
PF Payable	493,651.00	322,402.00
ESI payable	87,926.00	78,924.00
TDS payable	246,024.00	561,187.00
Interest Accrued But Not Due	137,725.00	117,139.50
Salary & wages Payable	4,500,413.00	3,280,619.00
Other Expenses payable	271,011.00	126,217.00
Bonus Payable	2,583,964.00	2,056,870.00
CSR Provision	964,392.00	459,668.00
<b>Total</b>	<b>9,285,106.00</b>	<b>7,003,026.50</b>



# 14<sup>TH</sup> ANNUAL REPORT

# BETA DRUGS LIMITED

Note No. 9 Fixed Assets Chart as at 31st March 2019

As at 31st March 2019														
Assets				Gross Block					Accumulated Depreciation/ Amortisation				Net Block	
		Useful Life (In Years)	Shift	Balance as at 1st April 2018	Additions during the year	Addition on account of business	Deletion during the year	Balance as at 31st March 2019	Balance as at 1st April 2018	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2019	Balance as at 31st March 2019	Balance as at 31st March 2018
A	Tangible assets													
	Own Assets													
			Single	4,291,730.00	1,500,000.00	-	-	5,791,730.00				-	5,791,730.00	4,291,730.00
		30	Single	58,374,927.52	-	-	-	58,374,927.52	11,016,312.76	4,504,940.24	-	15,521,253.00	42,853,674.52	47,358,614.76
		15	Single	79,718,139.46	2,198,110.75	-	-	81,916,250.21	25,521,725.10	10,151,468.98	-	35,673,194.08	46,243,056.13	54,196,414.36
		10	Single	2,255,394.00	626,900.00	-	-	2,882,294.00	775,475.39	418,954.05	-	1,194,429.44	1,687,864.56	1,479,918.61
		3	Single	423,955.85	1,182,199.14	-	-	1,606,154.99	241,110.36	522,372.49	-	763,482.85	842,672.14	182,845.49
		8	Single	26,168,476.00	3,059,852.19	-	-	29,228,328.19	8,620,288.74	6,343,200.13	-	14,963,488.87	14,264,839.32	17,548,187.26
		5	Single	3,055,654.93	622,822.26	-	-	3,678,477.19	1,805,589.69	708,489.38	-	2,514,079.07	1,164,398.12	1,250,065.24
		10	Single	6,263,217.01	859,589.75	-	-	7,122,806.76	700,056.35	1,582,668.27	-	2,282,724.62	4,840,082.14	5,563,160.66
				180,551,494.77	10,049,474.09	-	-	190,600,968.86	48,680,558.39	24,232,093.54	-	72,912,651.93	117,688,316.93	131,870,936.38
				111,242,965.71	69,308,529.06			180,551,494.77	30,173,851.83	18,506,706.56	-	48,680,558.39	131,870,936.38	81,069,113.88
B	Capital work in progress													
				8,370,000.00	32,425,656.22	-	-	40,795,656.22	-	-	-	-	40,795,656.22	8,370,000.00
				4,704,652.00	100,639,685.55	-	-	105,344,337.55	-	-	-	-	105,344,337.55	4,704,652.00
				-	750,000.00	-	-	750,000.00	-	-	-	-	750,000.00	-
				400,000.00	3,125,745.11	-	-	3,525,745.11	-	-	-	-	3,525,745.11	400,000.00
				13,474,652.00	136,941,086.88	-	-	150,415,738.88	-	-	-	-	150,415,738.88	13,474,652.00
				24,871,517.00	13,474,652.00	-	-	38,346,169.00	24,871,517.00	-	-	24,871,517.00	13,474,652.00	-
				194,026,146.77	146,990,560.97	-	-	341,016,707.74	48,680,558.39	24,232,093.54	0.00	72,912,651.93	268,104,055.81	145,345,588.38
				136,114,482.71	82,783,181.06	-	-	218,897,663.77	55,045,368.83	18,506,706.56	0.00	73,552,075.39	145,345,588.38	81,069,113.88



<b>BETA DRUGS LIMITED</b>		
<b>Note 10 Non Current investments</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Investment In Beta UBK International Pvt. Ltd. ( Uzbekistan)	3,520,592.62	-
Investment In Adley Formulation Pvt. Ltd. ( Wholly Owned Subsidiary)	12,600,000.00	-
<b>Total</b>	<b>16,120,592.62</b>	<b>-</b>
<b>Note 11 Long-term loans and advances</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Security Deposit</b>		
Secured, considered good	-	-
MAT Credit Entitlement	42,587,046.70	27,216,624.00
Provision for subsidy deposit taken		-
<b>loan and advances to realted parties</b>		
Unsecured, considered good		
<b>Total</b>	<b>42,587,046.70</b>	<b>27,216,624.00</b>
<b>Note 12 Inventories</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	5,360,501.10	5,069,063.00
(b) Raw Material	12,898,602.62	13,559,484.00
(c) WIP	34,039,036.01	7,599,293.00
(d) Others	11,798,910.21	1,806,962.00
<b>Total</b>	<b>64,097,049.94</b>	<b>28,034,802.00</b>
<b>Note 13 Trade receivables</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Exceeding six months</b>		
Secured, considered good	11,141,282.70	2,598,207.80
<b>Total</b>	<b>11,141,282.70</b>	<b>2,598,207.80</b>
<b>Less than six months</b>		
Secured, considered good	162,153,389.92	141,824,267.51
<b>Total</b>	<b>162,153,389.92</b>	<b>141,824,267.51</b>
<b>Grand Total</b>	<b>173,294,672.62</b>	<b>144,422,475.31</b>

<b>BETA DRUGS LIMITED</b>		
<b>Note 14 Cash and cash equivalents</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>CASH IN HAND</b>		
(a) Cash in hand	791,554.69	378,035.69
Balwant Singh Imprest	90,657.51	-
<b>Total</b>	<b>882,212.20</b>	<b>378,035.69</b>
<b>(b) Balances with banks</b>		
(i) In current accounts		
Axis Bank	171,907.17	7,536,952.50
ICICI Bank	7,345,134.56	1,690,558.59
RBL Bank	-	9,973,863.48
Vijaya Bank	83.00	8,997,653.00
Vijaya Bank ( Imprest)	1,581.20	61,380.20
HDFC Bank	95,649.66	-
(iv) In earmarked accounts		
- Share application money received for allotment of	14.00	14.00
- Balances held as margin money or security against	-	-
<b>(c) Others (specify nature)</b>		
FDR With Axis Bank	-	72,000,000.00
FDR With Vijaya Bank	454,000.00	9,000,000.00
FDR With SIDBI (Against Bank Loan)	18,592,135.00	3,447,157.00
FDR With HDFC (Against Bank Loan)	-	5,003,699.00
FDR With Vijaya Bank (Against Bank Gurantee)	759,883.00	-
FDR With ICICI Bank (Against Bank Gurantee)	877,595.00	852,279.00
FDR With Excise Authority (Against Export)	-	125,204.00
<b>Total</b>	<b>28,297,982.59</b>	<b>118,688,760.77</b>
<b>Grand Total</b>	<b>29,180,194.79</b>	<b>119,066,796.46</b>
<b>Note 15 Short-term loans and advances</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Loans and advances to related parties	-	-
(b) Loans and advances		
Advances To Supplier	10,287,532.48	1,666,252.48
Advances To Supplier ( Machinery)	1,209,016.00	9,898,700.00
Other Advances ( Staff)	2,109,789.00	2,565,010.00
<b>Total</b>	<b>13,606,337.48</b>	<b>14,129,962.48</b>
<b>Note 16 Other current assets</b>		
Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Other Assets</b>		
Income Tax Refund due	260,690.00	-
Cheque Deposited Yet not Cleared	246,200.00	4,262,561.00
PLA	-	13,398.36
Sales Tax Security	215,297.00	215,297.00
Prepaid Expenses	387,225.00	120,574.00
Security Deposit	4,625,866.00	4,389,262.00
GST Recoverable	32,835,196.63	8,585,695.31
<b>Total</b>	<b>38,570,474.63</b>	<b>17,586,787.67</b>



<b>BETA DRUGS LIMITED</b>			
<b>Note 17 Revenue from operations</b>			
	Particulars	For the year ended 31 March, 2019	For the year ended 31 March, 2018
		Amount in Rs.	Amount in Rs.
	<b>Sale Of Products</b>		
	Other Export Sales	9,094,560.93	-
	Central Sales 5%	-	3,258,107.40
	Central Sales 1.5%	-	70,939,193.75
	Sales Local 4%	-	253,869.25
	Sales Local 18%	-	5,845,023.10
	Export Sales	39,406,113.07	14,597,414.91
	Sales Loan Licence	-	239,068.00
	Sales Exempt	500.00	190,514.60
	GST Sales 12%	463,611,046.33	376,654,288.75
	GST Sales 5%	52,576,456.69	29,798,721.50
	GST Sales 18%	15,798,161.97	3,891,670.00
	<b>Total</b>	<b>580,486,838.99</b>	<b>505,667,871.26</b>

<b>Note 18 Other income</b>			
	Particulars	For the year ended 31 March, 2019	For the year ended 31 March, 2018
		Amount in Rs.	Amount in Rs.
(a)	Interest Income	2,351,892.00	2,110,151.00
(b)	Other non-operating income (net of expenses directly attributable to such income)	635,197.00	333,747.26
(c)	Foreign Currency Exchange Gain	170,759.77	-
	<b>Total</b>	<b>3,157,848.77</b>	<b>2,443,898.26</b>

<b>Note 19 Cost of materials consumed</b>		
Particulars	For the year ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
Opening stock	15,366,446.00	18,075,909.00
Add: Purchases	340,523,806.48	275,913,271.42
Less: Closing stock	24,697,512.83	15,366,446.00
<b>Cost of material consumed</b>	<b>331,192,739.65</b>	<b>278,622,734.42</b>
<b>Total</b>	<b>331,192,739.65</b>	<b>278,622,734.42</b>

## BETA DRUGS LIMITED

**Note 20 Changes in inventories of finished goods, work-in-progress and stock-in-trade**

Particulars	For the year ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b><u>Inventories at the end of the year:</u></b>		
Finished goods	5,360,501.10	5,069,063.00
Work In Progress	34,039,036.01	7,599,293.00
	<b>39,399,537.11</b>	<b>12,668,356.00</b>
<b><u>Inventories at the beginning of the year:</u></b>		
Finished goods	5,069,063.00	3,481,752.00
Work In Progress	7,599,293.00	2,409,946.00
	<b>12,668,356.00</b>	<b>5,891,698.00</b>
<b><u>(Increase)/ decrease in Inventory</u></b>		
Finished goods	(291,438.10)	(1,587,311.00)
Work In Progress	(26,439,743.01)	(5,189,347.00)
	<b>(26,731,181.11)</b>	<b>(6,776,658.00)</b>

**Note 21 Other Manufacturing Expenses**

Particulars	For the year ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
Consumeable Stores	13,095,363.51	10,186,912.08
Generator running expenses	2,594,633.00	1,283,619.00
Power & Fuel	7,952,949.00	7,583,879.54
Direct labour	39,900,756.00	37,502,088.00
Excise Expenses	-	153,807.64
Repairs & maintenance (machinery & Building)	4,275,998.93	2,127,975.63
Freight Inward	428,523.02	262,985.28
Factory Expenses	372,965.00	317,084.00
Packing & Forwarding expense	1,575,054.00	2,864,660.87
Solid Waste Pollution expenses	76,289.00	39,685.00
Testing Charges	3,422,667.67	1,488,110.22
<b>Total</b>	<b>73,695,199.13</b>	<b>63,810,807.26</b>



<b>BETA DRUGS LIMITED</b>		
<b>Note 22 Employee benefits expense</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Salaries and wages</b>		
Director	9,692,000.00	6,252,000.00
Employees	15,356,716.84	5,810,048.61
Employer Share of ESI	747,344.00	676,913.00
Employer Share of PF	2,420,994.00	1,872,678.00
Bonus	2,583,964.00	2,119,370.00
Staff welfare expenses	1,600,281.89	1,174,992.16
Staff Uniform Expenses	194,481.00	476,961.00
Rent Free Accomodation to Staff	-	-
Gratuity Provision	1,577,788.00	444,513.00
<b>Total</b>	<b>34,173,569.73</b>	<b>18,827,475.77</b>
<b>Note 23 Finance costs</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>(a) Interest expense on:</b>		
(i) Borrowings		
Bank Interest CC	2,527,662.00	4,576,522.00
Interest on Term Loan	2,596,165.80	3,115,231.00
Interest on Term Loan (Vehicle)	970,421.40	822,489.85
(ii) Others	392,034.00	676,919.73
<b>- Interest on delayed / deferred payment of income tax</b>		
Interest on Term Loan		
<b>(b) Other borrowing costs (Processing Fees)</b>		
Bank charges	850,080.27	951,827.49
Processing fee for renewal		
<b>Total</b>	<b>7,336,363.47</b>	<b>10,142,990.07</b>





<b>BETA DRUGS LIMITED</b>		
<b>Note 24 Other expenses</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Advertisement Expenses	863,842.00	569,885.61
Audit Fee	1,302,500.00	1,302,500.00
Books & Periodical	26,000.00	38,000.00
Business Promotion Expenses	1,721,685.56	2,532,631.68
Daily Pooja Expenses	274,160.00	333,338.00
Commission Paid	3,917,595.00	4,636,615.00
Conference Expenses	7,416,816.40	902,258.76
Convenyance Expenses	3,317,563.24	2,848,597.47
Corporate Expenses	1,279,733.58	-
Corporate Social Responsibility Expenses	964,392.00	459,668.00
Sponsorship A/C	130,000.00	-
Donation A/C	120,000.00	-
Diwali Expenses	440,145.00	534,367.20
Expired & damages Goods Return	2,577,154.03	2,224,331.09
Freight Outward	3,959,373.92	1,706,206.48
Foreign Travel	1,687,707.74	-
Guest House expenses	735,000.00	680,500.00
Insurance Apportion Cost	504,363.98	383,843.00
Legal & Professional Expenses	5,107,249.80	4,635,217.95
Medical Expenses	60,184.38	27,684.00
Misc. Expenses	24,350.00	73,484.00
Office Expenses	603,062.23	1,012,943.78
Printing & Stationary	3,296,931.11	1,865,836.88
Rate Difference	3,936,429.47	8,329,243.69
Rate Fee & taxes	843,191.50	1,422,755.00
Rent	7,898,740.00	7,998,042.00
Repair & maintenance ( Vehicle)	843,058.82	1,440,781.82
Round Off	-3,746.19	-21,310.24
Small Balance Written Off	35,627.72	8,901.12
Software Expenses	199,700.00	288,068.24
Telephone & Postage	425,142.94	370,751.50
Trade Discount Expenses	1,982,327.05	3,595,229.48
Travelling Expenses	8,594,078.28	6,420,421.88
<b>Total</b>	<b>65,084,359.56</b>	<b>56,620,793.39</b>



**BETA DRUGS LIMITED**  
**NOTE '3' : SIGNIFICANT ACCOUNTING POLICIES**  
**(Forming part of Accounts)**  
**FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019**

**3.1. Basis of Accounting**

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

**3.2. Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognised in the period in which the results are known/materialised.

**3.3. Fixed Assets**

**-Tangible Assets**

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

**- Capital Work-in-Progress**

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. WIP as on 31.03.2019 is Rs. 15,04,15,738.88.

**3.4. Depreciation/Amortisation**

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013. **(Refer note 4.7).**
- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided upto the month in which such fixed assets are sold or scrapped.

**3.5. Impairment of Assets**

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognised in prior years is recorded when there is an indication that the impairment losses recognised for the assets no longer exist or have decreased.

**3.6. Valuation of Inventories**

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods Oncology products comprises of Injections, Tablets & Capsules
- Work In Progress (Semi Finished Goods)
- Is valued at cost or estimated realisable value, whichever is lower. The company has determined the cost of Inventory using the First-In, First Out method.

The company has appointed cost auditor to ascertain and verify the authenticity of cost records maintained by the company. The valuation of Finished Goods as well as Work in Process material has been taken as certified by the cost auditor. The value of raw material and packing material has been taken at cost.

**3.7. Revenue Recognition**

- Revenue from sale of goods is recognised when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognised when services are rendered and related costs are incurred.
- Other income is recognised on accrual basis unless otherwise stated.
- Insurance and other claims are accounted for on settlement of claims/on receipt.
- Revenue from sales/services are shown net of taxes, as applicable.

**3.8. Employee Benefits**

**a) Short-term Employee Benefits:**



- Leave Encashment, on the basis of actual computation, is accounted for on accrual basis, during the tenure of employment the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has made the provision of Rs. 25,83,964.00 as per The Payment of Bonus Act, 1965.

#### b) Post-Employment Benefits

##### (i) Defined Contribution Plans :

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

##### (ii) Defined Benefit Plans :

Gratuity is accounted for on accrual basis - the Company is in the process of taking the Gratuity policy with Life Insurance Corporation of India or any other insurer covered under the specified provisions of the Income Tax Act, 1961.

The company has got the Actuarial Valuation done by independent consultant for FY 2018-19 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2019 in accordance with Revises AS-15(Rev).

Details Calculation of Gratuity Provision as per Certified Actuary.

Particulars	Amount
Present Value of Benefit Obligation as on 31.03.2019	33,46,133.00
Fair Value of Plan Assets on 31.03.2018	-
Net Liability / (Asset) recognised in Balance Sheet	33,46,133.00
Current Service Cost	13,73,284.00
Interest Cost	1,36,163.00
Expected Return on Plan Assets	-
Net Actuarial Losses ( Gains) recognised in the year	68,341.00
Expenses recognised in Statement of Profit and Loss	15,77,788.00

Gratuity Provision for FY 2017-18 was provided for Rs. 4,44,513.00 and Rs. 15,77,788.00 for FY 2018-19.

#### c) Termination Benefits : Termination benefits are recognised as an expense as and when incurred.

#### 3.9. Foreign Currency Transactions

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of transaction or the average of opening and closing rates. The difference in the rate of exchange, if any, is accounted at the time of realisation or settlement and is recognized in the Statement of Profit and Loss.

Exchange differences (Gains) arising on foreign currency transactions for purchase of Plant and Machinery is adjusted against the cost of acquisition of that asset.

#### 3.10. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss. Details of the borrowing cost capitalized due the FY18-19 is as mentioned below :

During the year, the Company has capitalised borrowing costs of Rs. 8,30,397.00 (Previous year 2,24,094.00) relating to credit facility availed for installation of Plant and Machinery, included in Capital Work in Progress.

#### 3.11. Investments

- Current Investments are carried at cost or fair market value whichever is lower.
- Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

**3.12. Operating Lease**

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognised as an expense in the Statement of Profit & Loss on monthly due basis. The company has taken following premises on lease :

- 1.) Administrative office located at Panchkula-SCO 184, First floor, Sector 5, Panchkula -134114. The lease is entered into with M/s B.T. Associates, Panchkula for 10 years with monthly rent of Rs. 2,40,720.00 plus GST@18 percent.
- 2.) Branch office located at Peninsula Park, Office no-1101, 11th Floor, Andheri West, Mumbai-400053, Maharashtra. The lease is entered into with Mr. Rakesh Pravinchandra Desai and Mrs. Tejpal Rakesh Desai, Mumbai for 3 years with monthly rent of Rs. 1,43,000.00 plus GST@18 percent. The monthly rent paid by the company for financial year 2018-19 is Rs. 1,57,300.00 plus GST@18 percent with an increment of 10 percent from Feb-19 onwards.
- 3.) Company Guest House located at 101, Gopush Occupants Association, Vithal Nagar Chs Ltd., NS Road 11, JVPD Scheme, Vile Parle (W), Plot No. 27 NR, Juhu Bus Vile Parle (W), Mumbai, Maharashtra – 400049. The lease is entered into with Ms. Jagruti K Purohit and Sh. Kirit B Purohit, Mumbai for 3 years with monthly rent of Rs. 2,50,000.00 plus GST@18 percent. The monthly rent paid by the company for financial year 2018-19 is Rs. 2,68,750.00 plus GST@18 percent. with an increment of 7.5 percent from April-18 onwards.

**3.13. Taxes on Income**

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.
- Deferred tax is recognised, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.
- Minimum Alternate Tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will be in a position to avail of such credit under the provisions of the Income Tax Act, 1961.

**3.14. Earnings Per Share (EPS)**

- Annualised basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.
- Annualised diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

**3.15. Cash Flow Statement:**

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (AS) 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

**3.16. Contingencies and Provisions**

A provision is recognised when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.



Details of Contingent Liabilities in the form of Bank Guarantee as on 31.03.2019.

Bank Name	Bank Guarantee No.	Opening Date	Expiry Date	In Favour	Amount
ICICI Bank Ltd	0043BGFD003118	02.09.2017	31.08.2025	The President of India Through The Deputy Commissioner of Customs, Air Cargo Complex, New Delhi	8,22,770
Vijaya Bank	8304IBGIS180059	26.10.2018	30.05.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	90,000
Vijaya Bank	8304IBGIS180060	26.10.2018	30.05.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	37,000
Vijaya Bank	8304IBGIS180065	31.12.2018	04.10.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	76,000
Vijaya Bank	8304IBGIS180066	31.12.2018	29.09.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	79,000
Vijaya Bank	8304IBGIS180068	31.12.2018	29.09.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	52,000
Vijaya Bank	8304IBGIS180069	31.12.2018	04.10.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	61,000
Vijaya Bank	8304IBGIS180070	31.12.2018	04.10.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	38,000
Vijaya Bank	8304IBGIS180071	31.12.2018	04.10.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	32,000
Vijaya Bank	8304IBGIS180019	08.03.2019	08.06.2020	TAMILNADU MEDICAL SERVICES CORP, LTD,NO.417, PANTHEON ROAD,	2,33,883
Vijaya Bank	8304IBGIS180021	29.03.2019	22.11.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	1,26,000
Vijaya Bank	8304IBGIS180022	29.03.2019	20.11.2020	PRESIDENT OF INDIA THROUGH OFFICE OF DGAFMS,NEW DELHI	81,000
				<b>TOTAL</b>	<b>17,28,653</b>

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

**NOTE 4 : OTHER NOTES TO ACCOUNTS**  
**(Forming part of Accounts)**  
**FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019**

**4.1. Contingent Liabilities & Commitments:**

- a) Estimated amount of contracts remaining to be executed and not provided for in the books of account - Nil (previous year - Nil).
- b) Contingent Liabilities:
  - Claims against the Company not acknowledged as debt - Nil (previous year - Nil).
  - Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

**4.2. Issued, Subscribed & Paid up Capital:**

Issued, Subscribed and Paid-up capital of the company is Rs. 8,64,95,000.00 (Divided into 86,49,500.00 shares of Rs. 10 each)

**4.3. Reserves & Surplus:**

- The amount shown in the Reserve & Surplus represents only surplus carried forward from the earlier year plus the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2019 is Rs. 31,94,65,064.64 which includes Share Premium of Rs. 16,16,12,604.98 and Free Reserves of Rs. 15,78,52,459.66

**4.4. Long-term Borrowings**

**Secured :**

**Term Loan:**

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Sanctioned Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Vijaya Bank	Term Loan of Rs. 150.00 Lakhs ( A/c No. 830409041000055)	Term Loan	Rs. 32.59 Lakhs	13.20%	Total Installments of Rs 3.36 Lacs P.M. divided into 63 Equated monthly installment. First Installment Commenced from January, 2015.	(1)All stocks of raw material/ stock in process/ finished warehouse/goods goods kept at factory, in transit and all other locations belonging to company
		Term Loan of Rs. 50.00 Lakhs (A/c No 830408391000014)	Term Loan	Rs. 11.63 Lakh	13.20%	Total Installments of Rs 1.12 Lacs P.M. divided into 63 Equated monthly installment. First Installment Commenced from January,2015.	(2)Equitable mortgage of .factory land in village Nandpur comprised in Khewat/Khatoni no. 114/157 in khasra No. 733/465 (00-05), 466(00-02), 735/467 (02-00), village Nandpur Tehsil Nalagarh, Distt. Baddi measuring 2 Bigha 7 Biswa owned by M/s Beta Drugs Pvt. Ltd. vide sale deed no. 712 dated 24.03.2006 charged to



2	SIDBI Loan						ML of the Company.
		Term Loan of Rs. 50.00 Lakhs (A/c No. 830409041000064)	Term Loan	Rs. 28.59 Lakh	13.00%	Total Installments of Rs 1.15 Lacs P.M. divided into 60 Equated monthly installment. First Installment Commenced from April,2017.	(3)Hypothecation of Plant & Machinery & other movable fixed assets of the company.
		Term Loan of Rs. 15.00 Lakhs ( A/c No. 830408411000229)	Term Loan	Rs. 10.64 Lakh	10.05%	Total Installments of Rs .249 Lacs P.M. divided into 84 Equated monthly installment. First Installment Commenced from August,2016.	(4)Collateral Charge on Vacant Showroom site at Khata No. 9/10 in Khasra No. 56 (1-2), village Dharampur, Hadbast No. 152, Tehsil Kalka measuring 1 Biswa 2 Biswani i.e. 55 Sq. Yards owned by one of the director Mr. Rahul Batra S/o Vijay Batra vide sales Deed No. 674 dated 16.05.2011.
		Term Loan of Rs. 10.14 Lakhs ( A/c No. 830408411000259)	Term Loan	Rs. 8.62 Lakh	9.15%	Total Installments of Rs 0.21 Lacs P.M. divided into 60 Equated monthly installment. First Installment Commenced from May,2018.	(5) Personal Guarantee of Vijay Kumar Batra S/o Sh. Jiwan dass, Balwant Singh S/o Sh. Sadhu Ram, Varun Batra S/o Sh. Vijay Kumar batra, Neeraj Batra W/o Sh. Vijay Kumar Batra, Rahul Batra S/o Sh. Vijay Kumar Batra.
		Term Loan of Rs. 100.00 Lakhs (Sanctioned Amount Rs. 100 Lac and Disbursed amount Rs. 98.65 Lac)	Term Loan	Rs. 85.12 Lakhs	11.65%	Total Installments of Rs 1.23 Lacs P.M. divided into 80 Equated monthly installment. Last Installment i.e. 81st Installment is of Rs. 0.25 Lac.	(6) HYP of Motor Vehicles from the bank in the name of Company.  1) HYP of Machinery and Fixed Deposit amounted Rs. 34 Lac with SIDBI as collateral.



		Term Loan of Rs. 400.00 Lakhs	Term Loan	Rs. 400 Lakhs	8.09%	Total Installments of Rs 7.40 Lacs P.M. after moratorium of 6 months divided into 53 Equated monthly installment. Last Installment i.e. 54th Installment is of Rs. 7.80 Lac.	1) HYP of Machinery amounted Rs. 829.00 Lacs and Fixed Deposit amounted Rs.150 Lac with SIDBI as collateral. Also Extension of Charge on Fixed Deposit already lien marked against previous SIDBI loan.
3	Axis Bank	Vehicle Loan of Rs.69.25 Lakhs	Term Loan	Rs. 40.51 Lakhs	8.38%	Total Installments of Rs 2.18 Lacs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
		Vehicle Loan of Rs.8.00 Lakhs	Term Loan	Rs. 6.74 Lakhs	8.40%	Total Installments of Rs 0.16 Lacs P.M. divided into 60 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
4	HDFC Bank	Vehicle Loan of Rs. 43.00 Lakhs	Term Loan	Rs. 19.29 Lakhs	8.76%	Total Installments of Rs 1.36 Lacs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
5	HDFC Bank	Vehicle Loan of Rs. 7.50 Lakhs	Term Loan	Rs. 6.47 Lakhs	8.98%	Total Installments of Rs 0.15 Lacs P.M. divided into 60 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.

**Unsecured :****Term Loan:**

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	ICICI Bank Limited	Unsecured Business Loan Rs. 27.50 Lakhs	Term Loan	Rs. 3.93 Lakhs	16.00%	Total Installments of Rs 1.34 Lacs P.M. divided into 24 Equated monthly installment.	Unsecured Loan
2	Edelweiss	Unsecured Business Loan of Rs. 40 Lakhs	Term Loan	Rs. 18.36 Lakhs	18.50%	Total Installments of Rs 1.46 Lacs P.M. divided into 37 Equated monthly installment.	Unsecured Loan

*Interest on the above term loans is payable on monthly basis.*

- 4.5. In the opinion of the Directors, "Current Assets" and "Loans & Advances" are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge provisions for all the known liabilities have been made and, *as certified*, all the contractual and statutory obligations have been duly complied with.





4.6. Party balances have been incorporated in the financial statements at the value as per the books of accounts & are considered hopeful of recovery/good for payment. The balance confirmation letter for both debtor and creditors are sent by the company through registered post, and only in few cases the balance confirmation is received from them.

**4.7. Depreciation / Amortisation**

- The management estimates the remaining useful life of existing fixed assets as on 01<sup>st</sup> April, 2014 as follows:-

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Lab Equipment	10 years
Equipment (Other)	5 years
Vehicles	8 years

For these class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part-C of Schedule-II of the Companies Act, 2013. (Refer note 3.4).

**4.8. Earnings Per Share (AS-20)**

	<u>Year ended</u> <u>31<sup>st</sup> March, 2019</u>		<u>Year ended</u> <u>31<sup>st</sup> March, 2018</u>	
<b>Numerator</b>				
Net Profit/(Loss)				
attributable to Equity shareholders		` 7,71,40,924.85		` 6,76,36,664.85
<b>Denominator</b>				
Number of Equity shares	No.'s	86,49,500	No.'s	86,94,500
Nominal				
Value per Equity share		` 10		` 10
Earnings per Equity share				
- Basic and diluted		8.92/8.92		7.82/7.82

**4.9. Non-Current Investments:**

Investment in Joint ventures and Associates are accounted for using the equity method of accounting. Under the equity method of accounting, the investments are initially recognised at cost and adjusted thereafter to recognise Dividends received or receivable from associates or joint ventures are recognized as a reduction in the carrying amount of the investment.

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act, 2013 have been complied with.

During the financial year 2018-2019 the company has made investments in following entities : .

1. The company entered into a Joint Venture with SILUJIN Private Co. Ltd, Uzbekistan by incorporating subsidiary company namely BETA UBK INTERNATIONAL PRIVATE LIMITED in Republic of Uzbekistan registered with Department of Company Affairs, Tashkent Province, Uzbekistan dated 07.09.2018 to manufacture Oncology Drugs in Uzbekistan. The company holds 60 % in Joint Venture with 40 % share with SILUJIN Private Co. Ltd. The Company has invested \$48,000.00 and Silujin private Co. Ltd has invested

## 14<sup>TH</sup> ANNUAL REPORT



## BETA DRUGS LIMITED

\$32,000.00. The company has not included the accounts of M/s BETA UBK INTERNATIONAL PRIVATE LIMITED since the operations are not started yet.

2. The company has incorporated a 100 % Subsidiary in the name of M/s Adley Formulations Private Limited with an investment of Rs. 1,26,00,000.00. Having 12,59,999 Equity Shares of Rs.10 each in the name of Beta Drugs Limited thru Mr. Vijay Kumar Batra, Managing Director and balance 1 Equity Share of Rs. 10 each through beneficial holder Mr. Rahul Batra.

This Wholly owned subsidiary has acquired the entire business of Adley Formulations. Adley Formulations is a Proprietorship firm, owned by Mr. Vijay Kumar Batra and is in business of manufacturing of Oncology and general medicines both in form of tablets & injectables since year 2008.

### 4.10. Taxes

- The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate, till finalisation of assessments and no disputed dues or amounts were outstanding or remaining unpaid as at 31<sup>st</sup> March, 2019.
- MAT Credit Entitlement Rs. 1,53,70,422.70 i.e. additions during the year has been shown under the head 'Reserves & Surplus' with corresponding effect under the head 'Long-term Loans & Advances' in accordance with the accepted accounting principles; the opening MAT credit entitlement was Rs. 2,72,16,624.00
- The amount of tax credit determined shall be carried forward upto fifteen assessment years immediately succeeding the assessment year in which tax credit becomes allowable.

### 4.11. Segment Reporting

Since the Company primarily operates in one segment (i.e. Manufacturing of Oncology medicines), therefore segment reporting as required under Accounting Standard - 17 is not applicable - there is no reportable geographical segment as the export sale of the company is less than 10% of the total sales made in India.

### 4.12. Related Party Disclosures

Related parties & their relationship and related parties transactions.

S. NO.	Related Party	Nature of Relationship	Nature of Transaction	Amount Involved During the year
1.	Adley Lab Limited	Share holder are common ( Holding more than 50 % shares)	Purchase of Goods	7,18,82,648.20
2.	Adley Formulations - Baddi	Managing Director is Proprietor of the Firm.	Sale of Goods	20,72,137.47
			Purchase of Goods	5,29,257.00
3.	B.T. Associates Private Limited	Share holder are common ( Holding more than 50 % shares)	Payment of Building Rent	34,08,595.00
4.	Adley Formulations Private Limited	100 percent Subsidiary	Sale of Goods	10,64,392.00
5.	Varun Batra	Director	Salary	36,00,000.00
6.	Neeraj Batra	Director	Salary	32,00,000.00
7.	Balwant Singh	Director	Salary	16,32,000.00
8.	Rahul Batra	Director	Salary	12,00,000.00
9.	Jayant Kumar	Chief Financial Officer	Salary	11,04,000.00
10.	Rajni Brar	Company Secretary	Salary	5,28,000.00

### 4.13 Impairment of Assets

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of AS-28 on "Impairment of Assets" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognised for the year.

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

### 4.14 Fixed Assets:

- During the financial year 2018-19 the company has made an addition of Rs. 13,69,41,086.88 as Capital Work-in Progress.
- During the financial Year 2018-19 there was an addition of Rs. 15,00,000.00 under the head Land.
- During the financial Year 2018-19 there was no addition under the head Building.
- During the financial year, there was addition Of Rs. 85,49,474.09 made to Plant & Machinery, Furniture & Fixtures, Office Equipment, Vehicles & Computers.

### 4.15. Deferred Tax Assets & Liabilities

During the FY 2018-19 the company has made Deferred Tax Provision (Asset) of Rs. 24,79,381.06. Details of Calculation in mentioned below.

Calculation of Deferred Tax Asset / Liability	Amount in RS.
Deferred Tax Asset on depreciation	14,23,908.01
Deferred Tax Asset on provision of gratuity	3,24,866.55
Deferred Tax Asset on provision of bonus	5,32,038.19
Deferred Tax Asset on provision of CSR	1,98,568.31
<b>Total Deferred Tax Asset Created for the financial year 2018-19 in Profit and Loss Account.</b>	<b>24,79,381.06</b>
Less : Deferred Tax Liability as on 31.03.2018 ( Opening)	14,99,675.95
<b>Balance Deferred Tax Asset recognized in Balance Sheet</b>	<b>9,79,705.11</b>

### 4.16. Government Grants:

During the year, the company has received Government Subsidy amounting Rs. 6,35,197.00 against the asset which was fully depreciated, hence this amount credited to the Profit & Loss Account.

### 4.17. Micro, Small & Medium Enterprises

Based on the information presently available, total outstanding as on 31.03.2019 is Rs.5,84,21,720.40 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

### 4.18. Auditor's Remuneration (exclusive of GST)

	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
-As Statutory Auditors	4,02,500	4,02,500
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
 -As Internal Auditor	 9,00,000	 9,00,000
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
 - Reimbursement of out of pocket expenses	 -	 -
<b>TOTAL</b>	<b>13,02,500</b>	<b>13,02,500</b>

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

## 4.19 Other additional information

<u>Particulars</u>	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
<b>"A" Revenue from operations (under broad heads)</b>		
Sales		
-Sales With in India	53,19,86,164.99	49,12,52,621.35
-Export Sales	<u>4,85,00,674.00</u>	<u>1,44,15,249.91</u>
	58,04,86,838.99	50,56,67,781.26
<b>"B" Purchases</b>		
-Chemicals, Bulk Drugs & Packing Material	<u>28,61,00,183.50</u>	<u>23,32,46,427.98</u>
4.20. Expenditure In Foreign Currency (On Accrual Basis) :- Following Expenses were incurred by the company during the year 2018-19.		

	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
- Import of Capital Goods	3,04,603	1,01,25,321
Revenue Expenses ( Travel)	16,87,707	7,21,450
Revenue Expenses ( RM Purchase)	26,39,390	-
<b>TOTAL</b>	<u><b>46,31,700</b></u>	<u><b>1,08,46,771</b></u>

4.21. Earning in Foreign Currency	For The Year Ended	For the year Ended
Particulars	( 31.03.2019)	( 31.03.2018)
FOB Value of Export	4,85,00,674.00*	1,44,15,249.91*

\* This includes indirect export.

4.22. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation.

In terms of our attached report of even date.  
For Kalra Rai & Associates

**CHARTERED ACCOUNTANTS**  
F R No. – 008859N  
Sd/-  
**LAJPAT RAI KALRA**  
**PARTNER**  
M No. -087438

For and on behalf of the Board of Director

sd/-  
(Managing Director)

sd/-  
(Whole-time Director)

sd/-  
(Chief Financial Officer)

sd/-  
(Company Secretary)

Dated: 13/05/2019  
Place : Chandigarh



**CONSOLIDATED FINANCIAL STATEMENTS**

**OF**

**“BETA DRUGS LIMITED”**

**&**

**ITS WHOLLY –OWNED SUBSIDIARY**

**“ADLEY FORMULATIONS PRIVATE LIMITED”**

**FOR THE FINANCIAL YEAR**

**2018-19**



**KALRA RAI & ASSOCIATES  
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1<sup>st</sup> floor, Sector-43-A  
Chandigarh-160022**

## **Independent Auditors' Report**

Members of Beta Drugs Limited

### **Report on the Audit of the Consolidated Financial Statements**

#### **Opinion**

We have audited the accompanying Consolidated financial statements of Beta Drugs Limited ((hereinafter referred to as the "Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2019, the consolidated Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Consolidated Statement of Cash Flows for the year ended on that date, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006 as amended, ("AS") and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2019, the consolidated Profit and its cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the Consolidated Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated Financial Statements.

#### **Information Other Than the Consolidated Financial Statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the Consolidated Financial Statements and our auditor's report thereon. Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. We have been provided the aforesaid reports and based on the work we have performed, we did not observe any material misstatement of this other information and accordingly, we have nothing to report in this regard.

#### **Responsibilities of Management and those Charged with Governance for the Consolidated Financial Statements**

The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Consolidated Financial Statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of



adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial Statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Group's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.





We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

Financial statements of one subsidiary whose financial statements (before consolidation adjustments) reflect total Assets of Rs. 1964.02 lakhs as at March 31, 2019, total revenues of Rs. 793.89 lakhs and net cash flows amounting to Rs. (38.36) lakhs for the year ended on March 31, 2019, have been audited by us.

#### Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Companies Act, 2013, we report, to the extent applicable, that;

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Group so far as it appears from our examination of those books.

(c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.

(d) In our opinion, the aforesaid consolidated financial statements comply with the AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2019 taken on record by the Board of Directors of the Holding Company, none of the directors of the Group companies is disqualified as on March 31, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Group's internal financial controls over financial reporting.

(g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its directors during the year is in accordance with the provisions of section 197 of the Act and is not in excess of the limit laid down under this section. In the case of a subsidiary company incorporated in India, the managerial remuneration has not been paid or provided and accordingly, the requisite approvals mandated by the provisions of Section 197 read with Schedule V of the Act are not required.

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:

(I) The Group has no pending litigations which has any impact on their consolidated financial position in their consolidated Financial Statements;

(II) The Group did not have any long-term contracts including derivative contracts, for which there were any material foreseeable losses;

(III) There were no amounts that were required to be transferred to the Investor Education and Protection Fund by the Group.

**For Kalra Rai & Associates**

**Chartered Accountants**

**(FRN: 008859N)**

**Sd/-**

**Lajpat Rai Kalra**

**(Sr.Partner)**

**Membership No.087438**

**Date: 13/05/2019**





## Annexure- A

**To the Independent Auditors' Report:****Report on the Internal Financial Controls under clause (I) of Sub section 3 of Section 143 of the Companies Act, 2013 ("The Act")**

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2019, We have audited the internal financial controls over financial reporting of Beta Drugs Limited (hereinafter referred to as "the Holding Company") as of March 31, 2019.

**Management's Responsibility for Internal Financial Controls**

The respective Board of Directors of the Holding company and its subsidiary company, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

**Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and



---

directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Kalra Rai & Associates****Chartered Accountants****(FRN: 008859N)****Sd/-Lajpat Rai Kalra****(Sr.Partner)****Membership No.087438****Date: 13/05/2019**

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

**BETA DRUGS LIMITED (CONSOLIDATED)**  
**VILLAGE NANDPUR, BADDI, SOLAN 174101**  
**CIN : L24230HP2005PLC028969**  
**BALANCE SHEET AS AT 31 MARCH ' 2019**

Particulars		Note No.	As at 31 March' 2019	As at 31 March' 2018
			Amount in Rs.	Amount in Rs.
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Shareholders' funds</b>			
	(a) Share capital	1	86,495,000.00	86,495,000.00
	(b) Reserves and surplus	2	322,722,940.54	242,324,139.79
	(c) Money received against share warrants		-	-
			<b>409,217,940.54</b>	<b>328,819,139.79</b>
<b>2</b>	<b>Share application money pending allotment</b>		-	-
<b>3</b>	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	3	73,631,274.21	27,515,726.91
	(b) Deferred tax liabilities (net)	4	-	1,499,675.95
	(c) Other long-term liabilities	5	18,468,275.00	2,500,000.00
	(d) Long-term provisions		-	-
			<b>92,099,549.21</b>	<b>31,515,402.86</b>
<b>4</b>	<b>Current liabilities</b>			
	(a) Short-term borrowings	6	108,758,919.65	35,865,012.02
	(b) Trade payables	7	131,170,898.71	61,058,593.71
	(c) Other current liabilities	8	76,779,945.85	35,289,931.92
	(d) Short-term provisions		7,355,573.90	3,254,956.00
			<b>324,065,338.11</b>	<b>135,468,493.65</b>
	<b>TOTAL</b>		<b>825,382,827.86</b>	<b>495,803,036.30</b>
<b>B</b>	<b>ASSETS</b>			
<b>1</b>	<b>Non-current assets</b>			
	(a) Fixed assets			
	(i) Tangible assets	9	173,193,033.18	131,870,936.38
	(ii) Intangible assets		-	-
	(iii) Capital work-in-progress		150,415,738.88	13,474,652.00
	(iv) Intangible assets under development		-	-
	(v) Fixed assets held for sale		-	-
			<b>323,608,772.06</b>	<b>145,345,588.38</b>
	(b) Non-current investments	10	3,520,592.62	-
	(c) Deferred tax assets (net)	4	1,369,093.92	-
	(d) Long-term loans and advances	11	42,587,046.70	27,216,624.00
	(e) Other non-current assets		-	-
			<b>47,476,733.24</b>	<b>27,216,624.00</b>
<b>2</b>	<b>Current assets</b>			
	(a) Current investments		-	-
	(b) Inventories	12	95,293,672.65	28,034,802.00
	(c) Trade receivables	13	250,284,489.20	144,422,475.31
	(d) Cash and cash equivalents	14	33,016,247.09	119,066,796.46
	(e) Short-term loans and advances	15	15,378,352.48	14,129,962.48
	(f) Other current assets	16	60,324,561.15	17,586,787.67
			<b>454,297,322.57</b>	<b>323,240,823.92</b>
	<b>TOTAL</b>		<b>825,382,827.86</b>	<b>495,803,036.30</b>
	<b>See accompanying notes forming part of the financial statements</b>			

In terms of our report attached.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN: 008859N)

sd/-

LAJPAT RAI KALRA

Partner

MEMBERSHIP NO. 087438

Place : Chandigarh

Date : 13.05.2019

sd/-

JAYANT KUMAR

C.F.O

sd/-

RAJNI BRAR

C.S.

sd/-

BALWANT SINGH

DIRECTOR

DIN: 1089968

sd/-

VIJAY KUMAR BATRA

MANAGING DIRECTOR

DIN: 01083215

For and on the behalf of the Board of Directors

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

<b>BETA DRUGS LIMITED (CONSOLIDATED)</b> <b>VILLAGE NANDPUR, BADDI, SOLAN 174101</b> <b>CIN : L24230HP2005PLC028969</b> <b>STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH' 2019</b>			
Particulars	Note No.	As at 31 March' 2019	As at 31 March' 2018
		Amount in Rs.	Amount in Rs.
<b>A CONTINUING OPERATIONS</b>			
1 Revenue from operations (gross)	17	659,290,672.52	505,667,871.26
Less: Excise duty		-	-
Revenue from operations (net)		659,290,672.52	505,667,871.26
2 Other income	18	3,742,886.77	2,443,898.26
3 <b>Total revenue (1+2)</b>		663,033,559.29	508,111,769.52
4 <b>Expenses</b>			
(a) Cost of materials consumed	19	370,954,107.26	278,622,734.42
(b) Purchases of stock-in-trade		-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20	-36,680,420.21	-6,776,658.00
(d) Other manufacturing expenses	21	79,464,541.99	63,810,807.26
(d) Employee benefits expense	22	52,688,637.73	18,827,475.77
(e) Finance costs	23	14,311,641.37	10,142,990.07
(f) Depreciation and amortisation expense	9	28,415,646.53	18,506,706.56
(g) Other expenses	24	74,815,325.84	56,620,793.39
<b>Total expenses</b>		<b>583,969,480.50</b>	<b>439,754,849.47</b>
5 <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		79,064,078.79	68,356,920.05
6 Exceptional items		-	-
7 <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>		<b>79,064,078.79</b>	<b>68,356,920.05</b>
8 Extraordinary items/Prior period items		-	-
9 <b>Profit / (Loss) before tax (7 ± 8)</b>		<b>79,064,078.79</b>	<b>68,356,920.05</b>
10 <b>Tax expense:</b>			
(a) Current tax expense for current year		16,904,470.60	13,937,189.89
(b) (Less): MAT credit (where applicable)		-15,370,422.70	-13,937,189.89
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		1,534,047.90	-
(e) Deferred tax		-2,868,769.87	720,255.20
		<b>-1,334,721.97</b>	<b>720,255.20</b>
11 <b>Profit / (Loss) from continuing operations (9 ± 10)</b>		<b>80,398,800.75</b>	<b>67,636,664.85</b>
<b>B DISCONTINUING OPERATIONS</b>			
12 <b>Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)</b>		-	-
<b>C TOTAL OPERATIONS</b>		<b>80,398,800.75</b>	<b>67,636,664.85</b>
13 <b>Profit / (Loss) for the year (11 ± 12)</b>		<b>80,398,800.75</b>	<b>67,636,664.85</b>
14 <b>Earnings per share (of `Rs10/- each):</b>			
(a) Basic			
(i) Continuing operations		9.30	7.82
(ii) Total operations		9.30	7.82
(b) Diluted			
(i) Continuing operations		9.30	7.82
(ii) Total operations		9.30	7.82
<b>See accompanying notes forming part of the financial statements</b>			
In terms of our report attached. <b>For KALRA RAI AND ASSOCIATES</b> Chartered Accountants (FRN: 008859N) <b>LAJPAT RAI KALRA</b> Partner MEMBERSHIP NO. 087438 Place : Chandigarh Date : 13.05.2019			
<div style="display: flex; justify-content: space-between;"> <div> sd/-  <b>JAYANT KUMAR</b>  C.F.O </div> <div> sd/-  <b>RAJNI BRAR</b>  C.S. </div> <div> sd/-  <b>BALWANT SINGH</b>  DIRECTOR  DIN: 1089968 </div> <div> sd/-  <b>VIJAY KUMAR BATRA</b>  MANAGING DIRECTOR  DIN: 01083215 </div> </div>			
<b>For and on the behalf of the Board of Directors</b>			

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

**BETA DRUGS LIMITED (CONSOLIDATED)**  
**VILLAGE NANDPUR, BADDI, SOLAN 174101**  
**CIN : L24230HP2005PLC028969**  
**CASHFLOW STATEMENT FOR THE YEAR ENDED 31 MARCH' 2019**

Particulars	As at 31 March' 2019	As at 31 March' 2018
	Amount in Rs.	Amount in Rs.
<b>A CASHFLOW FROM OPERATING ACTIVITIES</b>		
Net Profit before tax and extraordinary items(as per Statement of Profit & Loss)	79,064,078.79	68,356,920.05
Adjustments for non Cash/Non trade items:		
Depreciation & Amortization Expenses	28,415,646.53	18,506,706.56
Finance Cost	14,311,641.37	10,142,990.07
Interest received	(2,361,807.00)	(2,110,151.00)
Other inflows/ (outflows) of cash	(12,803,852.70)	124,078,206.98
<b>Operating profits before Working Capital Changes</b>	<b>106,625,706.99</b>	<b>218,974,672.66</b>
<b>Adjusted For:</b>		
(Increase)/Decrease in trade receivables	(105,862,013.89)	(39,280,470.19)
Increase/ (Decrease) in trade payables	70,112,305.00	(9,505,336.60)
(Increase)/Decrease in inventories	(67,258,870.65)	(4,067,195.00)
Increase/ (Decrease) in other current liabilities	41,490,013.93	16,142,321.92
(Increase)/Decrease in short term loans and advances	(1,248,390.00)	3,935,052.37
(Increase)/Decrease in other current assets	(42,737,773.48)	(15,153,737.67)
<b>Cash generated from Operations</b>	<b>1,120,977.90</b>	<b>171,045,307.49</b>
<b>Net cashflow from Operating Activities (A)</b>	<b>1,120,977.90</b>	<b>171,045,307.49</b>
<b>B CASHFLOW FROM INVESTING ACTIVITIES</b>		
Purchase of tangible assets	(206,678,830.21)	(82,783,181.06)
Interest received	2,361,807.00	2,110,151.00
Cash advances and loans made to other parties	(3,520,592.62)	(27,216,624.00)
<b>Net cash used in Investing Activities (B)</b>	<b>(207,837,615.83)</b>	<b>(107,889,654.06)</b>
<b>C CASHFLOW FROM FINANCING ACTIVITIES</b>		
Finance Cost	(14,311,641.37)	(10,142,990.07)
Increase in/ (Repayment) of Short term Borrowings	72,893,907.63	(1,650,116.05)
Increase in/ (Repayment) of Long term Borrowings	62,083,822.30	(10,133,224.07)
Increase/ (Decrease) in share capital	-	76,395,000.00
Other Inflows/ (Outflows) of cash	-	-
<b>Net cash used in Financing Activities (C)</b>	<b>120,666,088.56</b>	<b>54,468,669.81</b>
<b>D Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>(86,050,549.37)</b>	<b>117,624,323.24</b>
<b>E Cash &amp; Cash equivalents at beginning of period</b>	<b>119,066,796.46</b>	<b>1,442,473.22</b>
<b>F Cash &amp; Cash equivalents at end of period</b>	<b>33,016,247.09</b>	<b>119,066,796.46</b>
<b>G Net Increase/(Decrease) in cash &amp; cash equivalents (F-E)</b>	<b>(86,050,549.37)</b>	<b>117,624,323.24</b>

In terms of our report attached.

**For KALRA RAI AND ASSOCIATES**

**Chartered Accountants**

**(FRN: 008859N)**

**sd/-**

**LAJPAT RAI KALRA**

**Partner**

**MEMBERSHIP NO. 087438**

**Place : Chandigarh**

**Date : 13.05.2019**

**sd/-**

**JAYANT KUMAR**

**C.F.O**

**sd/-**

**RAJNI BRAR**

**C.S.**

**sd/-**

**BALWANT SINGH**

**DIRECTOR**

**DIN: 1089968**

**sd/-**

**VIJAY KUMAR BATRA**

**MANAGING DIRECTOR**

**DIN: 01083215**

**For and on the behalf of the Board of Directors**



<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>				
<b>Notes forming part of the financial statements</b>				
<b>Note 1 Share capital</b>				
Particulars	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares	Amount in Rs.	Number of shares	Amount in Rs.
(a) Authorised - Equity shares of Rs. 10 each	10,000,000.00	100,000,000.00	10,000,000.00	100,000,000.00
	-	-	-	-
(b) Issued - Equity shares of Rs. 10 each	8,649,500.00	86,495,000.00	8,649,500.00	86,495,000.00
	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	8,649,500.00	86,495,000.00	8,649,500.00	86,495,000.00
	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
<b>Total</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>	<b>8,649,500.00</b>	<b>86,495,000.00</b>
Details of shares held by each shareholder holding more than 5% shares:				
Class of shares / Name of shareholder	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mr. Vijay Kumar Batra	5,973,580	69.06%	5,924,780	68.50%
<b>Note 2 Reserves and surplus</b>				
Particulars	As at 31 March' 2019		As at 31 March, 2018	
	Amount in Rs.		Amount in Rs.	
(a) Capital reserve				
Opening balance	-	-	-	-
Closing balance	-	-	-	-
(b) Securities premium account				
Opening balance	-	-	-	-
Closing balance	161,612,604.98	161,612,604.98	161,612,604.98	161,612,604.98
(c) Surplus / (Deficit) in Statement of Profit and Loss				
Opening balance	80,711,534.81	50,609,267.96	50,609,267.96	50,609,267.96
Add :- Opening Provision For Mat	-	13,279,434.00	13,279,434.00	13,279,434.00
Less :- Provision for Gratuity	-	1,323,832.00	1,323,832.00	1,323,832.00
Less :- Used In Issue Of Share Capital ( Right Issue)	-	49,490,000.00	49,490,000.00	49,490,000.00
	80,711,534.81	13,074,869.96	13,074,869.96	13,074,869.96
Add: Profit / (Loss) for the year	80,398,800.75	67,636,664.85	67,636,664.85	67,636,664.85
Closing balance	<b>161,110,335.56</b>	<b>80,711,534.81</b>	<b>80,711,534.81</b>	<b>80,711,534.81</b>
<b>Total</b>	<b>322,722,940.54</b>	<b>242,324,139.79</b>	<b>242,324,139.79</b>	<b>242,324,139.79</b>

**BETA DRUGS LIMITED (CONSOLIDATED)**

Notes forming part of the financial statements

**Note 3 Long-term borrowings**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Term loans</b>		
<b>From banks</b>		
<b>Secured</b>		
Vijaya Bank ( Building)	-	1,216,714.88
Vijaya Bank ( Machinery New)	1,696,562.00	3,031,371.00
Vijaya Bank ( Machinery Old)	-	3,614,131.00
SIDBI ( Machinery New canada)	7,036,000.00	8,512,000.00
SIDBI ( Term Loan new)	35,560,000.00	-
HDFC Bank (Car Loan)	916,629.16	1,929,307.03
ICICI Bank ( Car Loan)	1,466,676.60	
Vijaya Bank ( Car Loan)	1,523,555.00	1,063,037.00
Axis Bank (Car Loan)	2,211,328.00	4,051,270.00
Kotak Bank LAP (Showroom)	17,353,355.71	-
HDFC Bank Loan	1,198,658.74	-
	<b>68,962,765.21</b>	<b>23,417,830.91</b>
<b>From other parties</b>		
Unsecured ( From Related Parties)	-	-
Secured	-	-
Edelweiss Limited	423,726.00	1,936,836.00
ICICI Bank	-	392,715.00
<b>Total - A</b>	<b>423,726.00</b>	<b>2,329,551.00</b>
Unsecured ( From Unrelated Parties)		
Provision For Gratuity	4,244,783.00	1,768,345.00
<b>Total - B</b>	<b>4,244,783.00</b>	<b>1,768,345.00</b>
	4,668,509.00	4,097,896.00
<b>The Above Amount Includes</b>		
Secured Borrowings	<b>68,962,765.21</b>	<b>23,417,830.91</b>
Unsecured Borrowings	<b>4,668,509.00</b>	<b>4,097,896.00</b>
<b>Total</b>	<b>73,631,274.21</b>	<b>27,515,726.91</b>



# 14<sup>TH</sup> ANNUAL REPORT



## BETA DRUGS LIMITED

BETA DRUGS LIMITED (CONSOLIDATED)						
Notes forming part of the financial statements						
Notes: Long-term borrowings						
Particulars	As at 31 March' 2019			As at 31 March, 2018		
	Amount in Rs.			Amount in Rs.		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
<b>Term loans</b>						
<b>From banks</b>						
<b>Secured</b>						
Vijaya Bank ( Building)*	-	1,162,845.88	1,162,845.88	1,216,714.88	1,044,269.00	2,260,983.88
Vijaya Bank ( Machinery New)**	1,696,562.00	1,162,785.00	2,859,347.00	3,031,371.00	865,645.00	3,897,016.00
Vijaya Bank ( Machinery Old)***	-	3,258,698.00	3,258,698.00	3,614,131.00	3,132,788.00	6,746,919.00
SIDBI ( Machinery New Canada)	7,036,000.00	1,476,000.00	8,512,000.00	8,512,000.00	1,353,000.00	9,865,000.00
SIDBI ( Term Loan new)	35,560,000.00	4,440,000.00	40,000,000.00	-	-	-
HDFC Bank Brezza	513,749.95	133,745.07	647,495.02	-	-	-
ICICI Bank BMW Loan	-	-	-	-	117,557.10	117,557.10
ICICI Bank Rangerover Loan	-	-	-	-	188,100.00	188,100.00
ICICI Bank POLO Loan	-	-	-	-	35,756.00	35,756.00
Vijaya Bank ( Force Traveller Loan)	-	-	-	-	209,961.00	209,961.00
Vijaya Bank ( Creta Car Loan)	678,201.00	183,810.00	862,011.00	-	-	-
Vijaya Bank (Innova Crysta Loan)	845,354.00	218,711.00	1,064,065.00	1,063,037.00	182,234.00	1,245,271.00
Axis Bank ( W-RV Car)	528,860.00	145,375.00	674,235.00	-	-	-
Axis Bank ( Porsche Car)	1,682,468.00	2,368,802.00	4,051,270.00	4,051,270.00	2,179,003.00	6,230,273.00
HDFC Bank ( Merc Sports)	402,879.21	1,526,427.82	1,929,307.03	1,929,307.03	1,398,841.32	3,328,148.35
ICICI Bank ( Merc ML-350)	1,466,676.60	1,024,685.40	2,491,362.00	-	-	-
Kotak Bank LAP (Showroom)	17,353,355.71	1,140,631.99	18,493,987.70	-	-	-
HDFC Bank Loan	1,198,658.74	1,490,405.27	2,689,064.01	-	-	-
	<b>68,962,765.21</b>	<b>19,732,922.43</b>	<b>88,695,687.64</b>	<b>23,417,830.91</b>	<b>10,707,154.42</b>	<b>34,124,985.33</b>
<b>From other parties</b>						
Unsecured ( From Related Parties)	-	-	-	-	-	-
Secured	-	-	-	-	-	-
Edelweiss Limited****	423,726.00	1,412,607.00	1,836,333.00	1,936,836.00	1,207,628.00	3,144,464.00
ICICI Bank	-	392,715.00	392,715.00	392,715.00	1,423,731.00	1,816,446.00
<b>Total - A</b>	<b>423,726.00</b>	<b>1,805,322.00</b>	<b>2,229,048.00</b>	<b>2,329,551.00</b>	<b>2,631,359.00</b>	<b>4,960,910.00</b>
Unsecured ( From Unrelated Parties)	-	-	-	-	-	-
Provision For Gratuity	4,244,783.00	-	4,244,783.00	1,768,345.00	-	1,768,345.00
<b>Total - B</b>	<b>4,244,783.00</b>	<b>-</b>	<b>4,244,783.00</b>	<b>1,768,345.00</b>	<b>-</b>	<b>1,768,345.00</b>
	<b>4,668,509.00</b>	<b>1,805,322.00</b>	<b>6,473,831.00</b>	<b>4,097,896.00</b>	<b>2,631,359.00</b>	<b>6,729,255.00</b>
<b>The Above Amount Includes</b>						
Secured Borrowings	<b>68,962,765.21</b>	<b>19,732,922.43</b>	<b>88,695,687.64</b>	<b>23,417,830.91</b>	<b>10,707,154.42</b>	<b>34,124,985.33</b>
Unsecured Borrowings	<b>4,668,509.00</b>	<b>1,805,322.00</b>	<b>6,473,831.00</b>	<b>4,097,896.00</b>	<b>2,631,359.00</b>	<b>6,729,255.00</b>
Amount disclosed under "Other Current Liabilities"		<b>-21,538,244.43</b>	<b>-21,538,244.43</b>		<b>-13,338,513.42</b>	<b>-13,338,513.42</b>
<b>Total</b>	<b>73,631,274.21</b>	<b>-</b>	<b>73,631,274.21</b>	<b>27,515,726.91</b>	<b>-</b>	<b>27,515,726.91</b>

\* The rate of interest changed from 13.25% to 9.55% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\* The rate of interest changed from 13% to 9.45% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\*\* The rate of interest changed from 14.05% to 9.55% from June 2018 onwards hence the principal repayments in current year were more than the current maturities taken last year.

\*\*\*\* TDS on interest paid - Rs. 1,00,503 is recoverable from Edelweiss.



**BETA DRUGS LIMITED (CONSOLIDATED)****BETA DRUGS LIMITED (CONSOLIDATED)****Note 4 Deferred Tax**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Deferred tax liabilities</b>		
Deferred tax on depreciation	-	1,499,675.95
<b>Deferred tax assets</b>		
Deferred tax on depreciation	1,579,647.82	-
Deferred tax on unabsorbed depreciation	-	-
Deferred tax on provision of gratuity	558,515.55	-
Deferred tax on provision of bonus	532,038.19	-
Deferred tax on provision of CSR	198,568.31	-
Less: Deferred Tax Liability as on 31.03.2018	-1,499,675.95	
<b>Net Deferred tax liabilities/assets</b>	<b>1,369,093.92</b>	<b>1,499,675.95</b>

**Continue Note 4 Current tax Provision**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Current Year Tax	16,904,470.60	3,254,956.00
Less :- Advance Tax Including TDS	-9,548,896.70	
<b>Short term Provision</b>	<b>7,355,573.90</b>	<b>3,254,956.00</b>
<b>Net Current Tax provision</b>	<b>7,355,573.90</b>	<b>3,254,956.00</b>

**Note 5 Other long-term liabilities**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Trade Payables: *	-	-
(i) Acceptances	-	-
(ii) Other than Acceptances	-	-
(b) Others:		
(i) Payables on purchase of fixed assets	-	-
(ii) Contractually reimbursable expenses	-	-
(iii) Interest accrued but not due on borrowings	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(vii) Advances from customers	-	-
(viii) Income received in advance (Unearned revenue)	-	-
(ix) Security received from customers	18,468,275.00	2,500,000.00
<b>Total</b>	<b>18,468,275.00</b>	<b>2,500,000.00</b>



<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>		
<b>Note 6 Short-term borrowings</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Other loans and advances		
Secured		
- From Vijaya Bank CC Limit Secured	11,566,270.95	35,865,012.02
- From Kotak Bank CC Limit Secured	56,066,815.00	
- From Kotak Bank OD Limit Secured	41,125,833.70	
<b>Total</b>	<b>108,758,919.65</b>	<b>35,865,012.02</b>
<b>Note 7 Trade payables</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Trade payables:		
Micro Enterprises And Small Enterprises	72,307,640.40	20,428,610.00
Others	58,863,258.31	40,629,983.71
<b>Total</b>	<b>131,170,898.71</b>	<b>61,058,593.71</b>
<b>Note 8 Other current liabilities</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
(a) Other payables	13,986,762.00	7,003,026.50
(i) Current Maturities of Long Term Debt ( Note No. 3)	21,538,244.43	13,338,513.42
(ii) Payables on purchase of fixed assets	24,092,372.34	-
(iii) Contractually reimbursable expenses	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(ii) Advances from customers	-	-
(viii) Others (specify nature)	-	-
(b) Cheque issued yet not presented for Payment	10,954,486.00	10,210,666.00
Advances From Customers	6,208,081.08	4,737,726.00
<b>Total</b>	<b>76,779,945.85</b>	<b>35,289,931.92</b>
<b>Note 8 (a) Other current liabilities</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
PF Payable	572,517.00	322,402.00
ESI payable	110,930.00	78,924.00
TDS payable	1,368,330.00	561,187.00
Interest Accrued But Not Due	302,120.00	117,139.50
Salary & wages Payable	7,562,356.00	3,280,619.00
Other Expenses payable	522,153.00	126,217.00
Bonus Payable	2,583,964.00	2,056,870.00
CSR Provision	964,392.00	459,668.00
<b>Total</b>	<b>13,986,762.00</b>	<b>7,003,026.50</b>



# 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

Note No. 9 Fixed Assets Chart as at 31st March 2019

	Assets	Useful Life (In Years)	Shift	Gross Block					Accumulated Depreciation/ Amortisation				Net Block	
				Balance as at 1st April 2018	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March 2019	Balance as at 1st April 2018	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2019	Balance as at 31st March 2019	Balance as at 31st March 2018
<b>A</b>	<b>Tangible assets</b>													
	<b>Own Assets</b>													
	LAND		Single	4,291,730.00	1,500,000.00	2,978,750.00	-	8,770,480.00				-	8,770,480.00	4,291,730.00
	BUILDING	30	Single	58,374,927.52	-	26,327,480.91	-	84,702,408.43	11,016,312.76	5,539,646.30		16,555,959.06	68,146,449.37	47,358,614.76
	PLANT AND MACHINERY	15	Single	79,718,139.46	2,205,810.75	16,149,202.07	-	98,073,152.28	25,521,725.10	11,360,968.21		36,882,693.31	61,190,458.97	54,196,414.36
	FURNITURE AND FIXTURES	10	Single	2,255,394.00	626,900.00	639,167.43	-	3,521,461.43	775,475.39	487,413.08		1,262,888.47	2,258,572.96	1,479,918.61
	COMPUTER	3	Single	423,955.85	1,182,199.14	44,048.05	-	1,650,203.04	241,110.36	533,881.90		774,992.26	875,210.78	182,845.49
	VEHICLE	8	Single	26,168,476.00	3,059,852.19	11,624,405.08	-	40,852,733.27	8,620,288.74	7,845,050.97		16,465,339.71	24,387,393.56	17,548,187.26
	OFFICE EQUIPMENTS	5	Single	3,055,654.93	622,822.26	1,917,515.70	-	5,595,992.89	1,805,589.69	1,066,017.80		2,871,607.49	2,724,385.40	1,250,065.24
	LAB EQUIPMENTS	10	Single	6,263,217.01	859,589.75	0.00	-	7,122,806.76	700,056.35	1,582,668.27		2,282,724.62	4,840,082.14	5,563,160.66
	<b>Total (A)</b>			<b>180,551,494.77</b>	<b>10,057,174.09</b>	<b>59,680,569.24</b>	<b>-</b>	<b>250,289,238.10</b>	<b>48,680,558.39</b>	<b>28,415,646.53</b>	<b>-</b>	<b>77,096,204.92</b>	<b>173,193,033.18</b>	<b>131,870,936.38</b>
	<b>P.Y Total</b>			<b>111,242,965.71</b>	<b>69,308,529.06</b>			<b>180,551,494.77</b>	<b>30,173,851.83</b>	<b>18,506,706.56</b>	<b>-</b>	<b>48,680,558.39</b>	<b>131,870,936.38</b>	<b>81,069,113.88</b>
<b>B</b>	<b>Capital work in progress</b>													
	BUILDING			8,370,000.00	32,425,656.22	-	-	40,795,656.22	-	-	-	-	40,795,656.22	8,370,000.00
	PLANT AND MACHINERY			4,704,652.00	100,639,685.55	-	-	105,344,337.55	-	-	-	-	105,344,337.55	4,704,652.00
	SOFTWARE DEVELOPMENT			-	750,000.00	-	-	750,000.00	-	-	-	-	750,000.00	-
	EUGMP Fee			400,000.00	3,125,745.11	-	-	3,525,745.11	-	-	-	-	3,525,745.11	400,000.00
	<b>Total (B)</b>			<b>13,474,652.00</b>	<b>136,941,086.88</b>	<b>-</b>	<b>-</b>	<b>150,415,738.88</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>150,415,738.88</b>	<b>13,474,652.00</b>
	<b>P.Y Total</b>			<b>24,871,517.00</b>	<b>13,474,652.00</b>	<b>-</b>	<b>-</b>	<b>38,346,169.00</b>	<b>24,871,517.00</b>	<b>-</b>	<b>-</b>	<b>24,871,517.00</b>	<b>13,474,652.00</b>	<b>-</b>
	<b>Current Year Total (A+B)</b>			<b>194,026,146.77</b>	<b>146,998,260.97</b>	<b>59,680,569.24</b>	<b>-</b>	<b>400,704,976.98</b>	<b>48,680,558.39</b>	<b>28,415,646.53</b>	<b>0.00</b>	<b>77,096,204.92</b>	<b>323,608,772.06</b>	<b>145,345,588.38</b>
	<b>Previous Year Total</b>			<b>136,114,482.71</b>	<b>82,783,181.06</b>	<b>-</b>	<b>-</b>	<b>218,897,663.77</b>	<b>55,045,368.83</b>	<b>18,506,706.56</b>	<b>0.00</b>	<b>73,552,075.39</b>	<b>145,345,588.38</b>	<b>81,069,113.88</b>

**BETA DRUGS LIMITED (CONSOLIDATED)**
**Note 10 Non Current investments**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Investment In Beta UBK International Pvt. Ltd. ( Uzbekistan)	3,520,592.62	-
<b>Total</b>	<b>3,520,592.62</b>	<b>-</b>

**Note 11 Long-term loans and advances**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Security Deposit</b>		
Secured, considered good	-	-
MAT Credit Entitlement	42,587,046.70	27,216,624.00
Provision for subsidy deposit taken		-
<b>loan and advances to realted parties</b>		
Unsecured, considered good		
<b>Total</b>	<b>42,587,046.70</b>	<b>27,216,624.00</b>

**Note 12 Inventories**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	15,309,740.20	5,069,063.00
(b) Raw Material	18,026,721.39	13,559,484.00
(c) WIP	34,039,036.01	7,599,293.00
(d) Others	27,918,175.04	1,806,962.00
<b>Total</b>	<b>95,293,672.65</b>	<b>28,034,802.00</b>

**Note 13 Trade receivables**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Exceeding six months</b>		
Secured, considered good	30,028,295.64	2,598,207.80
<b>Total</b>	<b>30,028,295.64</b>	<b>2,598,207.80</b>
<b>Less than six months</b>		
Secured, considered good	220,256,193.56	141,824,267.51
<b>Total</b>	<b>220,256,193.56</b>	<b>141,824,267.51</b>
<b>Grand Total</b>	<b>250,284,489.20</b>	<b>144,422,475.31</b>



<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>		
<b>Note 14 Cash and cash equivalents</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>CASH IN HAND</b>		
<b>(a) Cash in hand</b>	1,453,943.69	378,035.69
Balwant Singh Imprest	90,657.51	-
Ram Chandra Jha Imprest	4,304.00	-
<b>Total</b>	<b>1,548,905.20</b>	<b>378,035.69</b>
<b>(b) Balances with banks</b>		
(i) In current accounts		
Axis Bank	173,907.17	7,536,952.50
ICICI Bank	7,552,170.13	1,690,558.59
RBL Bank	-	9,973,863.48
Vijaya Bank	415,076.30	8,997,653.00
Vijaya Bank ( Imprest)	1,581.20	61,380.20
HDFC Bank	95,649.66	-
Capital Small Finance Bank Ltd	14,560.00	-
State Bank of India	4,590.03	-
Kotak Mahindra Bank	856,472.40	-
(iv) In earmarked accounts		
- Share application money received for allotment of	14.00	14.00
- Balances held as margin money or security against	-	-
<b>(c) Others (specify nature)</b>		
FDR With Axis Bank	-	72,000,000.00
FDR With Vijaya Bank	454,000.00	9,000,000.00
FDR With SIDBI (Against Bank Loan)	18,592,135.00	3,447,157.00
FDR With HDFC (Against Bank Loan)	-	5,003,699.00
FDR With Vijaya Bank (Against Bank Gurantee)	759,883.00	-
FDR With ICICI Bank (Against Bank Gurantee)	877,595.00	852,279.00
FDR With Excise Authority (Against Export)	-	125,204.00
FDR (Against Bank Guarantees)	1,669,708.00	-
<b>Total</b>	<b>31,467,341.89</b>	<b>118,688,760.77</b>
<b>Grand Total</b>	<b>33,016,247.09</b>	<b>119,066,796.46</b>
<b>Note 15 Short-term loans and advances</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
(a) Loans and advances to related parties	-	-
(b) Loans and advances		
Advances To Supplier	11,797,618.48	1,666,252.48
Advances To Supplier ( Machinery)	1,209,016.00	9,898,700.00
Other Advances ( Staff)	2,371,718.00	2,565,010.00
<b>Total</b>	<b>15,378,352.48</b>	<b>14,129,962.48</b>
<b>Note 16 Other current assets</b>		
<b>Particulars</b>	<b>As at 31 March' 2019</b>	<b>As at 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Other Assets</b>		
Income Tax Refund due	260,690.00	-
Insurance Claim receivable	11,200,000.00	-
Cheque Deposited Yet not Cleared	2,904,893.00	4,262,561.00
Rent Receivable	105,000.00	-
PLA	-	13,398.36
Sales Tax Security	215,297.00	215,297.00
Prepaid Expenses	547,484.00	120,574.00
Security Deposit	13,567,636.06	4,389,262.00
Preliminary Expenses	175,568.80	-
GST Recoverable	31,347,992.29	8,585,695.31
<b>Total</b>	<b>60,324,561.15</b>	<b>17,586,787.67</b>



<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>			
<b>Note 17 Revenue from operations</b>			
	<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
		<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
	<b>Sale Of Products</b>		
	Other Export Sales	16,966,100.87	-
	Central Sales 5%	-	3,258,107.40
	Central Sales 1.5%	-	70,939,193.75
	Sales Local 4%	-	253,869.25
	Sales Local 18%	6,358,272.40	5,845,023.10
	Export Sales	43,166,613.07	14,597,414.91
	Sales Loan Licence	-	239,068.00
	Sales Exempt	1,062,899.00	190,514.60
	GST Sales 12%	521,138,291.32	376,654,288.75
	GST Sales 5%	54,786,033.89	29,798,721.50
	GST Sales 18%	15,812,461.97	3,891,670.00
	<b>Total</b>	<b>659,290,672.52</b>	<b>505,667,871.26</b>
<b>Note 18 Other income</b>			
	<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
		<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
(a)	Interest Income	2,361,807.00	2,110,151.00
(b)	Rental Income	175,000.00	-
(c)	Other non-operating income (net of expenses directly attributable to such income)	1,035,320.00	333,747.26
(d)	Foreign Currency Exchange Gain	170,759.77	-
	<b>Total</b>	<b>3,742,886.77</b>	<b>2,443,898.26</b>
<b>Note 19 Cost of materials consumed</b>			
	<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
		<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
	Opening stock	15,366,446.00	18,075,909.00
	Add: Purchases	401,532,557.69	275,913,271.42
	Less: Closing stock	45,944,896.43	15,366,446.00
	<b>Cost of material consumed</b>	<b>370,954,107.26</b>	<b>278,622,734.42</b>
	<b>Total</b>	<b>370,954,107.26</b>	<b>278,622,734.42</b>

**BETA DRUGS LIMITED (CONSOLIDATED)**

<b>Note 20 Changes in inventories of finished goods, work-in-progress and stock-in-trade</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b><u>Inventories at the end of the year:</u></b>		
Finished goods	15,309,740.20	5,069,063.00
Work In Progress	34,039,036.01	7,599,293.00
	<b>49,348,776.21</b>	<b>12,668,356.00</b>
<b><u>Inventories at the beginning of the year:</u></b>		
Finished goods	5,069,063.00	3,481,752.00
Work In Progress	7,599,293.00	2,409,946.00
	<b>12,668,356.00</b>	<b>5,891,698.00</b>
<b><u>(Increase)/ decrease in Inventory</u></b>		
Finished goods	(10,240,677.20)	(1,587,311.00)
Work In Progress	(26,439,743.01)	(5,189,347.00)
	<b>(36,680,420.21)</b>	<b>(6,776,658.00)</b>
<b>Note 21 Other Manufacturing Expenses</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Consumeable Stores	13,628,258.85	10,186,912.08
Generator running expenses	2,612,333.00	1,283,619.00
Power & Fuel	9,537,142.00	7,583,879.54
Direct labour	43,131,191.00	37,502,088.00
Excise Expenses	-	153,807.64
Repairs & maintenance (machinery & Building)	4,284,352.93	2,127,975.63
Freight Inward	449,195.52	262,985.28
Factory Expenses	396,785.00	317,084.00
Packing & Forwarding expense	1,610,701.00	2,864,660.87
Solid Waste Pollution expenses	109,830.00	39,685.00
Testing Charges	3,704,752.69	1,488,110.22
<b>Total</b>	<b>79,464,541.99</b>	<b>63,810,807.26</b>



<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>		
<b>Note 22 Employee benefits expense</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Salaries and wages</b>		
Director	14,692,000.00	6,252,000.00
Employees	27,316,767.84	5,810,048.61
Employer Share of ESI	826,443.00	676,913.00
Employer Share of PF	2,571,403.00	1,872,678.00
Bonus	2,942,583.00	2,119,370.00
Staff welfare expenses	1,668,521.89	1,174,992.16
Staff Uniform Expenses	194,481.00	476,961.00
Rent Free Accomodation to Staff	-	-
Gratuity Provision	2,476,438.00	444,513.00
<b>Total</b>	<b>52,688,637.73</b>	<b>18,827,475.77</b>
<b>Note 23 Finance costs</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>(a) Interest expense on:</b>		
(i) Borrowings		
Bank Interest CC	7,998,617.00	4,576,522.00
Interest on Term Loan	3,626,505.50	3,115,231.00
Interest on Term Loan (Vehicle)	1,258,342.57	822,489.85
(ii) Others	392,034.00	676,919.73
<b>- Interest on delayed / deferred payment of income tax</b>		
Interest on Term Loan		
<b>(b) Other borrowing costs (Processing Fees)</b>		
Bank charges	1,036,142.30	951,827.49
Processing fee for renewal		
<b>Total</b>	<b>14,311,641.37</b>	<b>10,142,990.07</b>





# 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

<b>BETA DRUGS LIMITED (CONSOLIDATED)</b>		
<b>Note 24 Other expenses</b>		
<b>Particulars</b>	<b>For the year ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Advertisement Expenses	1,576,628.57	569,885.61
Audit Fee	1,302,500.00	1,302,500.00
Books & Periodical	26,000.00	38,000.00
Business Promotion Expenses	1,896,777.50	2,532,631.68
Daily Pooja Expenses	274,160.00	333,338.00
Commission Paid	5,126,033.00	4,636,615.00
Conference Expenses	7,707,633.40	902,258.76
Convenyance Expenses	3,396,983.24	2,848,597.47
Corporate Expenses	1,279,733.58	-
Corporate Social Responsibility Expenses	964,392.00	459,668.00
Sponsorship A/C	130,000.00	-
Donation A/C	120,000.00	-
Diwali Expenses	440,145.00	534,367.20
Expired & damages Goods Return	3,366,286.57	2,224,331.09
Freight Outward	5,028,082.23	1,706,206.48
Foreign Travel	1,687,707.74	-
Foreign Exchange Loss	455,590.73	-
Guest House expenses	735,000.00	680,500.00
Insurance Apportion Cost	576,325.98	383,843.00
Legal & Professional Expenses	5,111,379.80	4,635,217.95
Medical Expenses	60,184.38	27,684.00
Misc. Expenses	24,350.00	73,484.00
Office Expenses	651,542.66	1,012,943.78
Printing & Stationary	3,353,637.11	1,865,836.88
Preliminary expenses w/off	43,892.20	-
Rate Difference	4,251,763.47	8,329,243.69
Rate Fee & taxes	1,142,727.50	1,422,755.00
Rent	7,898,740.00	7,998,042.00
Repair & maintenance ( Vehicle)	1,023,357.82	1,440,781.82
Round Off	-3,880.64	-21,310.24
Small Balance Written Off	29,836.85	8,901.12
Software Expenses	223,700.00	288,068.24
Telephone & Postage	494,853.94	370,751.50
Trade Discount Expenses	2,561,376.05	3,595,229.48
Travelling Expenses	11,857,885.16	6,420,421.88
<b>Total</b>	<b>74,815,325.84</b>	<b>56,620,793.39</b>



## BETA DRUGS LIMITED

## 14<sup>TH</sup> ANNUAL REPORT

### NOTES TO CONSOLIDATED FINANCIAL STATEMENT

#### BETA DRUGS LIMITED

#### NOTE '3' : SIGNIFICANT ACCOUNTING POLICIES

#### (Forming part of Accounts)

#### FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019

### 3.1. i) Basis of Accounting

The consolidated financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

The Separate financial statements are presented in addition to the consolidated financial statements presented by the Company.

### ii) Principles of consolidation

#### a) Subsidiaries:

Subsidiaries are all entities over which the group has control. Control is achieved when the Group has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns.

The group combines the financial statements of the parent and its subsidiaries line by line adding together like items of assets, liabilities, equity, income and expenses. Inter Company transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.

Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of profit and loss, consolidated statement of changes in equity and balance sheet respectively.

#### Common control transactions`

Business combinations involving entities that are controlled by the group are accounted for using the pooling of interests method as follows:

- 1) The assets and liabilities of the combining entities are reflected at their carrying amounts.
- 2) No adjustments are made to reflect fair values, or recognise any new assets or liabilities. Adjustments are only made to harmonise accounting policies.

#### Changes in Company's Subsidiaries, Joint Ventures or Associate Companies during FY 2018-2019:

S. No.	Name and Address of the Company	CIN	Country of Incorporation	Holding / Subsidiary	% of Share Held	Applicable Section
1.	*Adley Formulation Private Limited	U24303HR2018PTC 076347	India	Subsidiary	100%	2(87)
2.	*Beta UBK International Private Limited	Foreign Company	Uzbekistan	Subsidiary	60%	2(87)



## BETA DRUGS LIMITED

### 14<sup>TH</sup> ANNUAL REPORT

\*Adley Formulations P Ltd. has purchased M/s Adley Formulations (via slump sale), a sole proprietorship firm owned by Sh. Vijay Kumar Batra vide Business Transfer Agreement dated 31.10.2018 which was engaged in the business of manufacturing of Pharmaceutical Drugs in the form of tablets and injectables. Therefore the accounts of the wholly owned subsidiary prepared for the periods of Five months (i.e. from 01/11/2018 to 31/03/2019).

\* The company has not included the accounts of M/s BETA UBK INTERNATIONAL PRIVATE LIMITED since the operations are not started yet.

#### 3.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

#### 3.3. Fixed Assets

##### -Tangible Assets

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use reflecting in each standalone financials of holding and subsidiaries companies.

Following Immovable assets are currently in the name of M/s Adley Formulations, post-acquisition of business, the title deed is to be transferred in M/s Adley Formulation Private Limited. As explained to us, registration of title deeds is in progress in respect of immovable properties.

Particulars	Address of Property
1. LAND	Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
2. BUILDING	Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
3. BUILDING SHOWROOM	SCO 42, Sector 12, Panchkula

In respect of movable properties, two vehicles are currently in the name of M/s Adley Formulations, post acquisition of business, the vehicle registration is to be transferred in M/s Adley Formulation Private Limited. As explained to us, transfer of vehicle along with endorsement of insurance is in progress in respect of two cars having registration no. HP 12J 0888 and PB 65AK 9829.

##### - Capital Work-in-Progress

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. WIP as on 31.03.2019 is Rs. 15,04,15,738.88.

#### 3.4. Depreciation/Amortisation

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013. **(Refer note 4.6).**
- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided upto the month in which such fixed assets are sold or scrapped.

#### 3.5. Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of



impairment losses recognized in prior years is recorded when there is an indication that the impairment losses recognized for the assets no longer exist or have decreased.

### 3.6. Valuation of Inventories

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods Oncology products comprises of Injections, Tablets & Capsules
- Work In Progress (Semi Finished Goods)
- Is valued at cost or estimated realizable value, whichever is lower. The company has determined the cost of Inventory using the First-In, First Out method.

The company has appointed cost auditor to ascertain and verify the authenticity of cost records maintained by the company. The valuation of Finished Goods as well as Work in Process material has been taken as certified by the cost auditor. The value of raw material and packing material has been taken at cost.

- Transfer of Stock – M/s Adley Formulations Private Limited (Transferee Undertaking) has received the closing stock, as certified by management, on cost from M/s Adley Formulations (Transferor Undertaking).

### 3.7. Revenue Recognition

- Revenue from sale of goods is recognized when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognized when services are rendered and related costs are incurred.
- Other income is recognized on accrual basis unless otherwise stated.
- Insurance and other claims are accounted for on settlement of claims/on receipt.
- Revenue from sales/services are shown net of taxes, as applicable.
- Revenue Recognition During Transition Phase of Purchase of M/s Adley Formulation by M/s Adley Formulation Private Limited (Subsidiary) - The company has purchased Adley Formulation, a sole proprietorship firm owned by Sh. Vijay Kumar Batra vide Business Transfer Agreement dated 31.10.2018 which was engaged in the business of manufacturing of Pharmaceutical Drugs in the form of tablets and injectable. Since it is mandatory to manufacture the pharmaceutical drugs after the receipt of manufacturing license from respective regulator i.e. Health and Family Welfare Department, Himachal Pradesh,, the company got the manufacturing approval dated 26.11.2018 in the name of M/s Adley Formulations Private Limited. During this transition phase from acquisition to receipt of manufacturing license, the company issued sales bills and other financial transactions in the name of M/s Adley Formulation (Transferor Firm). Financials post acquisition is prepared including financial transactions conducted in the name of M/s Adley Formulation during this transition phase.

### 3.8. Employee Benefits

#### a) Short-term Employee Benefits:

- Leave Encashment, on the basis of actual computation, is accounted for on accrual basis, during the tenure of employment the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has made the consolidated provision of Rs. 29,42,583.00 as per The Payment of Bonus Act, 1965.

#### b) Post-Employment Benefits

##### (i) Defined Contribution Plans :

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

##### (ii) Defined Benefit Plans :

Gratuity is accounted for on accrual basis - the Company has not taken any Gratuity policy with Life Insurance Corporation of India or any other insurer covered under the specified provisions of the Income Tax Act, 1961.

GRATUITY PROVISION FOR HOLDING COMPANY – BETA DRUGS LIMITED

**BETA DRUGS LIMITED****14<sup>TH</sup> ANNUAL REPORT**

The company has got the Actuarial Valuation done by independent consultant for FY 2018-19 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2019 in accordance with Revises AS-15(Rev).

Details Calculation of Gratuity Provision as per Certified Actuary.

Particulars	Amount
Present Value of Benefit Obligation as on 31.03.2019	33,46,133.00
Fair Value of Plan Assets on 31.03.2018	-
Net Liability / (Asset) recognized in Balance Sheet	33,46,133.00
Current Service Cost	13,73,284.00
Interest Cost	1,36,163.00
Expected Return on Plan Assets	-
Net Actuarial Losses ( Gains) recognized in the year	68,341.00
Expenses recognized in Statement of Profit and Loss	15,77,788.00

Gratuity Provision for FY 2017-18 was provided for Rs. 4,44,513.00 and Rs. 15,77,788.00 for FY 2018-19.

**GRATUITY PROVISIONS FOR SUBSIDIARY – ADLEY FORMULATIONS PRIVATE LIMITED**

Provision for Gratuity Liability for the financial year 2018-19 of Rs. 8,98,650.00 is created as per the Payment of Gratuity Act.

c) **Termination Benefits** : Termination benefits are recognized as an expense as and when incurred.

**3.9. Foreign Currency Transactions**

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of transaction or the average of opening and closing rates. The difference in the rate of exchange, if any, is accounted at the time of realisation or settlement and is recognized in the Statement of Profit and Loss.

Exchange differences (Gains) arising on foreign currency transactions for purchase of Plant and Machinery is adjusted against the cost of acquisition of that asset.

**3.10. Borrowing Costs**

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss. Details of the borrowing cost capitalized due the FY18-19 is as mentioned below :

During the year, the Company has capitalized borrowing costs of Rs. 8,30,397.00 (Previous year 2,24,094.00) relating to credit facility availed for installation of Plant and Machinery, included in Capital Work in Progress.

**3.11. Investments**

-Current Investments are carried at cost or fair value whichever is lower.

- Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

**3.12. Operating Lease**

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognized as an expense in the Statement of Profit & Loss on monthly due basis. The company has taken following premises on lease



## BETA DRUGS LIMITED

### 14<sup>TH</sup> ANNUAL REPORT

- 4.) Administrative office located at Panchkula-SCO 184, First floor, Sector 5, Panchkula -134114. The lease is entered into with M/s B.T. Associates, Panchkula for 10 years with monthly rent of Rs. 2,40,720.00 plus GST@18 percent.
- 5.) Branch office located at Peninsula Park, Office no-1101, 11th Floor, Andheri West, Mumbai-400053, Maharashtra. The lease is entered into with Mr. Rakesh Pravinchandra Desai and Mrs. Tejpal Rakesh Desai, Mumbai for 3 years with monthly rent of Rs. 1,43,000.00 plus GST@18 percent. The monthly rent paid by the company for financial year 2018-19 is Rs. 1,57,300.00 plus GST@18 percent with an increment of 10 percent from Feb-19 onwards.
- 6.) Company Guest House located at 101, Gopush Occupants Association, Vithal Nagar Chs Ltd., NS Road 11, JVPD Scheme, Vile Parle (W), Plot No. 27 NR, Juhu Bus Vile Parle (W), Mumbai, Maharashtra – 400049. The lease is entered into with Ms. Jagruti K Purohit and Sh. Kirit B Purohit, Mumbai for 3 years with monthly rent of Rs. 2,50,000.00 plus GST@18 percent. The monthly rent paid by the company for financial year 2018-19 is Rs. 2,68,750.00 plus GST@18 percent. with an increment of 7.5 percent from April-18 onwards.

#### 3.13. Taxes on Income

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.
- Deferred tax is recognized, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.
- Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will be in a position to avail of such credit under the provisions of the Income Tax Act, 1961.

#### 3.14. Earnings Per Share (EPS)

- Annualised basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.
- Annualised diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

#### 3.15. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (AS) 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

#### 3.16. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote. The Consolidated Contingent Liability in the form of Bank Guarantee as on 31.03.2019 is Rs. 19,91,408.00. Details of contingent liabilities are separately mentioned in standalone financials statement of each enterprise.



## 14<sup>TH</sup> ANNUAL REPORT

**BETA DRUGS LIMITED**

**NOTE 4 : OTHER NOTES TO ACCOUNTS**  
**(Forming part of Accounts)**  
**FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019**

**4.1. Contingent Liabilities & Commitments:**

- a) Estimated amount of contracts remaining to be executed and not provided for in the books of account - Nil (previous year - Nil).
- b) Contingent Liabilities:
  - Claims against the Company not acknowledged as debt - Nil (previous year - Nil).
  - Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

**4.2. Issued, Subscribed & Paid up Capital:**

Issued, Subscribed and Paid-up capital of the company are separately mentioned in standalone financials statement of each enterprise.

**4.3. Reserves & Surplus:**

- The amount shown in the Reserve & Surplus represents only surplus carried forward from the earlier year plus the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2019 is Rs. 32,27,22,940.53 which includes Share Premium of Rs. 16,16,12,604.98 and Free Reserves of Rs. 16,11,10,335.55

**4.4. Long-term Borrowings**

**Secured : Details of Consolidated Term Loan is mentioned below.**

Term Loan:

**DETAILS OF TERM LOAN - M/S BETA DRUGS LIMITED**

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Sanctioned Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Vijaya Bank	Term Loan of Rs. 150.00 Lakhs ( A/c No. 8304090410000 55)	Term Loan	Rs. 32.59 Lakhs	13.20%	Total Installments of Rs 3.36 Lacs P.M. divided into 63 Equated monthly installment. First Installment commenced from January, 2015.	(1)All stocks of raw material/ stock in process/ finished warehouse/goods kept at factory, in transit and all other locations belonging to company





2	SIDBI Loan	Term Loan of Rs. 50.00 Lakhs (A/c No 8304083910000 14)	Term Loan	Rs. 11.63 Lakh	13.20%	Total Installments of Rs 1.12 Lacs P.M. divided into 63 Equated monthly installment. First Installment commenced from January,2015.	(2)Equitable mortgage of .factory land in village Nandpur comprised in Khewat/Khatoni no. 114/157 in khasra No. 733/465 (00-05), 466(00-02), 735/467 (02-00), village Nandpur Tehsil Nalagarh, Distt. Baddi measuring 2 Bigha 7 Biswa owned by M/s Beta Drugs Pvt. Ltd. vide sale deed no. 712 dated 24.03.2006 charged to ML of the Company.
		Term Loan of Rs. 50.00 Lakhs (A/c No 8304090410000 64)	Term Loan	Rs. 28.59 Lakh	13.00%	Total Installments of Rs 1.15 Lacs P.M. divided into 60 Equated monthly installment. First Installment Commenced from April,2017.	(3)Hypothecation of Plant & Machinery & other movable fixed assets of the company.
		Term Loan of Rs. 15.00 Lakhs ( A/c No. 8304084110002 29)	Term Loan	Rs. 10.64 Lakh	10.05%	Total Installments of Rs .249 Lacs P.M. divided into 84 Equated monthly installment. First Installment Commenced from August,2016.	(4)Collateral Charge on Vacant Showroom site at Khata No. 9/10 in Khasra No. 56 (1-2), village Dharampur, Hadbast No. 152, Tehsil Kalka measuring 1 Biswa 2 Biswani i.e. 55 Sq. Yards owned by one of the director Mr. Rahul Batra S/o Vijay Batra vide sales Deed No. 674 dated 16.05.2011.
		Term Loan of Rs. 10.14 Lakhs ( A/c No. 8304084110002 59)	Term Loan	Rs. 8.62 Lakh	9.15%	Total Installments of Rs 0.21 Lacs P.M. divided into 60 Equated monthly installment. First Installment Commenced from May,2018.	(5) Personal Guarantee of Vijay Kumar Batra S/o Sh. Jiwan dass, Balwant Singh S/o Sh. Sadhu Ram, Varun Batra S/o Sh. Vijay Kumar batra, Neeraj Batra W/o Sh. Vijay Kumar Batra, Rahul Batra S/o Sh. Vijay Kumar Batra. (6) HYP of Motor Vehicles from the bank in the name of Company.
		Term Loan of Rs. 100.00 Lakhs (Sanctioned Amount Rs. 100 Lac and Disbursed amount Rs. 98.65 Lac)	Term Loan	Rs. 85.12 Lakhs	11.65%	Total Installments of Rs 1.23 Lacs P.M. divided into 80 Equated monthly installment. Last Installment i.e. 81st Installment is of Rs. 0.25 Lac.	1) HYP of Machinery and Fixed Deposit amounted Rs. 34 Lac with SIDBI as collateral.





		Term Loan of Rs. 400.00 Lakhs	Term Loan	Rs. 400 Lakhs	8.09%	Total Installments of Rs 7.40 Lacs P.M. after moratorium of 6 months divided into 53 Equated monthly installment. Last Installment i.e. 54th Installment is of Rs. 7.80 Lac.	1) HYP of Machinery amounted Rs. 829.00 Lacs and Fixed Deposit amounted Rs.150 Lac with SIDBI as collateral. Also Extension of Charge on Fixed Deposit already lien marked against previous SIDBI loan.
3	Axis Bank	Vehicle Loan of Rs.69.25 Lakhs	Term Loan	Rs. 40.51 Lakhs	8.38%	Total Installments of Rs 2.18 Lacs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
		Vehicle Loan of Rs.8.00 Lakhs	Term Loan	Rs. 6.74 Lakhs	8.40%	Total Installments of Rs 0.16 Lacs P.M. divided into 60 Equated monthly installments.	1) HYP of Motor Vehicles from the bank in the name of Company.
4	HDFC Bank	Vehicle Loan of Rs. 43.00 Lakhs	Term Loan	Rs. 19.29 Lakhs	8.76%	Total Installments of Rs 1.36 Lacs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
5	HDFC Bank	Vehicle Loan of Rs. 7.50 Lakhs	Term Loan	Rs. 6.47 Lakhs	8.98%	Total Installments of Rs 0.15 Lacs P.M. divided into 60 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.

**Unsecured :****Term Loan:**

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	ICICI Bank Limited	Unsecured Business Loan Rs. 27.50 Lakhs	Term Loan	Rs. 3.93 Lakhs	16.00%	Total Installments of Rs 1.34 Lacs P.M. divided into 24 Equated monthly installment.	Unsecured Loan
2	Edelweiss	Unsecured Business Loan of Rs. 40 Lakhs	Term Loan	Rs. 18.36 Lakhs	18.50%	Total Installments of Rs 1.46 Lacs P.M. divided into 37 Equated monthly installment.	Unsecured Loan



## DETAILS OF TERM LOAN – M/s ADLEY FORMULATION PRIVATE LIMITED

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	ICICI BANK LIMITED (VEHICLE LOAN)	Term Loan of Rs. 40.00 Lakhs (A/c No. LUPNC000358045 79)	Term Loan	Rs. 24.91 Lakhs	13.51 %	Total Installments of Rs 1.08 Lacs P.M. divided into 48 Equated monthly installment.	HYP of Motor Vehicles from the bank.
2	KOTAK BANK LAP (SHOWROOM)	Term Loan of Rs. 215.38 Lakhs (A/c No. CL5650452100)	Term Loan	Rs. 184.93 Lakhs	11.50 %	Total Installments of Rs 2.67 Lacs P.M. divided into 180 Equated monthly installment	Collateral - Commercial Property located at SCO 42, Sector 12, Urban Estate, Panchkula owned by Adley Formulation.
3	KOTAK MAHINDRA BANK	Cash Credit Limit of Rs. 555.00 Lacs	Cash Credit	Rs. 560.66 Lakh	MCLR *+3.8 5 %		Primary Security – First and Exclusive charge over Current Assets and Fixed Asset of borrower both present and future.  Collateral Security –
4	KOTAK MAHINDRA BANK A/C	Drop Line OD of Rs. 520.00 Lacs	CC	Rs. 411.25 Lakh	MCLR *+6.3 5 %		1. Industrial Property located at Plot No. 56, HSIIDC Industrial Estate, Kalka, Distt Panchkula Owned by Rishi Herbal Products. 2. Industrial Property at Pargan Doon, PO Barotiwala, Baddi owned by Adley Formulations 3. Guest House at Village Dochi, Near Garkhal, Tehsil Kasauli, Distt Solan (HP) owned by Sh. Vijay Batra 4. Residential Property located at 55 P, Sector 12, Panchkula, owned by Smt. Neeraj Batra. 5. Residential Property located at H-140, Sector 12, Urban Estate, Panchkula, owned by Vijay Batra 6. Commercial Property located at SCO 42, Sector 12, Urban Estate, Panchkula owned by Adley Formulations.



## BETA DRUGS LIMITED

### 14<sup>TH</sup> ANNUAL REPORT

5	HDFC BANK LOAN	Term Loan of Rs. 45 Lakhs	Term Loan	Rs. 26.89 Lakh	7.86%	Total Installments of Rs 1.37 Lacs P.M. divided into 37 Equated monthly installment.	HYP of Motor Vehicles from the bank.
---	----------------	---------------------------	-----------	----------------	-------	--------------------------------------------------------------------------------------	--------------------------------------

\*(MCLR at the time of sanction / renewal was 8.45%)

*Interest on the above term loans is payable on monthly basis.*

- 4.5. In the opinion of the Directors, "Current Assets" and "Loans & Advances" are approximately of the value Stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge provisions for all the known liabilities have been made and, *as certified*, all the contractual and statutory obligations have been duly complied with.
- 4.6. Party balances have been incorporated in the financial statements at the value as per the books of account & are considered hopeful of recovery/good for payment. The balance confirmation letter for both debtor and creditors are sent by the company through registered post, and in few cases balance confirmation is received from them.
- 4.7. **Depreciation / Amortisation**
- The management estimates the remaining useful life of existing fixed assets as on 01<sup>st</sup> April, 2014 as follows:-
- |                      |          |
|----------------------|----------|
| Building             | 30 years |
| Furniture & Fixtures | 10 years |
| Machinery            | 15 years |
| Lab Equipment        | 10 years |
| Equipment (Other)    | 5 years  |
| Vehicles             | 8 years  |

For these class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part-C of Schedule-II of the Companies Act, 2013. (Refer note 3.4).

#### 4.8. Earnings Per Share

	<u>Year ended</u> <u>31<sup>st</sup> March, 2019</u>	<u>Year ended</u> <u>31<sup>st</sup> March, 2018</u>
<b>Numerator</b>		
Net Profit/(Loss)		
attributable to Equity shareholders	` 8,03,98,800.75	` 6,76,36,664.85
<b>Denominator</b>		
Number of Equity shares	No.'s 86,49,500	No.'s 86,94,500
Nominal		
Value per Equity share	10	10
Earnings per Equity share		
- Basic and diluted	9.30/9.30	7.82/7.82

#### 4.9. Non-Current Investments:

Investment in Joint ventures and Associates are accounted for using the equity method of accounting. Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognise Dividends received or receivable from associates or joint ventures are recognized as a reduction in the carrying amount of the investment.

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act, 2013 have been complied with.

During the financial year 2018-2019 the company has made investments in following entities :

1. The company entered into a Joint Venture with SILUJIN Private Co. Ltd, Uzbekistan by incorporating subsidiary company namely BETA UBK INTERNATIONAL PRIVATE LIMITED in Republic of Uzbekistan registered with Department of Company Affairs, Tashkent Province, Uzbekistan dated 07.09.2018 to manufacture Oncology Drugs in Uzbekistan. The company holds 60 % in Joint Venture with 40 % share with SILUJIN Private Co. Ltd. The Company has invested \$48,000.00 ( Rs.35,20,592.62 in INR) and Silujin private Co. Ltd has invested \$32,000.00. The company has not included the accounts of M/s BETA UBK INTERNATIONAL PRIVATE LIMITED since the operations are not started yet.
2. The company has incorporated a 100 % Subsidiary in the name of M/s Adley Formulations Private Limited with an investment of Rs. 1,26,00,000.00. Having 12,59,999 Equity Shares of Rs.10 each in the name of Beta Drugs Limited thru Mr. Vijay ,Kumar Batra, Managing Director and balance 1 Equity Share of Rs. 10 each through beneficial holder Mr. Rahul Batra.

This Wholly owned subsidiary has acquired the entire business of Adley Formulations. Adley Formulations is a Proprietorship firm, owned by Mr. Vijay Kumar Batra and is in business of manufacturing of Oncology and general medicines both in form of tablets & injectables since year 2008.

#### 4.10. Taxes

- The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate pending finalisation of assessments and no disputed dues or amounts were outstanding or remaining unpaid as at 31<sup>st</sup> March, 2018.
- MAT Credit Entitlement Rs. 1,53,70,422.70 i.e. additions during the year has been shown under the head 'Reserves & Surplus' with corresponding effect under the head 'Long-term Loans & Advances' in accordance with the accepted accounting principles; the opening MAT credit entitlement was Rs. 2,72,16,624.00
- The amount of tax credit determined shall be carried forward upto fifteen assessment years immediately succeeding the assessment year in which tax credit becomes allowable.

#### 4.11. Segment Reporting

Since the Company primarily operates in one segment (i.e. Manufacturing of Oncology medicines), therefore segment reporting as required under Accounting Standard - 17 is not applicable - there is no reportable geographical segment as the export sale of the company is less than 10% of the total sales made in India.

#### 4.12. Related Party Disclosures

Related parties & their relationship and related parties transactions.

Related Party disclosure are made in separate standalone audited financials of each enterprise.

#### 4.13. Impairment of Assets

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of AS-28 on "Impairment of Assets" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognized for the year.

#### 4.14 Fixed Assets:

- During the financial year 2018-19 the company has made an addition of Rs. 13,69,41,086.88 as Capital Work-in Progress.
- During the financial Year 2018-19 there was an addition of Rs. 15,00,000.00 under the head Land.
- During the financial Year 2018-19 there was no addition under the head Building.



## 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

During the financial year, there was addition of Rs. 85,57,174.09 made to Plant & Machinery, Furniture & Fixtures, Office Equipment, Vehicles & Computers.

The above amount excludes the amount of assets transferred at book value on account of acquisition of Adley Formulations by Adley Formulations P. Ltd.

### 4.15. Deferred Tax Assets & Liabilities

During the FY 2018-19 the company has made Consolidated Deferred Tax Provision (Asset) of Rs. 28,68,769.87. Details of Calculation in mentioned below.

Calculation of Deferred Tax Asset / Liability	Amount in Rs.
Deferred Tax Asset on depreciation	15,79,647.82
Deferred Tax Asset on provision of gratuity	5,58,515.55
Deferred Tax Asset on provision of bonus	5,32,038.19
Deferred Tax Asset on provision of CSR	1,98,568.31
<b>Total Deferred Tax Asset Created for the financial year 2018-19 in Profit and Loss Account.</b>	<b>28,68,769.87</b>
Less : Deferred Tax Liability as on 31.03.2018 ( Opening)	14,99,675.95
<b>Balance Deferred Tax Asset recognized in Balance Sheet</b>	<b>13,69,093.92</b>

### 4.16. Government Grants:

During the year, Beta Drugs Limited has received Government Subsidy amounting Rs. 6,35,197.00 against the asset which was fully depreciated, hence this amount credited to the Profit & Loss Account.

### 4.17. Micro, Small & Medium Enterprises

Based on the information presently available, total outstanding as on 31.03.2019 is Rs.7,23,07,640.40 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

### 4.18. Auditor's Remuneration

(exclusive of GST)

	<u>31<sup>st</sup> March, 2019</u>	<u>31<sup>st</sup> March, 2018</u>
	<u>AMOUNT</u>	<u>AMOUNT</u>
<b>-As Statutory Auditors</b>	4,02,500	4,02,500
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
<b>-As Internal Auditor</b>	9,00,000	9,00,000
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
- Reimbursement of out of pocket expenses	-	-
<b>TOTAL</b>	<b><u>13,02,500</u></b>	<b><u>13,02,500</u></b>

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

### 4.19 Other additional information

<b>Particulars</b>	<b><u>31<sup>st</sup> March, 2019</u></b>	<b><u>31<sup>st</sup> March, 2018</u></b>
	<b><u>AMOUNT</u></b>	<b><u>AMOUNT</u></b>
<b>“A” Revenue from operations (under broad heads)</b>		
Sales		
-Sales With in India	59,91,57,958.58	49,12,52,621.35
-Export Sales	<u>6,01,32,713.94</u>	<u>1,44,15,249.91</u>
	<b><u>65,92,90,672.52</u></b>	<b><u>50,56,67,781.26</u></b>
<b>“B” Purchases</b>		
-Chemicals, Bulk Drugs & Packing Material	34,71,08,934.71	23,32,46,427.98

### 4.20. Expenditure In Foreign Currency (On Accrual Basis):- Following Expenses were incurred by the company during the year 2018-19.

	<b><u>31<sup>st</sup> March, 2019</u></b>	<b><u>31<sup>st</sup> March, 2018</u></b>
	<b><u>AMOUNT</u></b>	<b><u>AMOUNT</u></b>
- Import of Capital Goods	3,04,603	1,01,25,321
Revenue Expenses ( Travel)	16,87,707	7,21,450
Revenue Expenses ( RM Purchase)	26,39,390	-
<b>TOTAL</b>	<b><u>46,31,700</u></b>	<b><u>1,08,46,771</u></b>

### 4.21. Earning in Foreign Currency Particulars

	<b>For The Year Ended ( 31.03.2019)</b>	<b>For the year Ended ( 31.03.2018)</b>
FOB Value of Export	6,01,32,713.94*	1,44,15,249.91*

\* This includes indirect export



## Annexure-6

4.22 Additional Information, as required under Schedule III to the Companies Act, 2013 in respect of subsidiaries whose accounts are consolidated. Amount in Rs.

Name of the Enterprise	Net Assets i.e. Total assets minus total liabilities		Share in profit or (loss)	
	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount
<b>Parent</b>				
Beta Drugs Limited	99.20%	40,59,60,064.64	95.95%	7,71,40,924.85
<b>Subsidiary</b>				
Adley Formulations Private Limited	3.88%	1,58,57,875.89	4.05%	32,57,875.89
Inter-company eliminations	(3.08%)	(1,26,00,000)	-	-
<b>Total</b>	<b>100.00%</b>	<b>40,92,17,940.53</b>	<b>100.00%</b>	<b>8,03,98,800.74</b>

**4.23 SALIENT FEATURES OF FINANCIAL STATEMENTS OF SUBSIDIARIES / ASSOCIATES / JOINT VENTURES AS PER COMPANIES ACT, 2013**

[Pursuant to Section 129(3) of the Companies Act, 2013 and Rule 5 of the Companies (Accounts) Rules, 2014 -AOC 1]

Name of Subsidiary Company	Adley Formulations Private Limited
Reporting Period	01 <sup>st</sup> November 2018 to 31 <sup>st</sup> March 2019
Reporting Currency	Rupees (Rs.)
Share Capital	1,26,00,000.00
Reserves & Surplus	32,57,875.89
Total Assets	19,64,02,379.96
Total Liabilities	19,64,02,379.96
Investments	-
Turnover / Total Income	7,88,03,833.53
Profit/ (Loss) Before Taxation	44,02,534.99
Provision for Taxation	11,44,659.10
Profit / (Loss) After Taxation	32,57,875.89
Proposed Dividend	-
% of Shareholding	100%

4.24. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation. In terms of our attached report of even date. For and on behalf of the Board of Directors

For Kalra Rai & Associates  
CHARTERED ACCOUNTANTS  
FR No. – 008859N  
sd/-  
Lajpat Rai Kalra

sd/- (Managing Director) sd/- (Whole-time Director)

PARTNER  
M. No.087438  
Dated: 13/05/2019  
Place: Chandigarh

sd/- (Chief Financial Officer) sd/- (Company Secretary)



---

**STANDALONE FINANCIAL STATEMENT**

**OF**

**“ADLEY FORMULATIONS PRIVATE LIMITED”**

**FOR THE FINANCIAL YEAR**

**2018-19**





---

**KALRA RAI & ASSOCIATES  
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1<sup>st</sup> floor, Sector-43-A  
Chandigarh-160022**

---

## **Independent Auditors' Report**

Members of **ADLEY FORMULATIONS PVT. LTD**

### **Report on the Standalone Financial Statements**

We have audited the accompanying standalone Ind-AS financial statements of **ADLEY FORMULATIONS PVT. LTD** ('the Company'), which comprise the Balance Sheet as at March 31, 2019, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these standalone Ind AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the stand alone Ind AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.



An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

### Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection(11) of Section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
  - d. In our opinion, the aforesaid stand alone Ind AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
  - e. On the basis of written representations received from the directors as on March 31, 2019, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2019, from being appointed as a director in terms of Section 164 (2) of the Act;



f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in “**Annexure B**” ;

g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;

**Place:- Chandigarh**

**Date: 13/05/2019**

**For KALRA RAI & ASSOCIATES**

**Chartered Accountant**

**sd/-**

**(Lajpat Rai Kalra)**

**Partner**

**M. No- 087438**

**FRN: 008859N**



---

**CARO**

**Annexure 1 referred to in paragraph 1 of our report of even date**

**Re: ADLEY FORMULATIONS PVT. LTD ('the Company')**

- i. a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- b. All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- c. According to information and explanations given by the management, the title deeds of immovable properties, included in property, plant and equipment except for the following, are held in the name of the Company.
- ii. The management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies were noticed on such physical verification.
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii)(a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us ,the Company has not advanced loans to directors/to a Company in which the director is interested to which, the provisions of Section 185 of the Companies Act, 2013 apply and hence not commented upon. In our opinion and according to the information and explanations given to us ,the Company has made investments and given guarantees/provided security which is in compliance with the provisions of Section 186 of the Companies Act, 2013.
- v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended).Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- vi. The rules made by the Central Government for the maintenance of cost records under Section 148(1) of the Companies Act, 2013, related to the manufacture of Active Pharmaceutical Ingredients and Formulations and are not applicable to the company.
- vii. a. The Company is regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, service tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues applicable to it.
- b. According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance ,income tax, service tax, sales tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.
- viii. In our opinion and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans or borrowings to a bank or government. There are no dues which are payable to financial institutions or debenture holders.

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

- ix. In our opinion and according to the information and explanations given by the management, the Company has utilized the monies raised by way of term loans for the purposes for which they were raised..
- x. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
- xi. According to the information and explanations given by the management, the managerial remuneration has been paid/ provided in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Companies Act, 2013.
- xii. In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.
- xiii. According to the information and explanations given by the management, transactions with the related parties are in compliance with Sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- xiv. According to the information and explanations given to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.
- xv. According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in Section 192 of Companies Act, 2013.
- xvi. According to the information and explanations given to us, the provisions of Section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

**Place:- Chandigarh**

**Date: 13/05/2019**

**For KALRA RAI & ASSOCIATES**

**Chartered Accountant**

**sd/-**

**(Lajpat Rai Kalra)**

**Partner**

**M. No- 087438**

**FRN: 008859N**




---

**“ANNEXURE-B” TO THE AUDITORS’ REPORT”**

*Referred to in Paragraph 7 of Our Report of Even Date*

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **ADLEY FORMULATIONS PVT. LTD** (“the Company”) as of 31 March 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

***Management’s Responsibility for Internal Financial Controls***

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (‘ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

***Auditors’ Responsibility***

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

***Meaning of Internal Financial Controls over Financial Reporting***

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors



of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

***Inherent Limitations of Internal Financial Controls Over Financial Reporting***

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Opinion***

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**Place:- Chandigarh**

**Date: 13/05/2019**

**For KALRA RAI & ASSOCIATES**

**Chartered Accountants**

**sd/-**

**(Lajpat Rai Kalra)**

**Partner**

**M. No- 087438**

**FRN: 008859N**

<b>ADLEY FORMULATIONS PRIVATE LIMITED</b> <b>Cabin No. 1, 1ST FLOOR SCO-184, SECTOR-5 PANCHKULA Panchkula HR 134114 IN</b> <b>CIN : U24303HR2018PTC076347</b> <b>BALANCE SHEET AS AT 31 MARCH' 2019</b>			
Particulars	Note No.	As at 31 March' 2019	As at 31 March' 2018
		Amount in Rs.	Amount in Rs.
<b>A EQUITY AND LIABILITIES</b>			
<b>1 Shareholders' funds</b>			
(a) Share capital	1	12,600,000.00	-
(b) Reserves and surplus	2	3,257,875.89	-
(c) Money received against share warrants		-	-
		<b>15,857,875.89</b>	-
<b>2 Share application money pending allotment</b>		-	-
<b>3 Non-current liabilities</b>			
(a) Long-term borrowings	3	20,917,341.05	-
(b) Deferred tax liabilities (net)	4	-	-
(c) Other long-term liabilities	5	15,968,275.00	-
(d) Long-term provisions		-	-
		<b>36,885,616.05</b>	-
<b>4 Current liabilities</b>			
(a) Short-term borrowings	6	97,192,648.70	-
(b) Trade payables	7	29,554,248.20	-
(c) Other current liabilities	8	15,390,023.22	-
(d) Short-term provisions		1,521,967.90	-
		<b>143,658,888.02</b>	-
<b>TOTAL</b>		<b>196,402,379.96</b>	-
<b>B ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Fixed assets			
(i) Tangible assets	9	55,504,716.24	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(v) Fixed assets held for sale		-	-
		<b>55,504,716.24</b>	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)	4	389,388.81	-
(d) Long-term loans and advances		-	-
(e) Other non-current assets		-	-
		<b>389,388.81</b>	-
<b>2 Current assets</b>			
(a) Current investments		-	-
(b) Inventories	10	31,196,622.71	-
(c) Trade receivables	11	76,989,816.58	-
(d) Cash and cash equivalents	12	3,836,052.30	-
(e) Short-term loans and advances	13	5,244,492.47	-
(f) Other current assets	14	23,241,290.86	-
		<b>140,508,274.92</b>	-
<b>TOTAL</b>		<b>196,402,379.96</b>	-
See accompanying notes forming part of the financial statements			
<b>In terms of our report attached.</b> <b>For KALRA RAI AND ASSOCIATES</b> <b>Chartered Accountants</b> <b>sd/-</b> <b>LAJPAT RAI KALRA</b> <b>Partner</b> <b>MEMBERSHIP NO. 087438</b> <b>Place : Chandigarh</b> <b>Date : 13.05.2019</b>			
<b>For and on the behalf of the Board of Directors</b> <b>sd/-</b> <b>Vijay Kumar Batra</b> <b>Chairman cum Managing Director</b>			



# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

ADLEY FORMULATIONS PRIVATE LIMITED Cabin No. 1, 1ST FLOOR SCO-184, SECTOR-5 PANCHKULA Panchkula HR 134114 IN CIN : U24303HR2018PTC076347 STATEMENT OF PROFIT AND LOSS FOR THE PERIOD 1ST NOVEMBER 2018 TO 31ST MARCH 2019				
Particulars		Note No.	As at 31 March' 2019 Amount in Rs.	As at 31 March' 2018 Amount in Rs.
<b>A</b>	<b>CONTINUING OPERATIONS</b>			
<b>1</b>	Revenue from operations (gross) Less: Excise duty Revenue from operations (net)	15	78,803,833.53 - 78,803,833.53	- - -
<b>2</b>	Other income	16	585,038.00	-
<b>3</b>	<b>Total revenue (1+2)</b>		<b>79,388,871.53</b>	-
<b>4</b>	<b>Expenses</b>			
	(a) Cost of materials consumed	17	39,761,367.61	-
	(b) Purchases of stock-in-trade		-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	18	-9,949,239.10	-
	(d) Other manufacturing expenses	19	5,769,342.86	-
	(d) Employee benefits expense	20	18,515,068.00	-
	(e) Finance costs	21	6,975,277.90	-
	(f) Depreciation and amortisation expense	9	4,183,553.00	-
	(g) Other expenses	22	9,730,966.28	-
	<b>Total expenses</b>		<b>74,986,336.54</b>	-
<b>5</b>	<b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		4,402,534.99	-
<b>6</b>	Exceptional items		-	-
<b>7</b>	<b>Profit / (Loss) before extraordinary items and tax (5 + 6)</b>		<b>4,402,534.99</b>	-
<b>8</b>	Extraordinary items/Prior period items		-	-
<b>9</b>	<b>Profit / (Loss) before tax (7 + 8)</b>		4,402,534.99	-
<b>10</b>	<b>Tax expense:</b>			
	(a) Current tax expense for current year		1,534,047.90	-
	(b) (Less): MAT credit (where applicable)		-	-
	(c) Current tax expense relating to prior years		-	-
	(d) Net current tax expense		1,534,047.90	-
	(e) Deferred tax		(389,388.81)	-
			<b>1,144,659.10</b>	-
<b>11</b>	<b>Profit / (Loss) from continuing operations (9 + 10)</b>		<b>3,257,875.89</b>	-
<b>B</b>	<b>DISCONTINUING OPERATIONS</b>			
<b>12</b>	<b>Profit / (Loss) from discontinuing operations (B.i + B.ii + B.iii)</b>		-	-
<b>C</b>	<b>TOTAL OPERATIONS</b>		3,257,875.89	-
<b>13</b>	<b>Profit / (Loss) for the year (11 + 12)</b>		3,257,875.89	-
<b>14</b>	<b>Earnings per share (of ` Rs 10/- each):</b>			
	(a) Basic			
	(i) Continuing operations		2.59	-
	(ii) Total operations		2.59	-
	(b) Diluted			
	(i) Continuing operations		2.59	-
	(ii) Total operations		2.59	-
In terms of our report attached.				
For KALRA RAI AND ASSOCIATES Chartered Accountants sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 Place : Chandigarh Date : 13.05.2019			For and on the behalf of the Board of Directors  sd/- Vijay Kumar Batra Chairman cum Managing Director	

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

## ADLEY FORMULATIONS PRIVATE LIMITED Notes forming part of the financial statements

### Note 1 Share capital

Particulars	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares	Amount in Rs.	Number of shares	Amount in Rs.
(a) Authorised - Equity shares of Rs. 10 each	1,300,000.00 -	13,000,000.00 -	-	-
(b) Issued - Equity shares of Rs. 10 each	- 1,260,000.00	- 12,600,000.00	-	-
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	<b>1,260,000.00</b> 1,260,000.00	<b>12,600,000.00</b> 12,600,000.00	-	-
(d) Subscribed but not fully paid up	1,260,000.00 -	12,600,000.00 -	-	-
Total	1,260,000.00	12,600,000.00	-	-

Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2019		As at 31 March, 2018	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Beta Drugs Limited	1,259,999.00	100%		
Mr. Rahul Batra	1.00	0%		

### Note 2 Reserves and surplus

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Securities premium account		
Opening balance	-	-
Closing balance	-	-
(b) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	-	-
Add: Profit / (Loss) for the year	3,257,875.89	-
Closing balance	3,257,875.89	-
<b>Total</b>	<b>3,257,875.89</b>	<b>-</b>



## ADLEY FORMULATIONS PRIVATE LIMITED

## Notes forming part of the financial statements

## Note 3 Long-term borrowings

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Term loans		
From banks		
Secured		
Icici Bank Ltd (Car Loan)	1,466,676.60	-
Kotak Bank Lap (Showroom)	17,353,355.71	-
Hdfc Bank Loan	1,198,658.74	-
	<b>20,018,691.05</b>	-
From other parties		
Secured		
Unsecured ( From Related Parties)		
Mr. Vijay Kumar Batra	-	-
Total - A	-	-
Unsecured ( From Unrelated Parties)		
Provision For Gratuity	898,650.00	-
Total - B	898,650.00	-
	<b>898,650.00</b>	-
The Above Amount Includes		
Secured Borrowings	<b>20,018,691.05</b>	-
Unsecured Borrowings	<b>898,650.00</b>	-
	-	-
<b>Total</b>	<b>20,917,341.05</b>	-

## Notes: Long-term borrowings

Particulars	As at 31 March' 2019			As at 31 March, 2018		
	Amount in Rs.			Amount in Rs.		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
Term loans						
From banks						
Secured						
Icici Bank Ltd (Car Loan)	1,466,676.60	1,024,685.40	2,491,362.00	-	-	-
Kotak Bank Lap (Showroom)	17,353,355.71	1,140,631.99	18,493,987.70	-	-	-
Hdfc Bank Loan	1,198,658.74	1,490,405.27	2,689,064.01	-	-	-
	<b>20,018,691.05</b>	<b>3,655,722.66</b>	<b>23,674,413.71</b>	-	-	-
From other parties						
Secured	-	-	-	-	-	-
Unsecured ( From Related Parties)	-	-	-	-	-	-
Mr. Vijay Kumar Batra	-	-	-	-	-	-
Mr. Balwant Singh	-	-	-	-	-	-
Total - A	-	-	-	-	-	-
Unsecured ( From Unrelated Parties)	-	-	-	-	-	-
Provision For Gratuity	898,650.00	-	898,650.00	-	-	-
Total - B	<b>898,650.00</b>	-	<b>898,650.00</b>	-	-	-
	<b>898,650.00</b>	-	<b>898,650.00</b>	-	-	-
The Above Amount Includes						
Secured Borrowings	<b>20,018,691.05</b>	<b>3,655,722.66</b>	<b>23,674,413.71</b>	-	-	-
Unsecured Borrowings	<b>898,650.00</b>	-	<b>898,650.00</b>	-	-	-
Amount disclosed under "Other Current Liabilities"		<b>(3,655,722.66)</b>	<b>(3,655,722.66)</b>		-	-
<b>Total</b>	<b>20,917,341.05</b>	-	<b>20,917,341.05</b>	-	-	-



**ADLEY FORMULATIONS PRIVATE LIMITED**  
**Notes forming part of the financial statements**

**Note 4 Deferred Tax**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Deferred tax Asset</b>		
Deferred tax on depreciation	155,739.81	-
Deferred tax on gratuity	233,649.00	-
<b>Gross Deferred tax asset</b>	<b>389,388.81</b>	-
<b>Net Deferred tax asset</b>	<b>389,388.81</b>	-

**Continue Note 4 Current tax Provision**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Current Year Tax	1,534,047.90	-
Less :- Advance Tax Including TDS	-12,080.00	-
<b>Current Year Tax Provision</b>	<b>1,521,967.90</b>	-
<b>Short term provisions</b>	<b>1,521,967.90</b>	-
	-	-

**Note 5 Other long-term liabilities**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Trade Payables: *	-	-
(i) Acceptances	-	-
(ii) Other than Acceptances	-	-
(b) Others:		
(i) Payables on purchase of fixed assets	-	-
(ii) Contractually reimbursable expenses	-	-
(iii) Interest accrued but not due on borrowings	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(vii) Advances from customers	-	-
(viii) Income received in advance (Unearned revenue)	-	-
(ix) Security received from customers	15,968,275.00	-
<b>Total</b>	<b>15,968,275.00</b>	-

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

## ADLEY FORMULATIONS PRIVATE LIMITED

Notes forming part of the financial statements

### Note 6 Short-term borrowings

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Other loans and advances		
Secured		
- KOTAK Mahindra Bank CC	56,066,815.00	-
- KOTAK Mahindra Bank a/c 700	41,125,833.70	-
<b>Total</b>	<b>97,192,648.70</b>	<b>-</b>

### Note 7 Trade payables

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Trade payables:		
Micro Enterprises And Small Enterprises	13,885,920.00	-
Others	15,668,328.20	-
<b>Total</b>	<b>29,554,248.20</b>	<b>-</b>

### Note 8 Other current liabilities

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Other payables	6,188,860.34	-
(i) Current Maturities of Long Term Debt	3,655,722.66	-
(ii) Payables on purchase of fixed assets	-	-
(iii) Contractually reimbursable expenses	-	-
(iv) Interest accrued on trade payables	-	-
(v) Interest accrued on others	-	-
(vi) Trade / security deposits received	-	-
(ii) Advances from customers	-	-
(viii) Others (specify nature)	-	-
(b) Cheque issued yet not presented for Payment	1,547,101.00	-
Advances From Customers	3,998,339.22	-
<b>Total</b>	<b>15,390,023.22</b>	<b>-</b>

### Note 8(a) Other current liabilities

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
PF Payable	78,866.00	-
ESI payable	23,004.00	-
TDS payable	1,122,306.00	-
Interest Accrued But Not Due	164,395.00	-
Duties & Taxes	1,487,204.34	-
Salary & wages Payable	3,061,943.00	-
Security Received	-	-
Other Expenses payable	251,142.00	-
<b>Total</b>	<b>6,188,860.34</b>	<b>-</b>



# 14<sup>TH</sup> ANNUAL REPORT

## BETA DRUGS LIMITED

ADLEY FORMULATIONS PVT LTD.  
Notes forming part of the Financial statement

### Note No. 9 Fixed Assets Chart as at 31st March 2019

Assets			Gross Block					Accumulated Depreciation/ Amortisation				Net Block	
	Useful Life (In Years)	Shift	Balance as at 1st April 2018	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March 2019	Balance as at 1st April 2018	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2019	Balance as at 31st March 2019	Balance as at 31st March 2018
<b>A Tangible assets</b>													
<b>Own Assets</b>													
LAND	Single		-	-	358,750.00		358,750.00	-	-		-	358,750.00	-
SHOWROOM LAND	Single		-	-	2,620,000.00		2,620,000.00	-	-		-	2,620,000.00	-
BUILDING	30 Single		-	-	17,629,056.33		17,629,056.33	-	692,846.06		692,846.06	16,936,210.27	-
SHOWROOM SCO 42	30 Single		-	-	8,698,424.58		8,698,424.58	-	341,860.00		341,860.00	8,356,564.58	-
PLANT AND MACHINERY	15 Single		-	7,700.00	16,149,202.07		16,156,902.07	-	1,209,499.23		1,209,499.23	14,947,402.84	-
FURNITURE AND FIXTURES	10 Single		-	-	639,167.43		639,167.43	-	68,459.03		68,459.03	570,708.40	-
OFFICE EQUIPMENTS	5 Single		-	-	1,917,515.70		1,917,515.70	-	357,528.42		357,528.42	1,559,987.28	-
COMPUTER	3 Single		-	-	44,048.05		44,048.05	-	11,509.41		11,509.41	32,538.64	-
HEAVY VEHICLE	8 Single		-	-	1,845.91		1,845.91	-	238.49		238.49	1,607.42	-
VEHICLE	8 Single		-	-	11,622,559.17		11,622,559.17	-	1,501,612.35		1,501,612.35	10,120,946.82	-
<b>Total (A)</b>			-	<b>7,700.00</b>	<b>59,680,569.24</b>	-	<b>59,688,269.24</b>	-	<b>4,183,553.00</b>		<b>4,183,553.00</b>	<b>55,504,716.24</b>	-
<b>P.Y Total</b>			-	-	-	-	-	-	-	-	-	-	-
<b>B Capital work in progress</b>													
BUILDING			-	-	-		-					-	-
PLANT AND MACHINERY			-	-	-		-					-	-
SOFTWARE DEVELOPMENT			-	-	-		-					-	-
EUGMP Fee			-	-	-		-					-	-
<b>Total (B)</b>			-	-	-		-					-	-
<b>P.Y Total</b>			-	-	-		-					-	-
<b>Current Year Total (A+B)</b>			-	<b>7,700.00</b>	<b>59,680,569.24</b>	-	<b>59,688,269.24</b>	-	<b>4,183,553.00</b>		<b>4,183,553.00</b>	<b>55,504,716.24</b>	-
<b>Previous Year Total</b>			-	-	-	-	-	-	-	-	-	-	-

**ADLEY FORMULATIONS PRIVATE LIMITED**
**Note 10 Inventories**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	9,949,239.10	-
(b) Raw Material	5,128,118.77	-
(c) WIP	-	-
d) Others	16,119,264.83	-
<b>Total</b>	<b>31,196,622.71</b>	<b>-</b>

**Note 11 Trade receivables**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
Exceeding six months		
Secured, considered good	18,887,012.94	-
<b>Total</b>	<b>18,887,012.94</b>	<b>-</b>
Less than six months		
Secured, considered good	58,102,803.64	-
<b>Total</b>	<b>58,102,803.64</b>	<b>-</b>
<b>Total</b>	<b>76,989,816.58</b>	<b>-</b>

**Note 12 Cash and cash equivalents**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>CASH IN HAND</b>		
(a) Cash in hand	662,389.00	-
(b) Balwant Singh Imprest	-	-
(c) Ram Chandra Jha Imprest	4,304.00	-
<b>Total</b>	<b>666,693.00</b>	<b>-</b>
<b>(b) Balances with banks</b>		
(i) In current accounts		
Axis Bank	2,000.00	-
ICICI Bank	207,035.57	-
Kotak Mohindra Bank	856,472.40	-
Capital Small Finance Bank Ltd	14,560.00	-
Vijaya Bank	414,993.30	-
State Bank of India	4,590.03	-
(ii) In earmarked accounts		
- Unpaid dividend accounts		-
- Unpaid matured deposits		-
- Unpaid matured debentures		-
- Share application money received for allotment of		-
- Balances held as margin money or security against		-
- Other earmarked accounts (specify) (Refer Note (ii) below)		-
<b>(c) Others (specify nature)</b>		
FDR (Margin Money)	1,669,708.00	-
<b>Total</b>	<b>3,169,359.30</b>	<b>-</b>
<b>Grand Total</b>	<b>3,836,052.30</b>	<b>-</b>

**ADLEY FORMULATIONS PRIVATE LIMITED**
**Note 13 Short-term loans and advances**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Loans and advances to related parties		
(b) Loans and advances		
Advances To Supplier	4,982,563.47	-
Advances To Supplier ( Machinery)	-	-
Other Advances ( Staff)	261,929.00	-
<b>Total</b>	<b>5,244,492.47</b>	<b>-</b>

**Note 14 Other current assets**

Particulars	As at 31 March' 2019	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Other Assets</b>		
Income Tax Refund due	-	-
Insurance Claim receivable	11,200,000.00	-
Cheque Deposited Yet not Cleared	2,658,693.00	-
Rent receivable	105,000.00	-
Sales Tax Security	-	-
Prepaid Expenses	160,259.00	-
Security Deposit	8,941,770.06	-
Preliminary Expenses	175,568.80	-
<b>Total</b>	<b>23,241,290.86</b>	<b>-</b>

**Note 15 Revenue from operations**

Particulars	For the period ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b>Sale Of Products</b>		
Sales Local 18%	6,358,272.40	-
Export Sales	11,632,039.94	-
Sales Loan Licence	-	-
Sales Exempt	1,062,399.00	-
GST Sales 12%	57,511,694.99	-
GST Sales 5%	2,209,577.20	-
GST Sales 18%	-	-
GST Local Sale 18%	14,300.00	-
GST Local Sale 12%	15,550.00	-
<b>Total</b>	<b>78,803,833.53</b>	<b>-</b>

**Note 16 Other income**

Particulars	For the period ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
(a) Interest Income	9,915.00	-
(b) Rent Income	175,000.00	-
(c) Other non-operating income	400,123.00	-
(d) Foreign Currency Exchange Gain	-	-
<b>Total</b>	<b>585,038.00</b>	<b>-</b>



<b>ADLEY FORMULATIONS PRIVATE LIMITED</b>		
<b>Note 17 Cost of materials consumed</b>		
Particulars	For the period ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
Opening stock	-	-
Add: Purchases	61,008,751.21	-
Less: Closing stock	21,247,383.60	-
<b>Cost of material consumed</b>	<b>39,761,367.61</b>	-
<b>Total</b>	<b>39,761,367.61</b>	-
<b>Note 18 Changes in inventories of finished goods, work-in-progress and stock-in-trade</b>		
Particulars	For the period ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
<b><u>Inventories at the end of the year:</u></b>		
Finished goods	9,949,239.10	-
Work In Progress	-	-
	<b>9,949,239.10</b>	-
<b><u>Inventories at the beginning of the year:</u></b>		
Finished goods	-	-
Work In Progress	-	-
	-	-
<b><u>(Increase)/ decrease in Inventory</u></b>		
Finished goods	-9,949,239.10	-
Work In Progress	-	-
	<b>-9,949,239.10</b>	-
<b>Note 19 Other Manufacturing Expenses</b>		
Particulars	For the period ended 31 March, 2019	For the year ended 31 March, 2018
	Amount in Rs.	Amount in Rs.
Consumeable Stores	532,895.34	-
Generator running expenses	17,700.00	-
Power & Fuel	1,584,193.00	-
Direct labour	3,230,435.00	-
Repairs & maintenance (machinery & Building)	8,354.00	-
Freight Inward	20,672.50	-
Factory Expenses	23,820.00	-
Packing & Forwarding expense	35,647.00	-
Solid Waste Pollution expenses	33,541.00	-
Testing Charges	282,085.02	-
<b>Total</b>	<b>5,769,342.86</b>	-



<b>ADLEY FORMULATIONS PRIVATE LIMITED</b>		
<b>Note 20 Employee benefits expense</b>		
<b>Particulars</b>	<b>For the period ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>Salaries and wages</b>		
Director	5,000,000.00	-
Employees	11,960,051.00	-
Employer Share of ESI	79,099.00	-
Employer Share of PF	150,409.00	-
Bonus	358,619.00	-
Staff welfare expenses	68,240.00	-
Staff Uniform Expenses	-	-
Rent Free Accomodation to Staff	-	-
Gratuity Provision	898,650.00	-
<b>Total</b>	<b>18,515,068.00</b>	<b>-</b>

**Note 21 Finance costs**

<b>Particulars</b>	<b>For the period ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
<b>(a) Interest expense on:</b>		
(i) Borrowings		
Bank Interest CC	5,470,955.00	-
Interest on Term Loan	1,030,339.70	-
Interest on Term Loan (Vehicle)	287,921.17	-
(ii) Others	-	-
<b>- Interest on delayed / deferred payment of income tax</b>		
Interest on Term Loan		
<b>(b) Other borrowing costs (Processing Fees)</b>		
Bank charges	186,062.03	-
Processing fee for renewal		
<b>Total</b>	<b>6,975,277.90</b>	<b>-</b>

# 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

<b>Note 22 Other expenses</b>		
<b>Particulars</b>	<b>For the period ended 31 March, 2019</b>	<b>For the year ended 31 March, 2018</b>
	<b>Amount in Rs.</b>	<b>Amount in Rs.</b>
Advertisement Expenses	712,786.57	-
Audit Fee	-	-
Books & Periodical	-	-
Business Promotion Expenses	175,091.94	-
Daily Pooja Expenses	-	-
Commission Paid	1,208,438.00	-
Conference Expenses	290,817.00	-
Convenyance Expenses	79,420.00	-
Corporate Expenses	-	-
Corporate Social Responsibility Expenses	-	-
Sponsorship A/C	-	-
Donation A/C	-	-
Expired & damages Goods Return	789,132.54	-
Diwali Expenses	-	-
Foreign Travel	-	-
Foreign Exchange Gain/Loss	455,590.73	-
Freight Outward	1,068,708.31	-
Guest House expenses	-	-
Insurance Apportion Cost	71,962.00	-
Legal & Professional Expenses	4,130.00	-
Medical Expenses	-	-
Misc. Expenses	-	-
Office Expenses	48,480.43	-
Printing & Stationary	56,706.00	-
Preliminary expenses w/off	43,892.20	-
Rate Difference	315,334.00	-
Rate Fee & taxes	299,536.00	-
Rent	-	-
Repair & maintenance ( Vehicle )	180,299.00	-
Round Off	-134.45	-
Small Balance Written Off	-5,790.87	-
Software Expenses	24,000.00	-
Telephone & Postage	69,711.00	-
Trade Discount Expenses	579,049.00	-
Travelling Expenses	3,263,806.88	-
<b>Total</b>	<b>9,730,966.28</b>	<b>-</b>

**NOTES TO ACCOUNTS OF STANDLONE FINANCIALS OF M/S ADLEY FORMULATIONS PRIVATE LIMITED****NOTE '3' : SIGNIFICANT ACCOUNTING POLICIES****(Forming part of Accounts)****FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019****3.1. Basis of Accounting**

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable. The company was incorporated on 09.10.2018 and books of accounts are prepared from 01.11.2018 till 31.03.2019 since the operations were started from 1st November.

The company has purchased M/s Adley Formulations (via slump sale), a sole proprietorship firm owned by Sh. Vijay Kumar Batra vide Business Transfer Agreement dated 31.10.2018 which was engaged in the business of manufacturing of Pharmaceutical Drugs in the form of tablets and injectables. Therefore the financial results consists of five months figures (i.e. from 01/11/2018 to 31/03/2019)

**3.2. Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognised in the period in which the results are known/materialised.

**3.3. Fixed Assets****-Tangible Assets**

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Following Immovable assets are currently in the name of M/s Adley Formulations, post acquisition of business, the title deed is to be transferred in M/s Adley Formulation Private Limited. As explained to us, registration of title deeds is in progress in respect of immovable properties.

Particulars	Address of Property
4. LAND	Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
5. BUILDING	Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
6. BUILDING SHOWROOM	SCO 42, Sector 12, Panchkula

In respect of movable properties, two vehicles are currently in the name of M/s Adley Formulations, post acquisition of business, the vehicle registration is to be transferred in M/s Adley Formulation Private Limited. As explained to us, transfer of vehicle along with endorsement of insurance is in progress in respect of two cars having registration no. HP 12J 0888 and PB 65AK 9829.

**- Capital Work-in-Progress**

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. There was no Work in Progress during the FY 2018-19



### 3.4. Depreciation/Amortisation

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013. **(Refer note 4.7).**
- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided upto the month in which such fixed assets are sold or scrapped.

### 3.5. Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognised in prior years is recorded when there is an indication that the impairment losses recognised for the assets no longer exist or have decreased.

### 3.6. Valuation of Inventories

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods Oncology products comprises of Injections, Tablets & Capsules
- Work In Progress (Semi Finished Goods)
- Is valued at cost or estimated realisable value, whichever is lower. The company has determined the cost of Inventory using the First-In, First Out method.
- Transfer of Stock – M/s Adley Formulations Private Limited (Transferee Undertaking) has received the closing stock, as certified by management, on cost from M/s Adley Formulations (Transferor Undertaking).

### 3.7. Revenue Recognition

- Revenue from sale of goods is recognised when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognised when services are rendered and related costs are incurred.
- Other income is recognised on accrual basis unless otherwise stated.
- Insurance and other claims are accounted for on settlement of claims/on receipt.
- Revenue from sales/services are shown net of taxes, as applicable.
- Revenue Recognition During Transition Phase of Purchase of M/s Adley Formulation - The company has purchased Adley Formulation, a sole proprietorship firm owned by Sh. Vijay Kumar Batra vide Business Transfer Agreement dated 31.10.2018 which was engaged in the business of manufacturing of Pharmaceutical Drugs in the form of tablets and injectable. Since it is mandatory to manufacture the pharmaceutical drugs after the receipt of manufacturing license from respective regulator i.e. Health and Family Welfare Department, Himachal Pradesh,, the company got the manufacturing approval dated 26.11.2018 in the name of M/s Adley Formulations Private Limited. During this transition phase from acquisition to receipt of manufacturing license, the company issued sales bills and other financial transactions in the name of M/s Adley Formulation (Transferor Firm). Financials post acquisition is prepared including financial transactions conducted in the name of M/s Adley Formulation during this transition phase.

### 3.8. Employee Benefits

#### a) Short-term Employee Benefits:

- Leave Encashment, on the basis of actual computation, is accounted for on accrual basis, during the tenure of employment the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has paid Rs. 3,58,619.00 as per The Payment of Bonus Act, 1965.

#### b) Post-Employment Benefits

##### (i) Defined Contribution Plans :



Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

**(ii) Defined Benefit Plans :**

Gratuity is accounted for on accrual basis - the Company is in the process of taking the Gratuity policy with Life Insurance Corporation of India or any other insurer covered under the specified provisions of the Income Tax Act, 1961.

Provision for Gratuity Liability for the financial year 2018-19 of Rs. 8,98,650.00 is created as per the Payment of Gratuity Act.

**c) Termination Benefits :** Termination benefits are recognised as an expense as and when incurred.

**3.9. Foreign Currency Transactions**

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of transaction or the average of opening and closing rates. The difference in the rate of exchange, if any, is accounted at the time of realisation or settlement and is recognized in the Statement of Profit and Loss.

Exchange differences (Gains) arising on foreign currency transactions for purchase of Plant and Machinery is adjusted against the cost of acquisition of that asset.

**3.10. Borrowing Costs**

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss.

**3.11. Investments**

-Current Investments are carried at cost or fair value whichever is lower.

- Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

**3.12. Operating Lease**

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognised as an expense in the Statement of Profit & Loss on monthly due basis.

**3.13. Taxes on Income**

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.

- Deferred tax is recognised, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.

- Minimum Alternate Tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will be in a position to avail of such credit under the provisions of the Income Tax Act, 1961.

**3.14. Earnings Per Share (EPS)**

- Annualised basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.

- Annualised diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

**3.15. Cash Flow Statement:**

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (AS) 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

**3.16. Contingencies and Provisions**

A provision is recognised when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

**Details of Contingent Liabilities in the form of Bank Guarantee as on 31.03.2019.**

BANK NAME	BANK GUARANTEE NO	OPENING DATE	EXPIRY DATE	IN FAVOUR	AMOUNT
ICICI BANK LTD	0043BGFD005519	29.03.2019	30.01.2020	THE PRESIDENT OF INDIA THROUGH THE DEPUTY COMMISSIONER OF CUSTOMS, AIR CARGO COMPLEX, NEW DELHI	1,96,100
ICICI BANK LTD	0043BGFD005619	30.03.2019	30.04.2020	STATE HEALTH SOCIETY, ASSAM	66,655
				<b>TOTAL</b>	<b>2,62,755</b>

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

### (Forming part of Accounts)

FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2019

#### 4.1. **Contingent Liabilities & Commitments:**

- Estimated amount of contracts remaining to be executed and not provided for in the books of account - Nil (previous year - Nil).
- Contingent Liabilities:
  - Claims against the Company not acknowledged as debt - Nil (previous year - Nil).
  - Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

#### 4.2. **Issued, Subscribed & Paid up Capital:**

Issued Subscribed and paid up capital of the company is Rs. 1,26,00,000.00 (divided into 12,60,000 shares of Rs. 10 each)

#### 4.3. **Reserves & Surplus:**

- The amount shown in the Reserve & Surplus represents only the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2019 is Rs. 32,57,875.89.

#### 4.4. **Long-term Borrowings**

##### **Secured :**

##### **Term Loan:**

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2019	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	ICICI BANK LIMITED (VEHICLE LOAN)	Term Loan of Rs. 40.00 Lakhs (A/c No. LUPNC00035804579)	Term Loan	Rs. 24.91 Lakhs	13.51%	Total Installments of Rs 1.08 Lacs P.M. divided into 48 Equated monthly installment.	HYP of Motor Vehicles from the bank.
2	KOTAK BANK LAP (SHOWROOM)	Term Loan of Rs. 215.38 Lakhs (A/c No. CL5650452100)	Term Loan	Rs. 184.93 Lakhs	11.50%	Total Installments of Rs 2.67 Lacs P.M. divided into 180 Equated monthly installment	Collateral - Commercial Property located at SCO 42, Sector 12, Urban Estate, Panchkula owned by Adley Formulation.
3	KOTAK MAHINDRA BANK	Cash Credit Limit of Rs. 555.00 Lacs	Cash Credit	Rs. 560.66 Lakh	MCLR* +3.85 %		Primary Security – First and Exclusive charge over Current Assets and Fixed Asset of borrower both present and future. Collateral Security – 1. Industrial Property located at Plot No. 56, HSIIDC Industrial Estate, Kalka, Distt Panchkula Owned by Rishi Herbal Products. 2. Industrial Property at Pargan Doon, PO Barotiwala, Baddi owned by Adley Formulations
4	KOTAK MAHINDRA BANK A/C	Drop Line OD of Rs. 520.00 Lacs	CC	Rs. 411.25 Lakh	MCLR* +6.35 %	.	



# 14<sup>TH</sup> ANNUAL REPORT



## BETA DRUGS LIMITED

							<ol style="list-style-type: none"> <li>3. Guest House at Village Dochi, Near Garkhal, Tehsil Kasauli, Distt Solan (HP) owned by Sh. Vijay Batra</li> <li>4. Residential Property located at 55 P, Sector 12, Panchkula, owned by Smt. Neeraj Batra.</li> <li>5. Residential Property located at H-140, Sector 12, Urban Estate, Panchkula, owned by Vijay Batra</li> <li>6. Commercial Property located at SCO 42, Sector 12, Urban Estate, Panchkula owned by Adley Formulations.</li> </ol>
5	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs. 45 Lakhs	Term Loan	Rs. 26.89 Lakh	7.86%	Total Installments of Rs 1.37 Lacs P.M. divided into 37 Equated monthly installment.	HYP of Motor Vehicles from the bank.

\*(MCLR at the time of sanction / renewal was 8.45%)

Treatment of Secured Loan During Transition Phase : Existing Credit Facility in the name of M/s Adley Formulations (Transferor Undertaking) is transferred in the name of M/s Adley Formulations Private Limited after the Balance Sheet date. Interest on credit facility from acquisition date to 31.03.2019 is recognized as expenses in the company account.

4.5. In the opinion of the Directors, "Current Assets" and "Loans & Advances" are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge provisions for all the known liabilities have been made and, as certified, all the contractual and statutory obligations have been duly complied with. It is Pertinent to mention that the company has raised a claim of Rs.1,12,00,000 from the National Insurance Company against a loss on account of fire in the factory premises. This claim recovery is subject to assessment by the Insurance Company.

4.6. Party balances have been incorporated in the financial statements at the value as per the books of account & are considered hopeful of recovery/good for payment.

### 4.7. Depreciation/Amortisation

- The management estimates the remaining useful life of existing fixed assets as on 01<sup>st</sup> November, 2018 as follows:-

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Equipment	5 years
Lab Equipment	10 years
Vehicles	8 years

For these class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part-C of Schedule-II of the Companies Act, 2013. (Refer note 3.4).

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

### 4.8. Earnings Per Share (AS-20)

	<u>Year ended</u> <u>31<sup>st</sup> March, 2019</u>	<u>Year ended</u> <u>31<sup>st</sup> March, 2018</u>
<b>Numerator</b>		
Net Profit/(Loss)		
attributable to Equity shareholders	32,57,875.89	-
<b>Denominator</b>		
Number of Equity shares	No.'s 12,60,000	-
Nominal		
Value per Equity share	10	-
Earnings per Equity share		
- Basic and diluted	2.59/2.59	-

### 4.9. Non-Current Investments:

- Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.
- The provisions of Section 186 of the Companies Act, 2013 have been complied with.

### 4.10. Taxes

- The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate pending finalisation of assessments and no disputed dues or amounts were outstanding or remaining unpaid as at 31<sup>st</sup> March, 2019.

### 4.11. Segment Reporting

Since the Company primarily operates in one segment (i.e. Manufacturing of Oncology medicines), therefore segment reporting as required under Accounting Standard - 17 is not applicable - there is no reportable geographical segment as the export sale of the company is less than 10% of the total sales made in India

### 4.12. Related Party Disclosures

Related parties & their relationship and related parties transactions.

S. No.	Related Party	Nature of Relationship	Nature of Transaction	Amount Involved During the year
1.	Adley Lab Limited	Share holder are common ( Holding more than 50 % shares)	Purchase of Goods	84,03,144.00
2.	Vijay Kumar Batra	Director	Salary	50,00,000.00
3.	Beta Drugs Limited	100% Holding	Purchase of Goods	10,64,392.00
4.	Rishi Herbal Products	Proprietor Firm of Director	Purchase of Goods	15,96,000.00

### 4.13. Impairment of Assets

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of AS-28 on "Impairment of Assets" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognised for the year.

### 4.14 Fixed Assets:

After the acquisition of M/s Adley Formulations, there was a further addition of Rs. 7,700 to Plant & Machinery.

### 4.15. Deferred Tax Assets & Liabilities

During the FY 2018-19 the company has made Deferred Tax Provision (Asset) of Rs. 3,89,388.81. Details of Calculation in mentioned below.



Calculation of Deferred Tax Asset / Liability	Amount in Rs.
Deferred Tax Asset on depreciation	1,55,739.81
Deferred Tax Asset on provision of gratuity	2,33,649.00
<b>Total Deferred Tax Asset Created for the financial year 2018-19 in Profit and Loss Account.</b>	<b>3,89,388.81</b>
Less : Deferred Tax Liability as on 01.04.2018 ( Opening)	-
<b>Balance Deferred Tax Asset recognized in Balance Sheet</b>	<b>3,89,388.81</b>

4.16. **Micro, Small & Medium Enterprises**

Based on the information presently available, total outstanding as on 31.03.2019 is Rs.1,38,85,920.00 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

4.17. **Auditor's Remuneration**

(exclusive of service tax)

	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
	-	-
-As Auditors	-	-
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
- Reimbursement of out of pocket expenses	-	-
<b>TOTAL</b>	<b>-</b>	<b>-</b>

4.18 **Other additional information**

<u>Particulars</u>	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
<b>"A" Revenue from operations (under broad heads)</b>		
Sales		
-Sales With in India	6,71,71,793.50	0.00
-Export Sales	1,16,32,039.98	0.00
<b>Total</b>	<b>7,88,03,833.53</b>	<b>0.00</b>

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

**"B" Purchases**

-Chemicals, Bulk Drugs & Packing Material	6,10,08,751.21	0.00
-------------------------------------------	----------------	------

**4.19. Expenditure In Foreign Currency (On Accrual Basis):- Following Expenses were incurred by the company during the year 2018-19.**

	<u>31<sup>st</sup> March, 2019</u> <u>AMOUNT</u>	<u>31<sup>st</sup> March, 2018</u> <u>AMOUNT</u>
- Import of Capital Goods	-	-
- Revenue Expenses ( Travel)	-	-
<b>TOTAL</b>	<u>-</u>	<u>-</u>

**4.20. Earning in Foreign Currency**

<b>Particulars</b>	<b>For The Year Ended ( 31.03.2019)</b>	<b>For the year Ended ( 31.03.2018)</b>
FOB Value of Export	1,16,32,039.94*	0.00

\* This includes indirect export.

**4.21. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation.**

In terms of our attached report of even date.

For and on behalf of the Board of Directors

For KALRA RAI & ASSOCIATES  
CHARTERED ACCOUNTANTS  
F R No. – 008859N  
Sd/-  
LAJPAT RAI KALRA  
PARTNER  
M No. -087438

sd/-  
(Managing Director)

Dated: 13/05/2019

Place: Chandigarh



---

**BETA DRUGS LIMITED**

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pradesh.

Tel No. 01795-236196, Email: cs@betadrugslimited.com, Website:www.betadrugslimited.com

---

**PLEASE FILL ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE MEETING HALL**

**Joint Shareholders may obtain additional slip on request**

DP ID No. : \_\_\_\_\_

Client ID No. : \_\_\_\_\_

Ledger Folio No. : \_\_\_\_\_

NAME AND ADDRESS OF THE SHAREHOLDER: \_\_\_\_\_

No. of shares held \_\_\_\_\_

I hereby record my presence at the **ANNUAL GENERAL MEETING** of the Company held on Monday, the **30<sup>th</sup> day of September, 2019 at 12.30 p.m.** at Registered Office of the company situated at **Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101.**

- I certify that I am member/proxy of the company.

\_\_\_\_\_  
Signature of the shareholder or proxy

Note: You are requested to sign and handover this slip at the entrance of the meeting venue.

**BETA DRUGS LIMITED**

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pradesh.

Tel No. 01795-236196, Email: cs@betadrugslimited.com, Website: www.betadrugslimited.com

**Form No. MGT-11****Proxy form***[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]*

Name of the Member(s): \_\_\_\_\_

Registered address: \_\_\_\_\_

E-mail Id: \_\_\_\_\_

Folio No/ Clint Id-DP ID: \_\_\_\_\_

I/ We being the member (s) of shares of the above named company, hereby appoint

1. Name: \_\_\_\_\_

Address: \_\_\_\_\_

E-mail Id: \_\_\_\_\_ Signature: \_\_\_\_\_, or failing him;

2. Name: \_\_\_\_\_

Address: \_\_\_\_\_

E-mail Id: \_\_\_\_\_ Signature: \_\_\_\_\_, or failing him;

3. Name: \_\_\_\_\_

Address: \_\_\_\_\_

E-mail Id: \_\_\_\_\_ Signature: \_\_\_\_\_, or failing him;

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at **ANNUAL GENERAL MEETING** of the Company held on Monday, the **30<sup>th</sup> day of September, 2019** at 12.30 p.m. at **Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101** and at any adjournment thereof in respect of such resolutions as are indicated below:

Sr No.	Resolutions	Optional	
ORDINARY BUSINESS		For (✓)	Against (X)
1.	Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2019 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2019, together with the Report of the Auditors thereon		
2.	To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re appointment.		
3.	To appoint a Director in place of Mr Balwant Singh (DIN: 01089968), who retires by rotation and being eligible, offers himself for re appointment.		

Affix Revenue  
Stamp not less  
than Rs 1/-

## 14<sup>TH</sup> ANNUAL REPORT



**BETA DRUGS LIMITED**

4.	To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Nineteenth Annual General Meeting and to fix their remuneration.		
SPECIAL BUSINESS			
5.	To regularize Mrs Seema Chopra (DIN:08510586) as a Director of the company.		
6.	To appoint Mrs Seema Chopra (DIN:008510586) as Whole-time director of the Company & approve the remuneration.		
7.	Remuneration to Cost Auditor for the Financial Year ended 31 <sup>st</sup> March, 2020.		
8.	Re-appointment of Shri Vijay Kumar Batra (DIN:01083215) as Chairman Cum Managing Director of the company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.		
9.	Re-appointment of Mr Rahul Batra (DIN:02229234) as Whole-time Director of the Company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.		
10.	Re-appointment of Mr Varun Batra (DIN:02148383) as Whole-time Director of the Company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.		
11.	Re-appointment of Mr Balwant Singh (DIN:01089968) as Whole-time Director of the Company w.e.f. 5 <sup>th</sup> August, 2019 till 4 <sup>th</sup> August, 2024.		

Signed this \_\_\_\_\_ day of \_\_\_\_\_ 2019

Signature of Shareholder: \_\_\_\_\_

Signature of Proxy holder(s): \_\_\_\_\_

**Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting. A proxy need not be a member of the company.**

**14<sup>TH</sup> ANNUAL REPORT****BETA DRUGS LIMITED****BETA DRUGS LIMITED**

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pradesh.

Tel No. 01795-236196, Email: cs@betadrugslimited.com, Website: www.betadrugslimited.com

**BALLOT FORM**

Name of the member(s):	
Registered Address:	
Folio No	
No. of Shares	
*DP ID	
* Client ID	

\* Applicable to holders holding shares in demat/electronic form

I/We hereby exercise my/our vote in respect to the Ordinary/Special Resolution to be passed through Postal Ballot for the Business stated in the Postal Ballot Notice by sending my/our assent (FOR) or dissent (AGAINST) to the said resolution by placing the right mark (✓) at the appropriate box below:

Item No.	Item	Nature of Resolution	Assent (FOR)	Dissent (AGAINST)
1.	Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2019 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2019, together with the Report of the Auditors thereon	Ordinary		
2.	To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re appointment.	Ordinary		
3.	To appoint a Director in place of Mr Balwant Singh (DIN: 01089968), who retires by rotation and being eligible, offers himself for re appointment.	Ordinary		
4.	To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Nineteenth Annual General Meeting and to fix their remuneration.	Ordinary		
5.	To regularize Mrs Seema Chopra (DIN:08510586) as a Director of the company.	Ordinary		
6.	To appoint Mrs Seema Chopra (DIN:08510586) as Whole-time director of the Company & approve the remuneration.	Ordinary		
7.	Remuneration to Cost Auditor for the Financial Year ended 31 <sup>st</sup> March, 2020.	Ordinary		
8.	Re-appointment of Shri Vijay Kumar Batra (DIN:01083215) as Chairman Cum Managing Director of the company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.	Ordinary		
9.	Re-appointment of Mr Rahul Batra (DIN:02229234) as Whole-time Director of the Company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.	Ordinary		
10.	Re-appointment of Mr Varun Batra (DIN:02148383) as Whole-time Director of the Company w.e.f. 2 <sup>nd</sup> February, 2020 till 1 <sup>st</sup> February, 2025.	Ordinary		
11.	Re-appointment of Mr Balwant Singh (DIN:01089968) as Whole-time Director of the Company w.e.f. 5 <sup>th</sup> August, 2019 till 4 <sup>th</sup> August, 2024.	Ordinary		

Place:

Date:


\_\_\_\_\_  
Signature of Member





BETA DRUGS LIMITED

## AGM VENUE MAP



## BETA DRUGS LIMITED

Registered Office:  
Village Nandpur, Lodhimajra Road  
Baddi, Distt Solan, H.P. 174101



BETA DRUGS LIMITED

We team of BETA DRUGS LTD.,  
wants to thank you from bottom  
of our hearts for supporting us  
in achieving this newer heights.



**THANK  
YOU!**

Beta Drugs Limited:-  
Village Nandpur, Lodhimajra Road  
Baddi, Distt Solan, H.P. 174101  
Tel No. 01795-236196,

Email: [cs@betadrugslimited.com](mailto:cs@betadrugslimited.com),  
Website: [www.betadrugslimited.com](http://www.betadrugslimited.com)